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Abstract 
The term Synthetic Cannabinoid Receptor Agonists (SCRAs) describes a group of 
hundreds of compounds which are not derived from the Cannabis plant but bind at 
the cannabinoid receptors. These compounds have been available for recreational 
use since the late 2000s and have been linked to a variety of adverse effects and 
death. Due to the number of compounds available, and their novel nature, 
controlling the manufacture, sale and possession of SCRAs has proved 
challenging under current legislative structure. The introduction of the 
Psychoactive Substances Act 2016 brought under control the manufacture, 
distribution and possession in a custodial facility of any SCRA which had not 
already been controlled by the Misuse of Drugs Act 1971.  
Whilst clarification has been brought to the legal status of these drugs, what 
remains largely unknown is the scale of use within Scotland, and different sub-
populations.  
Simple and quick protocols were developed for the extraction of 40 SCRAs 
(comprising parent compounds and metabolites) from blood and urine. Sensitive 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) methods were 
developed to detect and quantify the most commonly encountered compounds at 
realistic blood and urine concentrations. Depending on the timing of cohort sample 
receipt, one of these methods was then applied to cohorts of individuals from 
various sub-populations within Scotland. Optimised methods for detection and 
quantitation in blood and urine then underwent validation.  
Overall, in 1177 cases tested, SCRA prevalence was found to be low, relative to 
the prevalence of more ‘traditional’ drugs of abuse such as opiates/opioids or 
benzodiazepines. The detection of SCRAs was highest in the cohort of individuals 
presenting at an Emergency Department (ED) with suspected drug toxicity, with 
56% of cases tested positive. Second highest was the cohort of deceased 
individuals undergoing post-mortem (PM) examination, with SCRAs found in 11% 
of cases tested. It should be noted, though, that samples from both these cohorts 
were only tested if SCRA use had been suspected. Samples collected from 
individuals undergoing admission to or liberation from Scottish Prison Service 
(SPS) facilities were found to contain SCRAs at a rate of 3% for all samples. All of 
the positive samples in this cohort were admission samples (except one which 
was not labeled admission or liberation), thus 5% of admission samples were 
  xxviii 
positive for SCRAs. Out of 73 samples collected from individuals under the 
jurisdiction of the Glasgow Drug Court (GDC), only 1 sample was positive (1.4%). 
All 95 samples collected from individuals being treated by the NHS Greater 
Glasgow and Clyde Forensic Directorate (FD) were negative for all SCRAs 
included in the panel.  
These results indicate that SCRAs are having negative effects on the health of 
users and that they are being used by the offending community, both of which 
have been reported in mainstream media. Another suspected aspect of SCRA use 
was the intention of avoiding detection by mandatory drug tests. Both the GDC 
and FD cohorts were aware of their required compliance with drug abstinence and 
mandatory drug testing regime, but the low findings of SCRAs in these groups 
suggest this is not the case.  
It is acknowledged that the numbers of individuals tested in the cohorts were 
relatively low, and that the studies were not a true calculation of prevalence. In 
addition to this, not all SCRAs were included in the analytical method, and those 
not included would not be identified in samples. Nonetheless, important 
information was gained about the scale and nature of SCRA use within Scotland. 
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1. Introduction 
1.1. Background 
The term synthetic cannabinoid receptor agonist (SCRA) refers to any exogenous 
compound not present in the natural cannabis plant which exhibits an agonistic 
action on the cannabinoid receptors in the human body. While there is limited 
information on the activity of SCRA metabolites on these receptors, for simplicity in 
this thesis, the term SCRA will also include metabolites. In order to understand the 
existence, pharmacology, toxicology and abuse potential of these compounds, it is 
first necessary to discuss the cannabinoid receptors, phytocannabinoids and 
endocannabinoids. 
1.2. Cannabinoid Receptors  
Cannabinoid receptors are classical G-protein coupled receptors and can be 
separated into cannabinoid receptor type-1 (CB1) and cannabinoid receptor type-2 
(CB2), although there is some evidence for a cannabinoid receptor type-3 (1-5). 
They were discovered, initially in rat brain and then human brain, in 1990 (CB1) 
and 1993 (CB2) (3). CB1 receptors are located primarily within the central nervous 
system (CNS) and are therefore responsible for the psychoactive effects of 
cannabinoids, such as changes in perception and memory, anxiety and paranoia 
(1-4, 6-9). Activation of these receptors mainly cause inhibitory responses, such as 
a reduction in neurotransmitter release (acetylcholine, glutamate, dopamine), 
hypothermia, analgesia, cataplexy and suppression of locomotion (the latter 4 
known as the ‘cannabinoid-tetrad’) (1, 2, 4, 6). The relatively low concentration of 
CB1 receptors in the brain stem, medulla and thalamus may explain why even high 
concentrations of cannabinoids do not tend to be considered a threat to life (6). 
CB2 receptors are located more peripherally, primarily within the immune system, 
although are present within the CNS, and are thought to play a role in the 
modulation of pain and inflammation (1-4, 6, 8, 9). Due to the effects of their 
agonists including analgesia and the reduction of inflammation and nausea, the 
cannabinoid receptors elicited significant interest in their potential therapeutic 
value.  
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1.3. Phytocannabinoids 
The first steps to the development and abuse of SCRAs were taken thousands of 
years ago with the use of the cannabis plant for its pharmacological properties. 
Possibly the earliest written record of cannabis use in medicine dates back to ca. 
2350 BCE in Egypt, with the psychoactive effects having been noted in Sanskrit, 
Hindu and Chinese writings from ca. 10 CE (6, 10).  
Although not isolated or characterized at the time, the compounds these cultures 
were exploiting were the phytocannabinoids, present naturally in cannabis plant 
material. The term phytocannabinoids refers to a group of over 60 compounds 
unique to the cannabis genus (11). These can be sub-divided into 10 classes, 
including the Δ-9-tetrahydrocannabinol (Δ9-THC) class and cannabidiol (CBD) 
class containing their respective namesake compounds (11). Δ9-THC and CBD 
are arguably the most relevant phytocannabinoids when discussing SCRAs due to 
their actions on the cannabinoid receptors in the human body.  
Δ9-THC (Figure 1, left) is the main psychoactive component in cannabis and the 
synthesis of this was first reported in 1965 by Raphael Mechoulam (6, 8, 11-14). 
By acting predominantly as a partial agonist at the CB1 receptor with an inhibition 
constant (Ki) value in the low nanomolar range, and binding at the CB2 receptor, 
Δ9-THC is responsible for the “high” felt after cannabis use (1, 2, 4, 7, 8, 11, 13). It 
has been hypothesized that the increasing content of Δ9-THC in cannabis causes 
an increase in the schizotype psychotic effects when smoked, and thus that Δ9-
THC may cause these effects (7, 9, 15). Strains of cannabis, such as sinsemilla 
(translates as “without seed”) and skunk, which are developed to contain high 
levels of Δ9-THC, cannot also produce high CBD levels, so these are low as a 
result (7). 
The structure of CBD (Figure 1, right) was elucidated in 1963 and reports of 
pharmacological aspects of the compound were reported from the 1970s (16). The 
affinity of CBD as an agonist at both CB1 and CB2 is significantly less than that of 
Δ9-THC, within the micromolar range, but it acts as an antagonist at both 
receptors in the low nanomolar concentration range (4). CBD has been found to 
possess anticonvulsant, antipsychotic and antiemetic properties, as well as 
producing analgesia without the effects on memory produced by Δ9-THC (4, 6, 9, 
16, 17). 
  3 
Currently, a mixture of Δ9-THC and CBD is approved in the UK as treatment for 
musculoskeletal disorders such as multiple sclerosis. After some confusion as to 
whether CBD qualified as a medicine under the Medicines and Healthcare 
Products Regulations Agency (MHRA), the agency issued an opinion stating that 
CBD was a medicine and required a license to be legally sold (18, 19). 
Δ9-Tetrahydrocannabinol 
 
Cannabidiol 
 
Figure 1 – Structural Formulae of Δ9-tetrahydrocannabinol (left) and 
cannabidiol (right) 
 
1.4. Endocannabinoids 
The two endogenous cannabinoid receptor ligands of most interest in this context 
are N-arachidonoylethanolamide (anandamide, from the Sanskrit word for “bliss”; 
Figure 2, left) and 2-arachidonoylglycerol (2-AG; Figure 2, right) (2, 7). These 
appear to be produced post-synaptically for use as neurotransmitters when 
required, and are eliminated via reuptake and hydrolysis by fatty acid amide 
hydrolases and other enzymes (2, 7, 9).  
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Anandimide 
 
2-arachidonoylglycerol 
 
Figure 2 – Structural formulae for anandimide (left) and 2- 
arachidonoylglycerol (right) 
 
Like Δ9-THC, anandamide acts as a partial agonist at the CB1 receptor, with 
limited activity at CB2 (2, 4). The potency and duration of action of the latter is less 
than the former (6). However, 2-AG has agonistic activity at both cannabinoid 
receptors which is higher than that of anandamide, with higher affinity for CB1 than 
CB2 (2, 4, 20). Both anandamide and 2-AG play a role in the prevention and 
healing of inflammation-induced pain, but the mechanism through which this is 
induced remains unclear (6). In an attempt to clarify the role of endo- and 
phytocannabinoids in pain and immune modulation, compounds similar to those 
produced in nature were synthesized (17, 21). 
1.5. Synthetic Cannabinoid Receptor Agonists 
Research into the cannabinoid receptors and their ligands has been ongoing since 
the 19th century, but the synthesis of novel cannabinoid receptor agonists began 
around 1940, with the work of Roger Adams in the US and Alan Todd in the UK 
(22). The first compounds were synthesized in attempts to produce pure forms of 
the naturally occurring active components of cannabis, but in doing so synthetic 
analogues of compounds such as Δ9-THC (e.g. parahexyl (3-hexyl-6,6,9-trimethyl-
7,8,9,10-tetrahydrobenzo[c]chromen-1-ol)) were produced (22). During the years 
that followed, completely novel SCRAs were developed and patented by the likes 
of John W. Huffman (the JWH- series of compounds), researchers at the Hebrew 
University (the HU- series of compounds), and Pfizer (the CP- series of 
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compounds) (3, 5, 13, 21-23). Structure-activity relationship and receptor binding 
studies were undertaken using these novel compounds with the intention of further 
elucidating the role of the cannabinoid receptors and probing the potential of this 
system in medical therapeutics (5, 24). Given the number of SCRAs produced in 
pursuit of these goals, it is not surprising that great variation exists in the affinities 
and actions of these compounds at the CB1 and CB2 receptors. Table 1 provides 
the binding affinities at the cannabinoid receptors for selected original SCRAs, with 
those of Δ9-THC given for reference.  
Table 1 – Binding affinities of selected original synthetic cannabinoid 
receptor agonists, with that of Δ9-tetrahydrocannabinol for reference 
Compound Ki (nM) Reference 
CB1 CB2 
Δ9-THC 41 ± 2 36 ± 10 
(5) WIN-55,212-2 1.9 ± 0.1 0.28 ± 0.16 
JWH-018 9 ± 5 2.9 ± 2.6 
JWH-072 1050 ± 55 170 ± 54 
 
The inhibition constant (Ki) provides a measure of the receptor binding of a 
compound, traditionally via determination of the concentration of the compound 
required to inhibit a specified enzyme. This can be calculated by plotting the 
inverse rate of a substrate-enzyme reaction at different concentrations of enzyme 
against the concentration of the inhibiting compound. Where these lines converge 
is –Ki. The lower the Ki value, the higher the affinity of binding of that compound. 
The degree of binding affinity does not, however, equate to the potency of action 
of that compound.  
There has been no evidenced authorisation of SCRAs for medicinal therapies 
within Europe, and the recreational use of them is a relatively new phenomenon 
(21). It is thought that SCRAs have been available for abuse since around 2004, 
but that the use of them has shifted more into the mainstream since around 2008 
(9, 13, 17, 25-30). The first compounds to be detected were JWH-018, HU-210 
and CP-47,497, found to be ingredients in ‘K2’, described on the packaging as 
‘herbal incense, not for consumption’ (9, 25, 31). ‘Spice’ products were also 
among the first to contain SCRAs (29, 32, 33). These first series of SCRAs (JWH-, 
HU-, and CP-) came to be known as ‘1st generation’ SCRAs due to their presence 
in the first wave of SCRA products (21). Figure 3 shows the Google Trends UK 
data for worldwide searches of terms related to SCRAs from January 1st 2004 to 
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January 1st 2019. This illustrates the varying interest in these compounds. ‘Spice 
Gold’ searches were on the rise first – around August 2005 – before peaking 
around October 2008 and declining since then. ‘Spice drug’ and ‘K2 drug’ have 
similar trends, increasing around February 2009 before gradually decreasing from 
around November 2012. They then both have various spikes in interest from 
around April 2015 onwards to the end of the search period. The terms ‘fake weed’ 
and ‘synthetic weed’ show similar trends to each other, with their popularity 
increasing from around March 2010, before peaking around June 2012 and 
gradually decreasing from then.  
While it is acknowledged that the search terms selected will affect the data, these 
terms were chosen as they tend to be commonly used to describe SCRAs in the 
non-scientific community. It is also accepted that the number of Google searches 
does not necessarily correlate with prevalence of use, but is used to illustrate the 
interest in the drugs. 
 
 
Figure 3 – Google Trends UK plot showing the popularity of selected 
Synthetic Cannabinoid Receptor Agonist-related search terms over time 
 
It has been hypothesised that the rise of SCRAs could be down to a number of 
factors including: 
 A lack of a co-ordinated international response to the emerging compounds 
and their abuse; 
 Their potential for simple structural adaptation, circumventing legislation, 
e.g. addition of a terminal fluorine; and 
 The reputation smoking has of being straightforward, relatively safe and 
common (34). 
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The first point is interesting as, due to the uncontrolled nature of the psychoactive 
compounds in the SCRA products, there was little monitoring by national or 
international agencies regarding their manufacture, importation or distribution. 
Indeed, SCRA products were sold openly online and in shops specialising in 
smoking paraphernalia (so-called ‘head shops’). It appears that confusion 
regarding which agencies’ jurisdiction monitoring or control of such compounds fall 
under (i.e. legislators, medicine regulatory, public health, trading standards) may 
have contributed to this (21). 
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) began 
monitoring SCRAs in 2008, issuing a report in 2009 with the intention of clarifying 
the nature, availability and potential harms of SCRAs (21). Similarly, the Advisory 
Council for the Misuse of Drugs (ACMD) in the UK sent a report to the Home 
Secretary in July 2009 outlining the situation closer to home (33). Both concluded 
that, although there was a lack of comprehensive understanding regarding many 
aspects of SCRAs, their availability, popularity and evolution should be monitored 
with potential legal reforms considered. In what may now be considered an 
underestimation, the ACMD report surmised that the potential for harm of SCRAs 
may be “comparable” to those of herbal cannabis (33). 
In 2009, an amendment was made to the Misuse of Drugs Act 1971 (MDA) to 
classify the SCRAs WIN 55,212-2, HU-243, CP 50,556-1, HU-210, nabilone and 
any compounds produced via specified structural derivations of these drugs as 
Class B drugs. These were placed in Schedule 1, as they had no acknowledged 
medicinal use, with the exception of nabilone, which was placed in Schedule 2 
(35). This was the first legal acknowledgement of the potential for harm of SCRAs 
by the UK Government. 
A second report to the Home Secretary from the ACMD in 2012 highlighted the 
concern at the rise in SCRAs available and their popularity, and suggested further 
legislative control (36). The compounds discussed in this report - the so-called ‘2nd 
generation’ SCRAs - included AM2201, MAM-2201, RCS-4, and UR-144. The 
outcome of this, which came into effect in 2013, was the extension of the generic 
definitions introduced to MDA in 2009, covering, among others, structural 
derivatives of:  
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 Specified naphthoylindoles, specified adamantoylindoles 3-
phenylacetylindole, and 3-benzoylindole by specified substitution at the 
nitrogen atom of the indole ring; and 
 Naphthoylpyrroles by specified substitution at the nitrogen atom of the 
pyrrole ring; 
The substitutions specified included, but were not limited to, alkyl, haloalkyl, 
alkenyl, hydroxyalkyl and cycloalkylmethyl (36). This amendment to MDA brought 
under control the likes of AM2201, RCS-4, UR-144 and MAM-2201 as Class B 
drugs. These compounds were also placed into schedule 1, as the ACMD 
concluded they had no recognized medical use (36). 
In a third report to the Home Office in 2014, on the subject of ‘3rd generation’ 
SCRAs, the ACMD acknowledged the futility in repeatedly updating MDA with 
generic definitions given the relative speed and ease with which illicit chemists can 
synthesize uncontrolled variations (37). This report compiled information from the 
Home Office Forensic Early Warning Systems (FEWS) and the Drug Early 
Warning System (DEWS) to identify the most commonly encountered SCRAs. 
Both these systems highlighted the prevalence of 5F-AKB48 and 5F-PB-22, their 
non-fluorinated analogues, AB-FUBINACA and AB-PINACA as being identified in 
products seized from ‘head shops’ (37). The legislative recommendation from this 
report proposed a change in tack intended to prevent easy circumvention from 
illicit chemists, by taking the SCRA JWH-018 as a base and splitting it into 4 
components – the ‘ring’, the ‘link’, the ‘core’ and the ‘tail’ (26, 37). Compounds 
comprising functional groups specified for each of the 4 components, along with 
named modifications or substitutions were placed under Class B of MDA in 
Schedule 1 in November 2016, with the exception of certain named therapeutic 
drugs which remained prescription-only (37). 
The repeated revision to MDA’s coverage of SCRAs is reflective of the struggle 
faced internationally against the spread of these drugs since their emergence. 
Between 2009 and 2018 cumulatively, the group of NPS drugs with the highest 
number of new compounds notified to the EMCDDA Early Warning System (EWS) 
for the first time has been SCRAs (38-40). This data is presented in Figure 4 and 
illustrates the highly novel nature of SCRA compounds. 
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Figure 4 – European Monitoring Centre for Drugs and Drug Addiction Early 
Warning System data showing numbers of cannabinoid-type Novel 
Psychoactive Substances notified for the first time by year, 2009 - 2018 (38-
41) 
  
As of 26th May 2016, any SCRAs not controlled under MDA by the previous 
amendments are potentially covered by the Psychoactive Substances Act 2016 
(PSA). This Act prohibits any compound not controlled under MDA which is 
“capable of producing a psychoactive effect” and which is not exempted from the 
Act (42). In compounds where psychoactivity has not already been established, 
this is assessed by determining whether the compound in question binds to either 
CB1, GABA, 5HT2A, NMDA, µ-opioid or MAO transporter receptors present in the 
central nervous system and, in doing so, activates the receptor and elicits a 
biological response (43). In November 2018 a House of Commons debate took 
place discussing the reclassification of SCRAs from Class B to Class A. The 
ACMD were asked, informally, to produce a report on the motion, outlining their 
recommendations, by July of the next year (44, 45). As of August 2019 no such 
report had been released, however the request highlights the continued concern 
over the dangers of SCRAs. 
Prior to the implementation of the PSA, a joint operation between Trading 
Standards Scotland (TSS), the Society of Chief Officers of Trading Standards in 
Scotland (SCOTSS) and other contributors cracked down on the sale of Novel 
Psychoactive Substances (NPS), including SCRAs, in shops in Scotland (46). 
Operation Alexander, as it was named, was based on the premise that the 
products on sale had been linked to adverse reactions, and The General Product 
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Safety Rules 2005 were therefore implemented to prohibit their sale. In total, 7,323 
products with an estimated value of £146,460 were seized, although the report 
does not specify what proportion of these were SCRAs (46). This multiagency 
operation is another example of the battle waged against SCRAs. 
Examples of the types of products seized during Operation Alexander are given in 
Figure 5. Similar products have been received by the Welsh Emerging Drugs and 
Identification of Novel Substances (WEDINOS) project (47). This is a service, run 
by Public Health Wales, whereby users can send their drugs in and have the 
contents analytically confirmed. SCRA packaging tends to be <10cm in any 
dimension (for smaller amounts), and square or rectangular in shape, with 
colourful artwork and alluring branding. They are often marked as ‘not for human 
consumption’, ‘herbal incense’, or with the ‘18’ certification symbol; and are 
available in sizes from 1g to kilogramme amounts. Prices vary based on the 
product and size, but tend to be around £10-13 for 1g, with bigger quantities 
carrying reductions per gramme (48-50). 
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Sweet Leaf Obliteration 
 
 
Cherry Bomb 
 
 
Exodus Herbal Incense 
 
 
Blueberry Blitz 
 
 
Insane Joker Limited Edition 
 
 
Exodus Damnation Herbal Incense 
Figure 5 – Examples of synthetic cannabinoid receptor agonist 
product packaging showing colourful designs © WEDINOS (47) 
 
The products generally comprise dried plant material which has the SCRA 
compound or compounds sprayed onto it with a volatile solvent, although powders 
without plant material and liquid for e-cigarettes have also been seized (1, 13, 37). 
The original SCRA products used plants which had reputations for psychoactive 
properties, such as white and blue water lily (Nymphaea alba and N. caerulea) and 
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marshmallow (Althaea officinalis) (21, 27, 33). More recently, plant materials used 
have been considered psychoactively inert, such as damiana (Turner diffusa) and 
members of the mint and thyme genera, although little is known about the 
pharmacology of smoking such material (26, 51).  
It has been reported that the typical lifecycle of an SCRA product from its initial 
appearance on the market to its decline in popularity is around 6 – 9 months (31). 
This is potentially a result of updates to the legislation, prohibiting specific 
compounds, and has contributed to the exponential rise in SCRA products 
identified by various agencies. This has also made it incredibly challenging for 
forensic chemists and toxicologists to maintain current and fit-for-purpose methods 
of analysis, not least through the lack of commercially available reference 
standards. At the time of writing (July 2019) the number of compounds under the 
cannabinoids heading in the EMCDDA European Database for New Drugs 
(EDND) is around 190, however other sources have stated the number of SCRAs 
as over 400 (51, 52). While it is understandably difficult for manufacturers of 
certified reference materials (CRMs) to produce every SCRA potentially available 
to users, it is essential that agencies are able to confirm analytically which SCRAs 
are available and involved in adverse reactions. Dissemination of information on 
prevalence and potential harms of SCRAs is undertaken internationally by 
agencies such as the United Nations Office on Drugs and Crime (UNODC) and the 
EMCDDA. Within the UK, WEDINOS, Scottish Drug Forum and the UK Focal 
Point provide invaluable information regarding drugs available to users, and user-
reported effects of these drugs. There is, however, a lack of real-time intelligence 
regarding the availability of analytically confirmed compounds in Scotland.  
WEDINOS compiles (approximately) quarterly and annual reports highlighting 
developments and the current state of the drugs market from its perspective, 
including the top 10 most identified substances. Information concerning SCRAs 
garnered from these quarterly reports, beginning in late 2013 and titled PHILTRE, 
is presented in Figure 6. From this it is clear to see the main offenders between 
2013 and 2016 are 5F-AKB48 and 5F-PB-22, and the rise of MDMB-CHMICA is 
documented from 2015. 5F-MDMB-PINACA is mentioned from the beginning of 
2016 and MMB-FUBINACA from the end of 2016.
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Figure 6 – Timeline of synthetic cannabinoid receptor agonist appearances in the WEDINOS PHILTRE bulletins (53-
66). The shifting trends from the likes of 5F-PB-22 and 5F-AKB48 in late 2013 to MDMB-CHMICA (2014), and 5F-MDMB-
PINACA and MMB-FUBINACA (both 2016) are shown. 
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1.5.1. Chemistry and Nomenclature 
SCRAs can be classed into a variety of structural groups, varying in number by 
publication. A recent publication by Presley et al. groups them - quite specifically - 
into the following 18 classes (31): 
 Naphthoylindoles e.g. JWH-018 
 Halogenated naphthoylindoles e.g. AM2201 
 Classical dibenzopyrans e.g. HU-210 
 Cyclohexylphenyls e.g. CP47,497 
 Benzoylindoles e.g. RCS-4 
 Phenylacetylindoles e.g. JHW-250 
 Tetramethylcyclopropanoylindoles e.g. XLR-11 
 Adamantoylindoles e.g. AM1248 
 Indolecarboxamides e.g. MDMB-CHMICA, APICA 
 Indazolecarboxamides e.g. AKB48, AB-FUBINACA 
 Quinolinylindolecarboxylates e.g. PB-22, BB-22 
 Naphthoylindazoles e.g. THJ-2201 
 Naphthoylindolecarboxylates e.g. NM2201 
 Naphthylindazolecarboxylates e.g. 5F-SDB-005 
 Quinolinylindazolecarboxylates e.g. 5F-NPB-22 
 Pyrazolecarboxamides e.g. AB-CHFUPYCA 
 Naphthoylbenzimidazoles e.g. FUBIMINA 
 ‘Others’ e.g. methanandamide  
A paper by Castaneto et al. groups these more broadly into 13 classes, while the 
ACMD condensed these further still into 7 classes (14, 33). It should be noted, 
though, that at the time of publication certain SCRAs representing an evolutionary 
step may not yet have been identified. The groups most relevant to this work are 
the indolecarboxamides, indazolecarboxamides, quinolinylindolecarboxylates and 
quinolinylindazolecarboxylates. 
The classifications are based on distinguishing functional groups within the 
chemical structure, i.e. the same components of the molecules referred to in the 
ACMD’s 3rd report to the Home Office, which led to the 2016 amendment to MDA 
(see section 1.5). The EMCDDA built an interactive online tool within their 
Perspectives on Drugs series which designates these groups the ‘ring’, ‘link’, ‘core’ 
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and ‘tail’, although ‘head’ - as features in the Cayman Chemicals Synthetic 
Cannabinoids Flipbook - may be a better term for ‘ring’ as some compounds do 
not feature a ring in this position (26, 67). The practical application of this process 
to MDMB-CHMICA is illustrated in Figure 7.  
Ring/Head
Link
Core
Tail
MDMB-CHMICA
 
Figure 7 – Substructures of synthetic cannabinoid receptor 
agonists as designated by the European Monitoring Centre 
for Drugs and Drug Addiction Perspectives on Drugs and 
Cayman Chemical Synthetic Cannabinoids Flipbook (26, 
67). MDMB-CHMICA is given as an example. 
 
The process of naming SCRAs is inconsistent and confusing: many go by multiple 
names, different compounds can go by very similar names, and some names are 
practically unpronounceable. The system most commonly adopted for newer 
SCRAs is based on abbreviating the IUPAC systematic name for the compound 
and rearranging the abbreviations into the order head-tail-core-link. Although it is 
unclear where this system derived from, and its application is not universal, it does 
provide structural information on the compound to which it refers. Two examples 
are given using the IUPAC names for MDMB-CHMICA and AB-FUBINACA, shown 
below, and rearranging the abbreviated capital letters into the head-tail-core-link 
sequence. The coloured letters correspond to the colouring of the functional 
groups in Figure 7. 
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Methyl (S)-2-(1-(CycloHexylMethyl)-1H-Indole-3-CarboxAmido) -3,3-
DiMethylButanoate 
MDMB-CHMICA 
N-[(1S)-1-(AminocarBonyl)-2-methylpropyl]-1-[(4-FlUorophenyl)methyl]-1H-
INdAzole-3-CarboxAmide 
AB-FUBINACA 
While the process is relatively straightforward for deriving the name of MDMB-
CHMICA, with the exception of the split in the head component name, it is not 
entirely comprehensive for AB-FUBINACA. Firstly, the first and third letters of the 
tail component, and the first, second and fourth letters of the core group are used 
as abbreviations, which is not entirely intuitive. A ‘b’ also appears in ‘FUBINACA’ 
which does not appear in the IUPAC name. It is not clear whether this arose as a 
requirement to make the name pronounceable or whether this refers to the 
benzene ring the fluorine atom is attached to. These are, however, idiosyncrasies 
that are consistent throughout the process and appear in other compounds, 
allowing the process to be learned and understood.  
It appears that this naming process was brought into use after some SCRAs 
already had widely known names. As a result of this some drugs are known by 
several aliases. For example, the compound designated the name APINACA by 
the above process was originally called AKB48, seemingly after a Japanese girl 
band. When this compound went on to be halogenated at the 5’ position on the 
pentyl chain, both names were simply prefixed by ‘5F’, rather than completely 
renaming them. This is not necessarily the case with all compounds though, as 
5F-APICA is also known as STS-135 (named after the US space shuttle 
programme). 
As well as potential confusion surrounding SCRA naming, the structural 
components can cause issues in the interpretation of mass spectra originating 
from SCRAs. Certain functional groups are observed frequently in different 
compounds, for example the adamantyl group appears in the head position for 
AKB48, APICA and AM1248; the quinolinyl group appears in the head position for 
PB-22 and BB-22; and the indole group appears in the core position for APICA, 
MDMB-CHMICA and AM2201. Fragmentation within SCRAs in the mass 
spectrometer tends to occur in analogous positions, so if the formula weight of 
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different compounds is the same or similar (in the absence of suitable resolution) 
and they contain the same functional group, the same or similar ion transitions can 
result. In these circumstances, resolution must be provided by the 
chromatographic system or by way of High Resolution Mass Spectrometry 
(HRMS).  
1.5.2. Pharmacology 
Generally, the pharmacology of SCRAs is poorly understood: there is a lack of 
clinical studies, on mostly ethical grounds, and much conjecture is based on the 
pharmacology of Δ9-THC and other phytocannabinoids. Reports from receptor 
binding and animal studies for specific compounds are emerging, but the number 
of SCRAs means the full picture of their pharmacology remains incomplete.  
SCRAs are mostly smoked in rolled-up joints either with cannabis, tobacco or 
alone, or inhaled via e-cigarette vapourisers, however they are reported to have 
been snorted and ingested orally as well (1, 3, 9, 13, 25, 37, 68-70). Onset of 
action is not well documented in published literature, but reports from user forums 
indicate psychoactive and physiological effects are felt almost immediately after 
inhalation (9, 69, 70). Effects can last from around 45 min. to several days, 
although it is unclear the role active metabolites or co-administered substances 
play in the duration of action (9, 23, 69, 71, 72).  
Once administered, SCRAs distribute rapidly into brain and fat tissues due to their 
lipophilicity (73, 74). This results in blood concentrations of parent compounds 
being relatively low, even shortly after administration.  
SCRAs, by definition, then act on the CB1 and/or CB2 receptors. Four papers 
investigating the pharmacology of, among others, APICA (75); AM2201, PB-22, 
5F-PB-22, APICA and STS-135 (76); AB-FUBINACA, AB-PINACA and 5F-AB-
PINACA (8); and MMB2201, 5F-MDMB-PINACA, MDMB-CHMICA and MDMB-
CHMINACA (77) found that all were significantly more potent at both CB1 and CB2 
receptors than Δ9-THC. With the exception of APICA and STS-135, all relevant 
compounds were more potent at CB1 than CB2. When looking at the effect of 
terminal fluorination on a SCRA potency between PB-22/5F-PB-22 and 
APICA/STS-135, a 2-3-times increase at both CB1 and CB2 receptors was 
observed in fluorinated analogues (76). Similarly, indazole-substituted forms of 
indole-core SCRAs (AB-FUBINACA/AB-FUBICA, AB-PINACA/AB-PICA and 5F-
  18 
AB-PINACA/5F-AB-PICA) showed an increase in CB1 and CB2 potency (8). 
Interestingly, when the indole core was substituted for indazole in MDMB-
CHMICA, to form MDMB-CHMINACA, a decrease of potency was observed at the 
CB2 receptor only, with no change at CB1 (77). The potencies, in effective 
concentration (EC), and CB1 selectivities of selected SCRAs with Δ9-THC for 
reference are given in Table 2. 
 
Table 2 – Potencies at CB1 and CB2 receptors and CB1 selectivities of 
selected Synthetic Cannabinoid Receptor Agonists with Δ9-
tetrahydrocannabinol for reference 
Compound 
CB1 potency 
(EC50, nM) 
CB2 potency 
(EC50, nM) 
CB1 
selectivity* 
Reference 
Δ9-THC 250 1157 4.6 (76) 
AM2201 38 58 1.5 (76) 
APICA 128 29 0.2 (76) 
STS-135 51 13 0.3 (76) 
PB-22 5.1 37 7.3 (76) 
5F-PB-22 2.8 11 3.9 (76) 
AB-PINACA 1.2 2.5 2.1 (8) 
5F-AB-PINACA 0.48 2.6 5.4 (8) 
5F-MDMB-PINACA 0.59 7.5 12.7 (77) 
MDMB-CHMICA 10 71 7.1 (77) 
MDMB-CHMINACA 10 128 12.8 (77) 
AB-FUBINACA 1.8 3.2 1.8 (8) 
MMB2201 2.4 4.6 1.9 (77) 
* Ratio of CB2 potency to CB1 potency. 
Doses of 0.3 – 3.0 mg/kg of AB-FUBINACA and AB-PINACA lead to significant 
hypothermic responses in male rats, with AB-FUBINACA producing a more 
substantial (>2 °C decrease) and enduring (ca. 4 h) effect than AB-PINACA (>1.5 
°C decrease, lasting ca. 2 h) (8). For AM2201, PB-22 and 5F-PB-22, significant 
hypothermic responses (>1.5 °C decrease) resulted from doses of 3 mg/kg, while 
no such response was observed for APICA and STS-135 until a dose of 10 mg/kg 
was administered (76).  
Doses ranging from 0.1 – 3.0 mg/kg of AB-FUBINACA, AB-PINACA, AM2201, PB-
22, 5F-PB-22, APICA and STS-135 elicited significant decreases in heart rate in 
rats (8, 76). 
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Canazza et al. investigated the pharmacodynamics of AKB48 and 5F-AKB48 on 
mice (78). The study found that a 6 mg/kg dose of AKB48 induced convulsions in 
30%; hyperreflexia in 25%; myoclonias in 45%; and spontaneous and induced 
aggressiveness in 50% and 70% respectively of treated animals (78). 5F-AKB48 
administered in 3 and 6 mg/kg doses induced convulsions in 30% and 90%, 
hyperreflexia in 30 and 75%; and myoclonias in 90 and 100% of treated animals 
respectively. A 6 mg/kg dose of 5F-AKB48 induced both spontaneous and 
stimulated aggressive behavior in 100% of treated animals (78). Effects of these 
SCRAs on core and surface body temperatures were also studied: the 
administration of either AKB48 or its fluorinated analogue led to reductions in body 
temperature, with “prolonged and significant” effects observed from AKB48 at 6 
mg/kg and 5F-AKB48 at 3 and 6 mg/kg (78). Additionally, it was observed that 
both drugs provided analgesia during pain-inducement experiments, with even low 
doses (0.01 mg/kg) being effective for 5F-AKB48 in tail-pinch tests. Doses of 6 
mg/kg provided increased pain threshold during equivalent thermal stimulus tests 
(78).  
Research conducted by De Luca et al. studied the effects of 5F-AKB48, 5F-PB-22, 
BB-22 and STS-135 on rat and mouse brain and found that all were full and potent 
agonists exhibiting high affinity at the CB1 receptors (79). Their results indicated 
that all 4 SCRAs activate G-protein receptors coupled with CB1 and stimulate 
dopamine transmission. This latter activity, the authors suggested, could equate to 
potential abuse, through the dopamine-associated reward pathway (79).  
After administration, SCRAs are sequestered in fat (due to high lipophilicity) and 
metabolised rapidly (73, 74). From the limited information available, there appears 
to be great variation in the half-lives (t1/2) of SCRAs. Castaneto et al. reported the 
t1/2 of CP55,940 to be 8 H, WIN55,212-2 to be 7.2 min, and STS-135 to be 3.1 min. 
in dog, guinea pigs and in vitro (human hepatocytes and human liver microsomes 
(HLM)) respectively (74). The metabolism of SCRAs has been more widely 
studied, and processes such as oxidative defluorination; mono-, di- and tri-
hydroxylation; carboxylation; hydrolysis; carboxylic acid and ketone formation and 
glucuronidation have been identified, controlled by a variety of hepatic enzymes 
(31, 68, 74, 80-86). Resulting metabolites are numerous, differ in abundance, and 
are often shared between similar compounds leading to complications in 
interpretation (84, 87, 88).  
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Generally speaking, due to high potency and low active dose, SCRAs tend to be 
present at lower concentrations than many other, more ‘traditional’ drugs of abuse 
in biological matrices. Parents and metabolites can be detected in blood, serum or 
plasma at concentrations ranging from fractions of a nanogramme to tens of 
nanogrammes per millilitre (71, 72, 89-93). Concentrations in urine tend to be 
quantified less frequently than in whole blood or blood products. This is likely 
because urinary concentrations suffer more from inter-individual difference and 
cannot be correlated to physiological effects. Where concentrations in urine are 
reported, these tend to be higher than blood for metabolites, with parent 
compounds not detected as often (94, 95). 
Hasegawa et al. reported the concentrations of MAB-CHMINACA in various body 
tissues and found urine (not-detected) < femoral blood < skeletal muscle < 
stomach contents ≈ heart blood < pericardial fluid < spleen ≈ adipose tissue < 
brain < lung < heart muscle < pancreas < kidney << liver (89).  
The potency of metabolites varies, with at least some retaining significant activity 
(85, 96-98). Gamage et al. reported a decrease in affinity and an increase in 
selectivity for CB2 over CB1 in hydroxypentyl metabolites of AB-PINACA, 5F-AB-
PINACA, MDMB-PINACA, 5F-MDMB-PINACA, 5F-CUMYL-PINACA, AMB-
PINACA, 5F-MMB-PINACA, AKB48, and 5F-AKB48 (97). Hutchison et al. also 
found that full agonist activity remained in the 4- and 5-hydroxy pentyl metabolites 
of AB-PINACA (96). 
1.5.3. Prevalence and Risk of Harm 
The nature and scale of drug use in the general population is difficult to quantify. 
For this reason, prevalence studies often focus on defined sub-populations such 
as school-age individuals, individuals in prison, or individuals seeking or receiving 
treatment for substance misuse.  
The Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) 
receives questionnaire answers from secondary school pupils in local authority 
and independent schools on a variety of smoking and drug use habits (99). The 
2015 report identified cannabis as the most commonly used drug by 15 year-old 
Scots, with 10% having used this drug in the last month and 17% having used it in 
their lifetime (99). In comparison, only 2% of 15 year olds had used “legal highs” in 
the last month and 5% in their lifetime, although no further information is available 
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on the specific type of substance used (99). It is important to consider the 
terminology used in the questionnaire and what respondents would think of as 
included in the term “legal highs”. A question relating specifically to SCRA use was 
included in the 2013 survey, when 2% of respondents reported having used an 
SCRA in their lifetime (100). (In this instance the term used was “synthetic 
cannabis” and the most common product names were given as examples.)  
Vulnerable groups were targeted for survey completion in another study reported 
to the Scottish Government by MacLeod et al in 2016. This cohort was comprised 
of vulnerable young people (defined as children who are ‘looked after’ by a social 
work system, or accommodated, care leavers, young homeless, and/or those not 
in education, employment or training), people in contact with mental health 
services, people affected by homelessness, people who inject drugs, and men 
who have sex with men (101). Of 424 respondents to the survey, 252 (59%) said 
they had ever used NPS, 185 (74%) within the last month. SCRAs were the most 
commonly used NPS, with 104 respondents (41%) reporting use (101). 
Cannabis was found to be the most commonly used drug in the Crime Survey 
England and Wales (CSEW) in 2017 – 2018, with 7.2% of individuals aged 16 – 59 
having used it within the last year. This increased to 16.7% for younger adults (16 
– 24 years old) (102). The same report stated that last year NPS use was 0.4% 
and 1.2% for 16 – 59 year olds and 16 – 24 year olds respectively (102). Of those 
who had used NPS in the last year, 33% of both age ranges said they had used a 
“herbal smoking mixture”, indicating an SCRA was the substance used (102). 
Questions relating specifically to ‘Spice’ and other SCRAs have not been included 
in the study since 2011 – 2012, when prevalence of these drugs was reported at 
0.1% (100). 
Conducted in Northern Ireland, The Young Persons’ Behaviour and Attitudes 
Survey (YPBAS) asked about SCRAs in the 2015 campaign, with 0.7% of 
respondents reporting having ever used a compound of this type (100).  
The use of SCRAs appears to be much more significant in prisons. A 2015 report 
on substance misuse by Her Majesty’s Inspectorate of Prisons (HMIP) found that 
6% of prisoners had used SCRAs in the 2 months prior to being incarcerated. This 
number rose to 10% when prisoners were asked whether they had used SCRAs 
since being in prison (103). In a study by User Voice, 33% of prisoners questioned 
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had used ‘Spice’ in the last month, and of them almost 46% reported ‘almost daily’ 
use (104).  
In terms of drugs seized en route to prisons, SCRAs were detected in 39% of 
seizures made across 10 establishments in North West England in 2017 (105). 
Within these, 5F-AKB48 and 5F-PB-22 were the most commonly identified 
compounds, present in 29% and 24% of all seizures respectively (105). 
The results of the 2012 Global Drug Survey determined that 16.8% of almost 
15000 respondents had used SCRAs in their lifetime with 40.6% of these 
individuals having used them in the last month (51). Twenty-three respondents 
had sought emergency medical treatment after SCRA use, reporting symptoms 
such as panic and anxiety, paranoia, breathing difficulties, visual and auditory 
hallucinations, and extreme agitation (51). A follow up study was conducted and 
compared the relative risk of harm of SCRAs and cannabis, taking into account the 
number of days of use of both compounds (106). It was calculated that individuals 
who had used SCRAs in the last year had, on average, a 30-fold increased 
chance of seeking emergency medical treatment than the corresponding cannabis 
user group (106). Symptoms associated with SCRA use were similar to those 
reported in the 2012 survey, with cannabis users tending to report more physical 
than psychological symptoms and the converse true for SCRAs (106). 
NEPTUNE is an initiative funded by the charity Health Foundation which aims to 
provide clinical guidance for the treatment of harms associated with the use of club 
drugs and NPS (107). A report was produced through the NEPTUNE network 
relating to the harms associated with SCRAs and best practice for managing these 
in a clinical setting (108). This highlights the variation in SCRA compounds and 
consequently the symptoms that may result from their use. Symptoms of acute 
toxicity are categorised into neurological, cognitive and psychiatric, cardiovascular, 
renal, and other effects including both hyper- and hypo-glycaemia and serotonin 
syndrome (108). As no antidote is available for SCRA toxicity, supportive and 
symptom-based care is recommended. Administration of benzodiazepines and 
antipsychotic medication such as quetiapine has been effective in treating 
symptoms of acute SCRA toxicity (23, 108, 109).  
Tolerance to SCRAs has been reported both on practical (110, 111) and 
pharmacological (112) levels. Rubino et al. identified a decrease in cannabinoid 
receptor activated G-proteins in the brains of rats treated chronically with the 
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SCRA CP55,940, indicating desensitization and tolerance to the drug (112). In 
real-world terms, this is expressed as escalating use relating to amount of drug 
used and frequency of consumption (110, 111).  
Symptoms of withdrawal on discontinuing use of SCRAs have been reported (98, 
109, 110, 113). In a cohort of 47 individuals using a medical detoxification service 
in New Zealand, 41 reported withdrawal symptoms (113). These included mood 
swings (73%), anxiety (71%), and nausea and loss of appetite (12%) (113). More 
chronic issues such as disturbed sleep, problems in personal relationships and 
employment were also reported in this study (113). Treatment of withdrawal 
symptoms is similar to that for acute toxicity, with benzodiazepines and quetiapine 
having been used with some success (109). 
In Scotland in 2018, there was 1 incidence where SCRAs appeared on the death 
certificate as implicated in, or potentially causing the death of an individual (114). 
By comparison, the numbers for methadone, etizolam and cocaine are 564, 551 
and 278 respectively (114). By this measure SCRAs cause relatively little harm, 
however harmful effects on the individual’s general health and quality of life, family 
and dependents and society on the whole should be considered along with this. 
Social harms are more challenging to measure and little information is available on 
SCRAs in this respect.  
1.5.4. Analysis in Biological Matrices 
As discussed previously, SCRAs and their metabolites are present in biological 
matrices in low, often sub-nanogramme per mililitre, concentrations, and many 
have similar structures. For these reasons it is important that the instrumentation 
used to detect and quantify these drugs is sensitive and specific. 
The most widely-used analytical instruments in forensic toxicology are Gas 
Chromatography-Mass Spectrometry (GC-MS) and Liquid Chromatography-Mass 
Spectrometry (LC-MS). GC-MS tends to be used for compounds which are of 
relatively low molecular mass, basic in chemical nature, and are thermally labile. 
SCRAs are generally neutral-to-acidic in chemical nature and are of higher 
molecular mass than compounds associated with GC-MS analysis. LC-MS 
analysis, and specifically LC-MS/MS analysis, has the potential to provide 
sensitive and specific detection and quantitation for SCRA compounds in 
biological matrices. 
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LC-MS/MS (Figure 8) involves a mixture of compounds, for example an extracted 
blood sample, being separated by an analytical column before being drawn into a 
series of charged channels which filter specific components to be quantified by a 
detector.  
 
Figure 8 – Schematic representation of a Liquid Chromatography – tandem 
Mass Spectrometry (LC-MS/MS) system 
 
An aliquot of the extract is injected into a mixture of aqueous and solvent liquids 
(the mobile phase; MP) which carries it, at high pressure, into the analytical 
column. The analytical column is packed with sorbent particles (the stationary 
phase; SP) with chemical qualities selected specifically for the application. For 
SCRAs, for example, the column packing might be C18 chains. The analytes of 
interest interact with the SP to differing degrees, such that different analytes spend 
different lengths of time in the analytical column. The time spent retained on the 
analytical column (the retention time, tR) is characteristic of the compound, and 
can be specific for each compound in a certain chromatographic system. Once 
F
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elution from the column has taken place, the – now separated – components enter 
the mass spectrometer (MS).  
The first stage of mass spectrometric analysis is desolvation. The eluted 
component has come straight from the LC system and is consequently still 
enclosed within droplets of MP. In order to remove the MP, heat and nebulizer gas 
(nitrogen) are applied to the droplets. Once the component has been isolated from 
the MP, it is ionized in the ion source of the MS through application of an ionspray 
voltage to the capillary connecting the LC and the MS. This converts the neutral 
particles eluting from the LC into charged ions, the path of which can then be 
dictated through the use of applied voltages. The declustering potential (DP) is 
applied to the orifice plate, which the ions pass through to enter the MS. This 
prevents ions from forming adducts with other compounds, such as sodium. The 
entrance potential (EP) is applied to Q0 and is set at a voltage to guide the ions of 
interest through the aperture of the quadrupoles into the collision cell. The collision 
cell entrance potential (CEP) focuses the ions of interest into the collision cell and 
is mass-dependant. Once in the collision cell, the ions are fragmented by collision 
with nitrogen (the collision gas) and the application of collision energy (CE). The 
higher the CE, the more the precursor ion is fragmented and this can be optimised 
to give the best sensitivity and selectivity. For example, a CE can be selected that 
provides a high response for a fragment characteristic for one compound, and 
avoids the production of fragments common between other compounds included in 
the method. The amount of time the instrument spends applying the CE to each 
selected ion transition is termed the dwell time (DT). The route out of the collision 
cell is controlled by the collision cell exit potential (CXP). This focuses and 
accelerates the fragments of interest out of the collision cell, through Q3, and 
towards the detector. In summary, precursor ions are selected and filtered in Q0, 
fragmented into selected product ions in the collision cell, and product ions are 
filtered to the detector through Q3. The voltages at each section of the MS are 
automatically optimised by the instrument when compound optimisation is 
conducted. 
In this work, an AB Sciex 3200 QTrap MS system was used, which employed the 
QTrap apparatus as the collision cell. 
LC-MS/MS has been widely used for the analysis of SCRAs in biological matrices. 
Huppertz et al. (115) and Kneisel and Auwärter (30) developed methods for the 
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detection of SCRAs in blood with limits of detection (LODs) ranging from 0.1 – 0.5 
ng/mL and 0.1 – 2.0 ng/mL respectively. Method of analysis in whole blood were 
developed by Knittel et al. (116), Ambroziak and Adamowicz (117), Hess et al. 
(118) and Kacinko et al. (119), with LODs ranging from 0.025 – 0.1 ng/mL, 0.01 – 
0.48 ng/mL, 0.01 – 8.2 ng/mL and 0.006 – 0.016 ng/mL respectively. Knittel et al. 
(116), Borg, Tverdovsky and Stripp (120), Jang et al. (121), Gaunitz et al. (122) 
and Staeheli et al. (123) developed method of analysis in urine. LODs in these 
methods were 0.5 ng/mL, 0.01 – 0.5 ng/mL, 0.01 – 1 ng/mL, 0.025 – 0.5 ng/mL 
and 0.05 – 2.5 ng/mL respectively. 
Analytical methods have been also been reported for alternative matrices such as 
hair (124-126) and oral fluid (127). 
While LC-MS/MS can provide the necessary sensitivity and selectivity required for 
detection and quantitation of SCRAs, consideration must also be made into the 
most appropriate extraction techniques.  
Many researchers have employed liquid-liquid extraction (LLE), potentially due to 
the varied structures of SCRAs and the relatively non-specific nature of the 
extraction technique.  
LLE manipulates the solubilities of compounds in polar and non-polar solvents to 
concentrate analytes of interest and enable their separation from impurities such 
as proteins. Generally, the polar solvent used is an aqueous buffer at a pH that 
controls the degree of ionisation of acidic or basic analytes, while the non-polar 
solvent is one in which the analytes of interest have good solubility. The theory is 
that, upon mixing and centrifugation, the analytes of interest migrate into the non-
polar solvent which is separated and retained, while the unwanted impurities 
remain in the aqueous solvent and can be discarded. This is true for SCRA 
metabolites, which tend to be acidic in nature. Parent SCRAs, however, are 
neutral molecules. During LLE of these, the manipulation of the pH – and therefore 
degree of ionisation – of the aqueous phase rather than molecules themselves 
means the neutral compounds are preferentially compartmentalised into the non-
polar solvent. The non-polar solvent containing the analytes of interest can then be 
directly injected into the analytical instrumentation, diluted prior to injection, or 
evaporated and reconstituted into a solvent system more suitable for instrumental 
analysis. 
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Kneisel and Auwärter (30), Huppertz et al. (115), Knittel et al. (116), and Hess et 
al. (118) have all applied LLE with a basic buffer (pH 9.3 or 10 carbonate buffer) 
and n-hexane:ethyl acetate (99:1) solvent system to whole blood or serum. Knittel 
et al. (116) also employed LLE to urine samples, using a phosphate buffer of pH 
6.8 and 50:2 mixture of chlorobutane:hydrochloric acid. Staeheli et al. conducted 
LLE on urine using sodium acetate buffer (1M, pH5) and ACN with ammonium 
acetate (123). Kacinko et al. (119) applied to whole blood, an LLE method with the 
same solvent system as previously described for serum, but using saturated 
solutions of sodium bicarbonate and sodium chloride as the aqueous phase. The 
limits of detection in these methods ranged from 0.01 – 2.0 ng/mL indicating 
sufficient efficiency of extraction by LLE protocols using a variety of solvent 
systems. 
Protein precipitation (PP) is another broad extraction technique. This is similar to 
LLE but no aqueous component is used: non-polar solvent is added to the sample 
and these are then mixed and centrifuged. The analytes of interest are in the 
solvent layer while proteins and other unwanted impurities are compacted in the 
pellet. The solvent can then be treated as with LLE prior to injection into the 
instrument. 
Ambroziak and Adamowicz (117) applied a PP method using acetonitrile (ACN) as 
the solvent to whole blood samples.  
Supported Liquid Extraction (SLE) is similar to LLE in that polar and non-polar 
solvents are used to extract the compounds of interest. In SLE, though, a porous 
material is contained within a plastic cartridge to provide a high-surface area 
support on which extraction can occur. Disadvantages associated with this 
extraction type are the financial and environmental costs of the SLE cartridges, 
and the requirement for vacuum manifolds. 
Scheidweiler, Jarvis and Huestis (95) employed SLE in their method for the 
detection of SCRAs in urine.  
Solid Phase Extraction (SPE) is used less frequently with SCRAs, as it is quite 
specific for the compounds it separates from the biological matrix. In SPE, the – 
usually buffered – sample is passed through a column containing a porous 
polymer with certain physicochemical properties among a series of aqueous and 
non-polar solvents. The pH and ionisation of the analytes of interest are 
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manipulated by the solvents so they are retained on the polymer, until an elution 
solvent rinses them into a collection vial. As well as the disadvantages associated 
with SLE, SPE is relatively time consuming. Jang et al. (121) and Gaunitz et al. 
(122) did, however, apply this extraction technique to urine samples.  
As described previously, SCRAs can form glucuronidated metabolites which are 
eliminated in the urine. For this reason it is necessary to conduct hydrolysis prior 
to the extraction of urine samples, if glucuronidated reference standards are not 
being used. Many researchers employ the hydrolyzing activity of the β-
glucuronidase enzyme in SCRA urinalysis. Knittel et al. (116) used 20 µL of β-
glucuronidase from Escherichia coli (1250 units) per 2 mL of urine, and incubated 
the samples at 55 °C for 20 min prior to extraction. Jang et al. (121) used 40 µL of 
β-glucuronidase from Helix pomatia (ca. 10000 units) per 100 µL urine, and 
incubated at 60 °C for 1 H before extracting. Staeheli et al. also used β-
glucuronidase from Helix pomatia, employing 25 µL (2500 units) per 250 µL urine, 
and incubating at 60 °C for 1 H prior to extraction (123). Borg, Tverdovsky and 
Stripp (120) and Scheidweiler, Jarvis and Huestis. (95) both used β-glucuronidase 
from abalone, 50 µL (1250 units) and 40 µL (625 units) respectively. The former 
incubated at 56 °C for 45 min., and the latter 55 °C for 1 H prior to extracting the 
samples.  
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2. Aims and Objectives 
The overall aim of this project was to evaluate the scale and nature of the use of 
SCRAs in the Scottish population. In order to do so, the following objectives were 
set: 
1. To identify the most commonly encountered drugs and their most abundant 
metabolites and to develop and validate analytical methods for the 
detection and quantitation of these compounds in whole blood and urine.  
2. To apply these methods to blood and/or urine samples collected from a 
variety of different Scottish sub-populations, namely: 
a. Individuals undergoing treatment in an Emergency Department (ED) 
for suspected Novel Psychoactive Substances intoxication; 
b. Individuals undergoing admission to and liberation from Scottish 
Prison Service (SPS) facilities; 
c. Individuals receiving treatment from the National Health Service 
(NHS) Forensic Directorate (FD) in the Greater Glasgow and Clyde 
(GGC) region, for psychiatric illness with substance misuse co-
morbidities; 
d. Individuals under the jurisdiction of the Glasgow Drug Court (GDC), 
who have agreed to comply with drug abstinence and treatment in 
place of a custodial sentence for offending behaviour; and 
e. Deceased individuals undergoing post-mortem (PM) examination in 
East, West and North Fiscal Regions of Scotland, where SCRA use 
is either suggested by case circumstances or specifically requested 
by the pathologist. 
3. To collect demographic information, where possible, to determine the sub-
populations where SCRA use may be more prevalent. 
It was hypothesised that SCRA use would be generally low, particularly when 
compared to prevalence of traditional drugs of abuse. SCRA use was expected in 
SPS, FD and GDC cohorts due to their tendency to go undetected in current 
Mandatory Drug Tests and the requirement for observed drug abstinence in these 
participants. Higher rates of SCRA detection were expected in ED and PM cohorts 
as the samples underwent analysis because of the suspicion of their use by these 
participants.  
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3. Development and Validation of a Method for the Detection and 
Quantitation of MDMB-CHMICA in Blood 
3.1. Introduction 
On the 25th April 2015 an alert was issued by the EMCDDA European Union Early 
Warning System warning of 2 deaths and 3 non-fatal intoxications in Germany 
resulting from ingestion of MDMB-CHMICA (128). These events took place 
between September 2014 and January 2015 and in all cases the products 
ingested were found to contain MDMB-CHMICA, although this drug was only 
analytically confirmed in biological samples from one case. The drug products 
consumed in these cases were listed as AK47 Loaded, Manga Hot, Cloud 9 
Second Generation Mad Hatters Incense, and Black Diamond. Causes of death in 
the fatal cases were recorded as suffocation after aspiration of gastric contents 
under ethanol intoxication and probable methadone intoxication. Symptoms of 
suspected MDMB-CHMICA toxicity in the non-fatal intoxications included tremor, 
unresponsiveness, cramping seizures, ‘permanent’ vomiting, severe motor 
impairment, and slurred speech.  
On the 30th of June the same year a similar alert was issued by the Welsh 
Emerging Drugs and Identification of Novel Substances (WEDINOS) Project, 
containing details of an adverse reaction in North Wales following ingestion of 
what was – erroneously – referred to as ‘MMB-CHMINACA aka MDMD-CHMICA’ 
(129). A young male had inhaled 2 or 3 times from a rolled cigarette confirmed to 
contain MDMB-CHMICA and had been hospitalised overnight suffering from 
dizziness, shortness of breath, nausea, chest pains, irregular heart beat and 
convulsions. In addition to the German cases detailed within the EMCDDA EU 
EWS alert, further reports of deaths and adverse reactions were given within the 
WEDINOS alert. These included 4 deaths and 6 non-fatal intoxications in Sweden 
and 7 non-fatal intoxications in Austria. The specific product suspected of causing 
the adverse event in Wales was not provided, but products confirmed by 
WEDINOS to contain MDMB-CHMICA were given as Sweet Leaf Obliteration, 
SKYHIGH and Vertex Pirate Edition.  
The following month, Issue 2 of the Police Scotland Drug Trend Monitoring Bulletin 
reprinted the WEDINOS alert alongside details of a similar adverse reaction in an 
individual following ingestion of Sweet Leaf Obliteration in Glasgow (130).  
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Due to the significant concern surrounding this drug, it was important to develop 
and validate a method to accurately identify and quantify this drug in whole blood. 
3.2. Aims and Objectives 
The aim of this work was to develop and validate a LC-MS/MS method suitable for 
the accurate identification and quantitation of MDMB-CHMICA in whole blood. 
The objectives were two-fold: 
 To implement a simple extraction technique coupled to a targeted 
LC-MS/MS method; 
 To validate this to ensure its fitness-for-purpose as an accurate 
quantitative method. 
3.3. Materials 
MDMB-CHMICA (crystalline solid, >98% purity) was purchased from Chiron 
(Trondheim, Norway) and JWH-200-d5 (100 µg/mL solution in ACN) was 
purchased from LGC Standards (Teddington, UK). Phosphate buffer (pH 6, 0.1M) 
was prepared in-house from disodium hydrogen orthophosphate anhydrous and 
sodium dihydrogen orthophosphate dehydrate from Fisher Scientific 
(Loughborough, UK) and deionised water produced from a Purite (Thame, UK) 
deionised water system. Tertiary methyl butyl ether (tBME), formic acid, sodium 
chloride and ammonium acetate were purchased from Sigma Aldrich (Gillingham, 
UK). Methanol (MeOH) and acetonitrile (ACN), both HPLC grade, and formic acid 
were obtained from VWR (Lutterworth, Leicestershire, UK). Blood products were 
purchased from the Scottish National Blood Transfusion Service (SNBTS) based 
at Gartnavel Hospital (Glasgow, UK).  
3.3.1. Solutions 
3.3.1.1. 2M Ammonium acetate 
15.4 g of ammonium acetate was weighed accurately into a 100 mL volumetric 
flask and made up to volume with deionised H2O. The flask was inverted several 
times before transferring the contents to a reagent bottle and storing at RT for up 
to 6 months. 
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3.3.1.2. MeOH with 0.1% Formic Acid and 2mM Ammonium Acetate 
1 mL of concentrated formic acid and 1 mL of 2M ammonium acetate were added 
to 1 L of MeOH. This was inverted several times and sonicated at room 
temperature for 15 min. This was stored at RT for up to 3 months. 
3.3.1.3. H2O with 0.1% Formic Acid and 2mM Ammonium Acetate 
1 mL of concentrated formic acid and 1 mL of 2M ammonium acetate were added 
to 1 L of deionised H2O. This was inverted several times and sonicated at RT for 
15 min. This was stored at RT for up to 3 months. 
3.3.1.4. 50:50 MeOH:H2O 0.1% Formic Acid and 2mM Ammonium 
Acetate (Infusion Solution) 
1 mL of concentrated formic acid and 1 mL of 2M ammonium acetate were added 
to a mixture of 500 mL of deionised H2O and 500 mL of MeOH. This was inverted 
several times and stored at RT for up to 3 months. 
3.3.1.5. 100 µg/mL MDMB-CHMICA solution  
500 µL of a 1 mg/mL MDMB-CHMICA solution were added to ACN in a 5 mL 
volumetric flask and made up to volume with ACN. This was inverted several 
times, transferred to a reagent bottle and stored in the freezer (≤-20 °C) for up to 
12 months. 
3.3.1.6. 10 µg/mL MDMB-CHMICA solution 
500 µL of a 100 µg/mL MDMB-CHMICA solution were added to ACN in a 5 mL 
volumetric flask and made up to volume with ACN. This was inverted several 
times, transferred to a reagent bottle and stored in the freezer for up to 6 months. 
3.3.1.7. 1 µg/mL MDMB-CHMICA solution 
500 µL of a 10 µg/mL MDMB-CHMICA solution were added to ACN in a 5 mL 
volumetric flask and made up to volume with ACN. This was inverted several 
times, transferred to a reagent bottle and stored in the freezer for up to 6 months. 
3.3.1.8. 100 ng/mL MDMB-CHMICA solution 
500 µL of a 1 µg/mL MDMB-CHMICA solution were added to ACN in a 5 mL 
volumetric flask and made up to volume with ACN. This was inverted several 
times, transferred to a reagent bottle and stored in the freezer for up to 6 months. 
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3.3.1.9. 1 µg/mL MDMB-CHMICA in 50:50 MeOH:H2O 0.1% Formic 
Acid and 2mM Ammonium Acetate 
3 µL of a 1 mg/mL MDMB-CHMICA solution were added to 3 mL of infusion 
solution. The remainder of this solution was discarded after use. 
3.3.1.10. 10 µg/mL JWH-200-d5 solution 
500 µL of a 100 µg/mL JWH-200-d5 solution were added to ACN in a 5 mL 
volumetric flask and made up to volume with ACN. This was inverted several 
times, transferred to a reagent bottle and stored in the freezer for up to 12 months. 
3.3.1.11. 1 µg/mL JWH-200-d5 solution 
500 µL of a 10 µg/mL JWH-200-d5 solution were added to ACN in a 5 mL 
volumetric flask and made up to volume with ACN. This was inverted several 
times, transferred to a reagent bottle and stored in the freezer for up to 6 months. 
3.3.1.12. 100 ng/mL JWH-200-d5 solution 
500 µL of a 1 µg/mL JWH-200-d5 solution were added to ACN in a 5 mL volumetric 
flask and made up to volume with ACN. This was inverted several times, 
transferred to a reagent bottle and stored in the freezer for up to 6 months. 
3.3.1.13. 1 µg/mL JWH-200-d5 in 50:50 MeOH:H2O 0.1% Formic Acid 
and 2mM Ammonium Acetate 
300 µL of a 10 µg/mL JWH-200-d5 solution were added to 2.7 mL of infusion 
solution. The remainder of this solution was discarded after use. 
3.3.1.14. 0.1M pH6.0 phosphate buffer 
1.7 g of disodium hydrogen orthophosphate anhydrous were weighed out and 
added to a 1 L beaker. 12.14 g of sodium dihydrogen orthophosphate 
monohydrate were weighed and added to the same 1 L beaker. Ca. 800 mL 
deionised H2O were added to the beaker and the pH of the resulting solution was 
adjusted to pH6.0 with 0.1 M dibasic sodium phosphate (to increase pH) or 0.1 M 
monobasic sodium phosphate (to decrease pH). The solution was then transferred 
to a 1 L volumetric flask and made to volume with deionised H2O. This was 
inverted several times and transferred to a reagent bottle. This was stored at RT 
for up to 3 months. 
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3.3.1.15. 1% Saline Solution 
9.5 g of sodium chloride were transferred to a 1 L volumetric flask and made to 
volume with deionised H2O. This was inverted several times, transferred to a 
reagent bottle and stored at RT for up to 6 months. 
3.3.1.16. Blank Blood 
Expired packed red cells (whole blood with the plasma portion removed) were 
mixed 1:1 with 1% saline solution in a beaker. This was transferred to a reagent 
bottle, capped and inverted several times, then stored in the fridge (2 – 8 °C) for 
up to 6 months. 
3.4. Method Development and Optimisation 
3.4.1. Liquid Chromatography – Mass Spectrometry 
The instrument used for this method was an Agilent 1260 Infinity HPLC system 
coupled to an AB Sciex 3200 Qtrap MS. Chromatographic separation was 
undertaken using a Phenomenex Gemini C18 column (150 mm x 2.0 mm, 5 µm) 
fitted with a guard cartridge of the same packing material and held at 40 °C. 
Analyte detection was made using positive ESI and MRM. 
3.4.1.1. Optimisation of Analyte Precursor and Product Ions  
Determination of analyte ion transitions was made by infusing a solution of the 
analyte (at 1 µg/mL in infusion solution) directly in to the ion source of the MS 
using the in-built syringe driver on the instrument. The Compound Optimisation 
function of the Analyst Software (version 1.6.3) was employed to manipulate 
instrumental parameters for optimum analyte response. This process involves 
ramping the declustering potential (DP), entrance potential (EP), cell entrance 
potential (CEP) and cell exit potential (CXP) within the MS and recording the 
responses obtained for the precursor ion and 8 most abundant product ions. The 4 
most abundant product ions and their abundances were then recorded by the 
software and automatically incorporated into a method. These were then 
scrutinised with reference to the scientific literature and the structural formulae of 
the analytes to ensure they originated from the analytes and were not present due 
to contamination. 
This process was repeated for JWH-200-d5 which was used as an I.S.  
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3.4.1.2. Investigation Into Analyte Retention 
Isocratic mobile phase (MP) compositions of 0.1% formic acid and 2mM 
ammonium acetate in aqueous solutions of 50, 60, 70 and 80% MeOH were tested 
for best analyte retention, at a flow rate of 300 µL/min with an injection volume of 
20 µL. Retention times for analyte and I.S. were noted and considered acceptable 
for use in the final method if they were between 2 – 10 min. 
3.4.1.3. Final Method 
The instrumental parameters found to be most conducive to analyte sensitivity and 
specificity are given in Table 3. These comprise the final method and are 
discussed in more detail in section 3.5. 
Table 3 – Final instrumental parameters of MDMB-CHMICA method. Ion 
transitions for the analyte and Internal Standard, the Liquid Chromatography 
Mobile Phase programme, and Mass Spectrometer voltages are shown. 
Parameter Values 
MDMB-CHMICA 
Ion Transitions 
385.1 → 240.2 (QT), 144.1 (QL1), 116.1 (QL2) 
JWH-250-d5 Ion 
Transition 
390.1 → 155.1 
Liquid 
Chromatography 
Mobile Phase 
Programme 
Isocratic at 20:80 H2O:MeOH with 0.1% formic acid and 2mM 
ammonium acetate 
Mass 
Spectrometer  
Voltages 
Ion 
Transition 
Declustering 
Potential (V) 
Entrance 
Potential 
(V) 
Cell 
Entrance 
Potential 
(V) 
Collision 
Energy 
(eV) 
Cell Exit 
Potential 
(V) 
385.1 → 
240.2 
36 4 32 23 4 
385.1 → 
144.1 
36 4 32 47 4 
385.1 → 
116.1 
36 4 32 87 4 
390.1 → 
155.1 
61 9.5 20 29 4 
 
3.4.2. Extraction 
A relatively broad Liquid-Liquid Extraction (LLE) procedure was employed as 
previously developed (131): an aliquot of 100 µL blood was buffered with 2 mL 
0.1M pH6.0 phosphate buffer with I.S. present at 25 ng/mL. During each batch, 
matrix-matched calibrators prepared at 1, 5, 10, 25, 50 and 100 ng/mL were 
extracted alongside a ‘blank’ MDMB-CHMICA-free standard and a ‘spike’ at 42 
ng/mL prepared from a stock distinct from the calibrator stock solution. This 
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concentration was chosen as a spike due to it being within the mid-range of 
calibrators but not being equal to any calibrator. Calibrators and spike were 
prepared according to Table 4 and a 100 µL aliquot of each was added to the 
buffered blood. ACN (100 µL) was added to the blank and samples as well, to 
ensure equal volumes of solvent between standards and samples. 
Analyte extraction was induced through the addition of 2 mL tBME. All standards, 
samples and blank were vortex mixed vigorously before and after addition of this 
then centrifuged at 3000 rpm for 10 min. The solvent layer was then removed for 
evaporation under nitrogen at RT. Samples were then reconstituted in 500 µL of 
an aqueous solution of 50% MeOH before injection into the final LC-MS method 
(see Table 3). 
Table 4 – Preparation details for the calibrators and QC used in the 
analytical method for the detection and quantitation of MDMB-CHMICA 
in blood 
Standard 
Concentration 
(ng/mL) 
Volume of Working 
Standard/Spike Solution 
(µL) (1 µg/mL or *100 
ng/mL) 
Volume of ACN (µL) 
CAL 1 1 10* 990 
CAL 2 5 5 995 
CAL 3 10 10 990 
CAL 4 25 25 975 
CAL 5 50 50 950 
CAL 6 100 100 900 
QC 42 42 958 
 
3.4.3. Method Validation 
The method was validated for linearity, selectivity, sensitivity (LLOQ and LOD), 
inter- and intra-day precision and accuracy, process efficiency and matrix effects. 
3.4.3.1. Linearity 
Linearity was assessed with 1/χ weighting over the calibration range 1 – 100 
ng/mL, in triplicate. The linear model was determined and a correlation co-efficient 
using this model was deemed acceptable at ≥0.99, ensuring a minimum of 4 of 6 
calibration points were within 80 – 120% accuracy. Linearity was assessed in 
every batch which included samples to ensure the aforementioned criteria were 
met.  
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3.4.3.2. Selectivity 
Selectivity was monitored by analysing MDMB-CHMICA-free samples and 
ensuring any peak observed in the resultant chromatogram not originating from 
MDMB-CHMICA was baseline resolved from this analyte.  
3.4.3.3. Sensitivity 
The LOD was designated as the lowest standard at which the signal-to-noise ratio 
(SNR) of the ion transition with the lowest response was 3, with the LLOQ being 
the lowest standard at which the SNR of the same ion transition was 10. To 
assess this, unextracted calibrators of decreasing concentration were analysed 
and the SNR of the peak with the lowest response was assessed visually. The 
LLOQ was employed as the lowest calibrator. 
3.4.3.4. Accuracy  
Accuracy was calculated inter- and intra-day at 10 and 42 ng/mL using the 
calculation given in Equation 1, where   denotes the mean concentration of 
replicate measurements and   denotes the expected concentration, i.e. 10 or 42 
ng/mL. For intra-day (n=4) measurements, replicates were injected within 1 batch, 
and for inter-day (n=2) measurements, batches of triplicate standards were run on 
separate days. 
Equation 1 
               
  
 
       
Accuracy was deemed acceptable when the above equation yielded a result 
between 80 – 120%. 
3.4.3.5. Precision 
Precision was calculated inter- and intra-day at the same concentrations as 
accuracy by using the calculation for %CV. This is given by Equation 2, where   
denotes the standard deviation of the measurements as calculated using Equation 
3, and   denotes the number of measurements made. 
Equation 2 
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Equation 3 
    
       
 
 
Precision was deemed acceptable when %CV values were ≤15. 
3.4.3.6. Matrix Effects and Process Efficiency 
Matrix effects (ME) were calculated at 50 ng/mL and process efficiency (PE) was 
calculated at 5 and 50 ng/mL extracted in triplicate from 6 sources of blank blood 
according to the Matuszewski method (132), shown in Equation 4 and Equation 5. 
Equation 4 
                 
 
 
      
Equation 5 
                     
 
 
      
Where:  
A= peak area of an extracted standard 
B= peak area of a double blank extracted standard reconstituted in the unextracted 
standard 
C= peak area of an unextracted standard 
 
3.5. Results and Discussion 
3.5.1. Liquid-Chromatography – Mass Spectrometry 
3.5.1.1. Optimisation of Analyte Precursor and Product Ions 
From the analyte infusion work described in Section 3.4.1 the ion transitions and 
MS parameters in Table 5 provided the optimum response. These transitions 
relate to the fragmentation of MDMB-CHMICA and JWH-200-d5 as shown in 
Figure 9. Transition 385.109 → 240.2 gave the highest response and was 
therefore used as the quantitation transition (QT). Transitions 385.1 → 144.1 and 
385.1 → 116.1 also gave sufficiently high instrument responses and were used as 
qualifier transitions 1 and 2 (QL1 and QL2) respectively.  
  39 
Table 5 – Ion transitions and Mass Spectrometer parameters for MDMB-
CHMICA and internal standard JWH-200-d5 as determined for the analytical 
method by instrumental optimisation 
Analyte Ion Transition 
Dwell 
Time (ms) 
DP 
(V) 
EP 
(V) 
CEP 
(V) 
CE 
(eV) 
CXP 
(V) 
MDMB-
CHMICA 
385.1 → 240.2 150 36 4 32 23 4 
385.1 → 144.1 150 36 4 32 47 4 
385.1 → 116.1 150 36 4 32 87 4 
JWH-200-
d5 
390.1 → 155.1 150 61 9.5 20 29 4 
 
m/z 144
m/z 240
m/z 116
 
Molecular weight = 384.5 
 
 
m/z 155
 
 
Molecular weight = 389.5 
Figure 9 – Fragmentation in the Mass Spectrometer of MDMB-CHMICA (left) 
and JWH-200-d5 (right). For MDMB-CHMICA this takes place between the 
carboxamide link and the indole moiety (either between the carboxide and 
the indole, or between the amide and the indole), and between the indole 
moiety and the cyclohexylmethyl group. 
 
3.5.1.2. Investigation Into Analyte Retention 
From experiments into MP composition and retention time, 80:20 MeOH:H2O with 
0.1 % formic acid and 2mM ammonium acetate was found to be most appropriate. 
This gave a retention time of ca. 2 min for JWH-200-d5 and ca. 5.5 min for MDMB-
CHMICA. Increased retention for the I.S. on the column would have been 
desirable, however even a slight increase in the aqueous content of the MP 
caused a detrimental widening of MDMB-CHMICA peak shape, with very strong 
retention of MDMB-CHMICA resulting from lower solvent contents. These effects 
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can be observed in Figure 10 with example XICs of MDMB-CHMICA shown at 
60%, 70% and 80% MP B (bottom, middle and top traces respectively; note the 
difference in χ-axis scale on 60% B trace). 
 
 
Figure 10 – Retention times of MDMB-CHMICA at 60% (bottom), 70% (middle) 
and 80% (top) methanolic mobile phase (isocratic). Note the difference in χ-
axis scale on 60% methanolic mobile phase trace. Blue, red and green lines 
indicate QT, QL1 and QL2 ion transitions respectively and intensity is given 
in counts per second. 
 
3.5.1.3. Extraction  
The extraction procedure detailed in Section 3.4.2 provided good results in terms 
of peak area, peak shape and baseline noise and allowed method validation to go 
ahead. 
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3.5.2. Method Validation 
3.5.2.1. Linearity 
 
 
 
 
Figure 11 – Example extracted ion chromatograms of extracted MDMB-
CHMICA calibrators at 1 (top) and 100 (bottom) ng/mL run isocratically at 
80% methanolic mobile phase. QT, QL1 and QL2 ion transitions are shown in 
blue, red and green respectively and intensity is given in counts per second. 
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Linearity was established between 1 – 100 ng/mL using 1/χ-weighting yielding a 
correlation co-efficient of ≥0.99 with a minimum of 4 points in all replicates. 
Example XICs of extracted calibrators at 1 and 100 ng/mL are given in Figure 11 
and an example calibration is shown in Figure 12. It was believed that 
concentrations of MDMB-CHMICA found in case samples would be towards the 
bottom end of the calibration range, where absolute error would be higher, so 1/χ-
weighting was chosen to normalise the error over the range, taking the domination 
of the calibration curve away from the higher concentrations, where absolute error 
would be lower.  
 
 
 
Figure 12 – Example calibration of MDMB-CHMICA showing linearity, with 
1/χ weighting, between 1 – 100 ng/mL with R=0.9969.  
 
During analysis, it was observed that the 100 ng/mL calibrator would be removed 
on occasion to improve the linearity and accuracy of the calibrators. The 
calibration range was maintained as described for the duration of method 
validation for consistency, but taking the concentrations found in case samples 
into account, it was decided that the range should ideally contain lower 
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concentration calibrators and that a top calibrator of 50 ng/mL would be more 
appropriate. This was implemented in future methods.  
3.5.2.2. Selectivity 
Selectivity was established by observing the lack of a peak in MDMB-CHMICA ion 
transition channels in an MDMB-CHMICA-free standard, as exemplified in Figure 
13. A ‘blank’ (MDMB-CHMICA-free) standard was included in every batch of 
samples analysed to ensure this remained the case. 
 
 
Figure 13 – Example of method selectivity exhibited by a lack of response 
for MDMB-CHMICA ion transitions in an analyte-free standard. Intensity is 
given in counts per second. 
 
3.5.2.3. Sensitivity 
The LOD and LLOQ of the assay were determined to be 0.5 and 1 ng/mL 
respectively. Example XICs of standards at these concentrations are given in 
Figure 14 and Figure 15 for 0.5 and 1 ng/mL respectively. The SNR of the lowest 
responding ion transition, in this case qualifier ion 2, was used to determine LOD 
and LLOQ in order to maintain specificity for MDMB-CHMICA. It is noted that the 
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use of diluted packed red cells rather than whole blood would affect the sensitivity 
of the extraction as components such as plasma are absent and SCRAs may bind 
preferentially to this. As a result, the sensitivity of the method may be artificially 
improved by the use of diluted packed red cells. This is current standard practice 
in FMS and no whole blood was available at the time of the research. 
 
Figure 14 – Example extracted ion chromatogram from an unextracted 
standard at 0.5 ng/mL MDMB-CHMICA, the Limit of Detection (a signal-to-
noise ratio of ≥3). The QT, QL1 and QL2 ions are shown in blue, red and 
green respectively and intensity is given in counts per second. 
 
Figure 15 – Example extracted ion chromatogram from an unextracted 
standard at 1 ng/mL MDMB-CHMICA, the Lower Limit of Quantitation (a 
signal-to-noise ratio of ≥10). The QT, QL1 and QL2 ions are shown in blue, 
red and green respectively and intensity is given in counts per second. 
 
3.5.2.4. Accuracy and Precision 
Mean inter- and intra-day accuracy was found to be 102% and 96% respectively at 
10 ng/mL, with the equivalents being 104% and 108% respectively at 42 ng/mL. 
Inter- and intra-day precision was calculated to be 8.33% and 4.68% respectively 
at 10 ng/mL, and 5.31% and 3.65% respectively at 42 ng/mL. The data used to 
calculate these values can be found in Table 6 and Table 7.   
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Table 6 – Data used to calculate inter-day accuracy and precision at 10 and 
42 ng/mL (n=4) for MDMB-CHMICA. Accuracy and precision were both within 
acceptable limits of 100 ± 20% and ≤15% respectively. 
Expected 
conc. 
(ng/mL) 
Calculated 
conc. (ng/mL) 
  
(ng/mL) 
Accuracy 
(%) 
  
(ng/mL) 
%CV 
10 
11.16 
10.17 101.68 0.85 8.33 
10.01 
8.88 
10.62 
42 
43.19 
43.72 104.09 2.32 5.31 
42.06 
41.97 
47.65 
 
Table 7 – Data used to calculate mean intra-day accuracy and precision at 10 and 
42 ng/mL (n=2) for MDMB-CHMICA. Accuracy and precision were both within 
acceptable limits of 100 ± 20% and ≤15% respectively. 
Expected 
conc. 
(ng/mL) 
Day 
Calculated 
conc. 
(ng/mL) 
  
(ng/mL) 
Accuracy 
(%) 
  
(ng/mL) 
% 
CV 
Mean 
Accuracy 
(%) 
Mean 
%CV 
10 
1 
8.88 
9.16 91.63 0.45 4.92 
95.8 4.68 
8.81 
9.80 
2 
9.62 
10.00 99.97 0.44 4.44 10.62 
9.75 
42 
1 
41.97 
42.04 100.1 1.94 4.60 
108.3 3.65 
44.45 
39.71 
2 
47.65 
48.94 116.52 1.32 2.70 50.76 
48.41 
 
An accuracy of 100 ± 20% was deemed acceptable, and all the values obtained 
fell within this range. Similarly, all precision was less than 9%, within the deemed 
acceptable criterion of ≤15%.   
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3.5.2.5. Matrix Effects and Process Efficiency 
Process efficiency was calculated to be 58 and 90% at 5 and 50 ng/mL 
respectively. The data used to calculate these values are given in Table 8, where 
unextracted standards are denoted by ‘UE’. 
Table 8 – Data used to calculate process efficiency at 5 and 50 ng/mL 
for MDMB-CHMICA. Process efficiency at 50 ng/mL was within the 
desirable range, but the value for 5 ng/mL was sub-optimal. 
Standard 
Peak 
Area 
Mean Peak 
Area 
Process 
Efficiency % 
Mean Process 
Efficiency % 
(%CV) 
UE 5 ng/mL A 81036 
80142.5 
101.11 
100 
UE 5 ng/mL B 79249 98.89 
5 ng/mL A 44322 
46166 
55.30 
57.6 
(2.8) 
5 ng/mL B 47208 58.91 
5 ng/mL C 46968 58.61 
UE 50 ng/mL A 558639 
566927.5 
98.54 
100 
UE 50 ng/mL B 575216 101.46 
50 ng/mL A 533157 
511992 
94.04 
90.3 
(3.2) 
50 ng/mL B 492801 86.92 
50 ng/mL C 510018 89.96 
 
The sub-optimal process efficiency exhibited at 5 ng/mL is of concern as SCRAs 
tend to be present in low concentrations, and the process needs to be efficient to 
ensure low concentrations can be detected. Given the novelty of this compound, it 
was unknown at this stage in method development just how low concentrations of 
MDMB-CHMICA in blood would be, i.e. frequently <1 ng/mL. The LOD as 
calculated on unextracted standards, was therefore higher than desired when you 
take the process efficiency into account. Development and optimisation of a more 
comprehensive SCRAs method, including MDMB-CHMICA, was conducted at a 
later stage and addressed this. 
During the measurement of matrix effects, slight ion enhancement was detected, 
with the area of an extracted peak being 116% of its unextracted equivalent in the 
most significant example. The mean degree of ion enhancement was calculated to 
be 109%, with the median being 106%. The data used to calculate these values 
are presented in Table 9.  
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Table 9 – Data used to calculate matrix effects at 50 ng/mL for MDMB-
CHMICA. These were satisfactory at ≤17%. 
Standard 
Peak 
Area 
Mean Peak 
Area 
% Matrix 
Effect 
Mean (%) 
(%CV) 
Median 
(%) 
UE 50 ng/mL A 558639 
566927.5 100 100 100 
UE 50 ng/mL B 575216 
50 ng/mL 1A 601401 
593384.5 104.7 
108.6 
(5.6) 
105.9 
50 ng/mL 1B 585368 
50 ng/mL 2A 571627 
572893 101.1 
50 ng/mL 2B 574159 
50 ng/mL 3A 600903 
600327.5 105.9 
50 ng/mL 3B 599752 
50 ng/mL 4A 657195 
651192.5 114.9 
50 ng/mL 4B 645190 
50 ng/mL 5A 661079 661079 116.6 
 
The injection of standard 50 ng/mL 5B failed, hence only the result for 50 ng/mL 
5A is shown.  
Given the low process efficiency at 5 ng/mL, measuring matrix effects at this 
concentration would have provided more context as to what might be contributing 
towards this low value. Matrix effects for MDMB-CHMICA were further investigated 
during development, optimisation and validation of the more comprehensive 
method in Section 4. 
Overall, matrix effects as calculated at 50 ng/mL do not pose a significant threat to 
accurate quantitation of MDMB-CHMICA at similar concentrations.  
The comments made about the use of packed red cells in place of whole blood in 
Section 3.5.2.3 are valid as a limitation here too. The presence of plasma may 
affect the process efficiency and matrix effects of the extraction, and the ability of 
the extraction protocol to efficiently extract plasma-bound SCRAs has not been 
assessed.  
While no formal interference testing was conducted in the scope of this validation, 
it became apparent that the SCRA BB-22 exhibited the same ion transitions during 
MS analysis and could not be resolved from MDMB-CHMICA using the 
chromatographic method detailed in Section 3.4.1.3. It was therefore essential that 
the ratios of QT and QL ions were calculated to ensure designation as the correct 
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analyte. The ratios of extracted peak areas for QT to QL1 ion transitions, QT to 
QL2 ion transitions and QL1 to QL2 ion transitions were noted for 6 calibrators 
from 5 batches (n=30 calibrators) for MDMB-CHMICA. These were compared to 
the ratios for the same ion transitions for calibrators of BB-22 extracted and 
analysed in replicate at 0.5 ng/mL (n=6), 1 ng/mL (n=4) and 50 ng/mL (n=4). 
Ratios were calculated over different concentrations to ensure that they were not 
concentration dependant. The results from these experiments are shown, by 
concentration, in Table 10. 
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Table 10 – Comparison of ion ratios of MDMB-CHMICA and BB-22 to determine whether these compounds can be 
distinguished. Distinction can be made using the QT/QL2 ratio. 
Conc. 
(ng/mL) 
QT/QL1 QT/QL2 QL1/QL2 
MDMB-CHMICA BB-22 MDMB-CHMICA BB-22 MDMB-CHMICA BB-22 
Mean Range Mean Range Mean Range Mean Range Mean Range Mean Range 
0.5 N/A N/A 3.01 3.0 - 3.1 N/A N/A 10.94 10.8 - 11.0 N/A N/A 3.63 3.6 - 3.7 
1 2.42 2.1 - 2.6 3.04 3.0 - 3.1 8.27 6.2 - 10.7 10.96 10.8 - 11.2 3.39 2.9 - 4.1 3.60 3.6 - 3.7 
5 2.73 2.7 - 2.9 N/A N/A 8.40 7.9 - 9.3 N/A N/A 3.07 3.0 - 3.2 N/A N/A 
10 2.70 2.6 - 2.9 N/A N/A 8.05 7.8 - 8.6 N/A N/A 2.99 2.9 - 3.1 N/A N/A 
25 2.72 2.6 - 2.8 N/A N/A 8.06 7.9 - 8.2 N/A N/A 2.97 2.9 - 3.1 N/A N/A 
50 2.68 2.7 - 2.7 3.01 3.0 - 3.0 8.19 7.9 - 8.3 10.94 10.9 - 11.1 3.05 3.0 - 3.1 3.63 3.6 - 3.7 
100 2.72 2.7 - 2.7 N/A N/A 8.24 8.1 - 8.3 N/A N/A 3.03 3.0 - 3.1 N/A N/A 
Mean 2.66 2.1 - 2.9 3.02 3.0 - 3.1 8.20 6.2 - 10.7 10.95 10.8 -11.2 3.08 2.9 - 4.1 3.62 3.6 - 3.7 
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It is acknowledged that the data set included is limited and, while no overlap exists 
for QT/QL1 and QT/QL2 ratios in the data presented, the ranges are very close 
and would likely vary further in a larger sample. Similarly, it is not known how the 
ratios would be affected by the presence of both BB-22 and MDMB-CHMICA.  
The distinction between MDMB-CHMICA and BB-22 was noted as a limitation of 
the method, and was taken into account during further method development and 
optimisation.  
3.6. Conclusion 
The work conducted and presented in this section resulted in a validated LC-
MS/MS method which was shown to be able to accurately and precisely quantify 
the SCRA MDMB-CHMICA between 1 – 100 ng/mL in whole blood. Whilst no 
chromatographic distinction can be made between this analyte and the structurally 
similar SCRA BB-22, the ratio of the QT/QL2 ion transitions allows the identity of 
the analyte to be known, albeit with relatively limited certainty.  
A further limitation of this work is the use of diluted packed red cells rather than 
whole blood, including plasma. While this would have an effect on validated 
parameters such as matrix effects and sensitivity, it is current standard practice in 
FMS and no drug-free whole blood was available at the time of the research. 
Whole blood was used in the validation of matrix effects, process efficiency and 
recovery for the optimised method discussed in Chapter 4. 
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4. Development and Validation of a Method for the Detection and 
Quantitation of Synthetic Cannabinoid Receptor Agonists in Blood and 
Urine 
4.1. Aims and Objectives 
The aim of this project was to develop and validate a method for the detection and 
quantitation of the most common SCRA compounds available in the UK and apply 
it to real forensic case samples. 
In order to do so, the following 4 objectives were set: 
 To identify the SCRA compounds most likely to be encountered in the UK 
population; 
 To develop extraction protocols for these compounds applied to blood and 
urine; 
 To develop an LC-MS/MS method to detect and quantitate these 
compounds; and  
 To validate the resultant methods to ensure fitness-for-purpose as accurate 
quantitative methods. 
4.2. Materials 
Standards of 5F-AB-PINACA, 5F-ADB-FUBINACA, 5F-AKB48, 5F-AKB48 N4OH 
pentyl metabolite, 5F-MDMB-PINACA, 5F-MDMB-PINACA O-desmethyl acid 
metabolite, 5F-NPB-22, 5F-PB-22, AB-CHMINACA, AB-FUBINACA, AB-
FUBINACA valine metabolite, AB-PINACA, AB-PINACA N4OH pentyl metabolite, 
AKB48, AKB48 N5OH pentyl metabolite, AM2201, AM2201 N4OH pentyl 
metabolite, AM2201 N5OH indole metabolite, APICA, APICA N4OH pentyl 
metabolite, BB-22, FUB-PB-22, MAB-CHMINACA, MAM2201 N4OH pentyl 
metabolite, MDMB-CHMICA, MDMB-CHMICA O-desmethyl acid metabolite, 
MDMB-CHMINACA, MMB2201, MMB-CHMICA, MMB-FUBINACA, PB-22, STS-
135, STS-135 N4OH pentyl, AKB48-d11, AM2201-d5, were purchased from Chiron 
(Trondheim, Norway). AB-CHMINACA metabolite 1A, AB-CHMINACA metabolite 
2, AB-FUBINACA metabolite 2B, AKB48 N-pentanoic acid metabolite, BB-22 3-
carboxyindole metabolite, CUMYL-PeGACLONE, MAB-CHMINACA metabolite 1, 
PB-22 N5OH pentyl metabolite, PB-22 N-pentanoic acid metabolite, PB-22 N-
pentanoic acid 3-carboxyindole metabolite, AB-FUBINACA-d4, and PB-22-d9 were 
purchased from LGC Standards (Teddington, UK). AKB48 N5 hydroxy pentyl 
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metabolite-d4, β-glucuronidase from Helix pomatia, tertiary methyl butyl ether 
(tBME), potassium hydroxide, sodium acetate trihydrate and ammonium acetate 
were purchased from Sigma Aldrich (Gillingham, UK). Phosphate buffer (pH 6, 
0.1M) was prepared in-house from disodium hydrogen orthophosphate anhydrous 
and sodium dihydrogen orthophosphate dehydrate from Fisher Scientific 
(Loughborough, UK), who also provided acetic acid. Deionised water was 
produced from a Purite (Thame, UK) deionised water system. MeOH (HPLC 
grade) and ACN (LC-MS gradient grade), cyclohexane, ethyl acetate, ammonium 
carbonate, sodium hydroxide and formic acid were obtained from VWR 
(Lutterworth, Leicestershire, UK). Packed red blood cells were purchased from the 
Scottish National Blood Transfusion Service (SNBTS) based at Gartnavel Hospital 
(Glasgow, UK). Blank urine was obtained from healthy adult volunteers. Drug-free 
whole blood was purchased from Biological Specialty Corporation, Pennsylvania, 
U.S.. 
4.3. Method 
4.3.1. Solutions 
4.3.1.1. Stock Standards of Analytes and I.S. 
Individual stocks of 10 µg/mL in ACN were prepared by taking 50 µL of a 1 mg/mL 
or 500 µL of a 100 µg/mL solution as received from supplier and making up to 5 
mL in a volumetric flask. These were inverted several times, transferred to glass 
vials fitted with screw caps and stored in the freezer for 1 year. 
If the analyte was received in solid form, stocks of 1 mg/mL were produced in ACN 
or MeOH as solubility dictated by taking a minimum of 2 mg (weighed accurately) 
and dissolving in the equivalent volume of solvent. These solutions were mixed 
thoroughly, ensuring complete dissolution of solid and placing in an ultrasonic bath 
if dissolution wasn’t immediate. Solutions were stored in the freezer for 1 year. 
Prior to each use, the solutions were checked to ensure no precipitation had 
occurred (and sonicated again prior to use in case of precipitation). 
4.3.1.2. Infusion Solutions of Analytes and I.S. 
Infusion solutions of all analytes individually were prepared at a starting 
concentration of 1 µg/mL by diluting the stock solutions with an aqueous solution 
of 50% MeOH containing 0.1% formic acid and 2mM ammonium acetate. Further 
dilutions, or solutions at higher concentrations, were prepared if it was required to 
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attain the necessary instrumental response. As it was a certain magnitude of 
instrumental response that was the goal, the concentration did not need to be 
accurate. 
4.3.1.3. Mixed Working Solutions of Analytes 
One solution containing the parent analytes and another containing the 
metabolites in ACN were prepared at 5 µg/mL. This was achieved by adding 25 µL 
of solutions at 1 mg/mL or 250 µL of solutions at 100 µg/mL to a 5 mL volumetric 
flask and making up to the line with ACN. The flask was inverted several times, the 
contents transferred to a glass vial fitted with a lid and stored in the freezer for 1 
year. 
These were then further diluted, by taking 1 mL of each solution into a 10 mL 
volumetric flask and making up to 10 mL with ACN, to form one solution at 500 
ng/mL containing all the analytes. This solution was stored in the freezer for 6 
months. 
A further solution containing all the analytes at 50 ng/mL was prepared by taking 
500 µL of the 500 ng/mL solution into a 5 mL volumetric flask and making up to the 
line with ACN. The flask was inverted several times, the contents transferred to a 
glass vial fitted with a lid and stored in the freezer for 6 months. 
4.3.1.4. Mixed Working Solutions of I.S. 
A mixed solution at 1 µg/mL was prepared by taking 500 µL of each individual 10 
µg/mL stock solutions into a 5 mL volumetric flask and making up to the line with 
ACN. The flask was inverted several times, the contents transferred to a glass vial 
fitted with a lid and stored in the freezer for 1 year. 
Latterly, a second mixed solution at 500 ng/mL was prepared by taking 500 µL of 
each individual 10 µg/mL stock into a 10 mL volumetric flask and making up to the 
line with ACN. The flask was inverted several times, the contents transferred to a 
glass vial fitted with a lid and stored in the freezer for 1 year. 
4.3.1.5. pH4.5 0.04M Sodium Acetate Buffer 
Sodium acetate trihydrate (5.86 g) was weighed out and dissolved in a small 
amount of deionized H2O in a beaker. This was then transferred to a 1 L 
volumetric flask and made up to the line with deionized H2O. To this, glacial acetic 
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acid was added drop-wise until the pH reached 4.5. The flask was inverted several 
times, the buffer transferred to a glass bottle and stored at RT for 1 month. 
4.3.1.6. pH6.0 0.1M Phosphate Buffer 
See Section 3.3.1.14. 
4.3.1.7. 0.1M pH7.4 Phosphate Buffer 
Potassium dihydrogen orthophosphate (13.6g) was added to ca. 800 mL deionized 
H2O and adjusted to pH7.4 with 10M potassium hydroxide. This was transferred to 
a 1 L volumetric flask and made up to the line with deionized H2O. This was then 
inverted several times, transferred into a glass bottle and stored in the fridge for 1 
month. 
4.3.1.8. 10M Potassium Hydroxide 
56g of potassium hydroxide was added to 100 mL deionized H2O, transferred to a 
glass bottle, inverted several times and stored at RT for 6 months. 
4.3.1.9. 0.01M pH9.3 Carbonate Buffer 
0.96g of ammonium carbonate was added to ca. 800 mL deionized H2O and 
adjusted to pH9.3 with 1M potassium hydroxide. This was then transferred to a 1 L 
volumetric flask, made up to the mark with deionized H2O and inverted several 
times. The resulting solution was transferred to a glass bottle and stored at RT for 
6 months. 
4.3.1.10. 1M NaOH 
40g sodium hydroxide was weighed out and added to a 1 L volumetric flask. The 
volume was made up to the mark with deionised H2O and the flask was inverted 
several times. The solution was then transferred to a glass bottle and stored at RT 
for 6 months. 
4.3.1.11. Cyclohexane with 1% Ethyl Acetate 
Ethyl acetate (1 mL) was added to a 100 mL volumetric flask approximately half 
full of cyclohexane. The volume was made up to the mark with cyclohexane and 
the flask was inverted several times. The solution was then transferred to a glass 
bottle and stored at RT for 6 months. 
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4.3.1.12. Acetonitrile:Deionised H2O (95:5) with 0.1% Formic Acid and 
2mM Ammonium Acetate 
Concentrated formic acid (1 mL) and 2M ammonium acetate (1 mL, for preparation 
details see Section 3.3.1.1) were added to 50 mL of deionised H2O. ACN (950 mL) 
was added to this and the solution was sonicated at RT for 15 min. to remove 
dissolved gases. This solution was stored at RT for 3 months. 
For aqueous (MP A) and methanolic (MP B) MP preparation details see Sections 
3.3.1.3 and 3.3.1.2 respectively. 
4.3.2. Selection of Analytes 
The parent compounds most relevant to the Scottish population were selected 
through a search of the published literature; by identifying the compounds 
detected most frequently by the WEDINOS service; and according to alerts issued 
by the EMCDDA and other agencies. When undertaking the literature search, 
peer-reviewed journal articles discussing cases of analytically confirmed SCRA 
use in members of the public in Western European countries were deemed of 
highest value. The availability and cost of certified reference materials for the 
SCRA compounds were also taken into account. 
Once a list of parent compounds had been devised, information was sought on the 
major metabolites of these compounds through a second search of the scientific 
literature. The findings from this search were cross-referenced with suppliers’ 
product listings, and one or two of the metabolites most likely to be encountered in 
urine were chosen for inclusion.  
Internal standards (I.S.) were selected by studying the chemical structures of the 
parent compounds and selecting a deuterated form of a structurally similar SCRA. 
Availability and cost of deuterated certified reference materials were the limiting 
factors with regards to selection of I.S. 
Due to constant flux in the SCRA market, compounds were added and, less 
frequently removed, from the method to maintain its fitness for purpose. In 
addition, further information was garnered from the analysis of residue from 
packets of SCRA products to justify and guide the analyte panel. 
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4.3.3. Liquid Chromatography – Mass Spectrometry 
4.3.3.1. Infusion of compounds 
Compounds were infused directly into the ion source of the mass spectrometer 
using a syringe pump at a rate of 5 – 10 µL/min (controlled by the instrument), 
employing the compound optimization infusion feature of the Analyst© software. 
Infusion solutions were prepared at a starting concentration of 1 µg/mL in an 
aqueous solution of 50% MeOH with 2mM ammonium acetate and 0.1% formic 
acid, mimicking the anticipated MP starting conditions. A response of 
approximately 1x106 counts was considered desirable and infusion solution 
concentrations were amended if the compound elicited a response significantly 
higher or lower than this value.  
All compounds were infused in positive mode with unit resolution, targeting the 
molecular ion. Initially, the individual compound methods were built with the 4 ion 
transitions which provided the highest responses. These were then reviewed, 
ensuring aspects such as peak shape were acceptable, and two ion transitions 
were selected based on sensitivity (response) and selectivity (number of other 
compounds employing that transition). In some cases a third ion transition was 
retained in the method, to be monitored in case the method sensitivity allowed a 
more selective ion transition (albeit giving a lower response) to be employed. 
During the infusion process, the m/z values of the fragments were checked against 
the chemical structure to ensure the drug compound could be confirmed as their 
source.  
4.3.3.2. Mobile Phase Experiments  
SCRA parent compounds have a strong retention on reverse phase (RP) HPLC 
columns due to their non-polar nature, so as a starting point a MP composed of 
2mM ammonium acetate and 0.1% formic acid in deionised water (MP A) and 
2mM ammonium acetate and 0.1% formic acid in methanol (MP B) at an isocratic 
ratio of 10:90 was employed. An unextracted standard of each individual 
compound at a concentration of 100 ng/mL in 50% methanol was run down this 
isocratic system and their retention time noted. A mixed standard containing all 
compounds at this concentration was also run in order to assess peak shape and 
spread of elution throughout the run time. This was repeated at ratios of 20:80 and 
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30:70 where elution of the compounds was too quick; a retention time between 2.5 
– 20 min. was considered desirable.  
When the approximate extent of retention for each compound was known, 
experiments into a gradient elution system were conducted. The MP gradient 
systems are shown in Figure 48 - Figure 65 in Appendix 9.1 and were devised to 
investigate analyte separation.  
For gradient systems A – J, MPs A and B were deionised water and methanol 
respectively with 2mM ammonium acetate and 0.1% formic acid. Systems K – N 
employed deionised water and ACN as MP A and C respectively, again with 2mM 
ammonium acetate and 0.1% formic acid. MP C for gradient systems O and P was 
a mixture of ACN and methanol (90:10) with 2mM ammonium acetate and 0.1% 
formic acid; whilst for gradient systems Q and R, MP C was a mixture of ACN and 
deionised water (95:5) with 2mM ammonium acetate and 0.1% formic acid. 
4.3.4. Extraction of Analytes  
A simple, non-specific LLE protocol was used as the starting point for extraction of 
analytes from both blood and urine. This involved the addition of 1 mL pH6.0 1M 
phosphate buffer, I.S. (50 µL of a 500 ng/mL solution to give a final concentration 
of 50 ng/mL) and analyte working solution (100 µL for calibrators and QCs only) to 
500 µL matrix. For urine samples 50 µL β-glucuronidase and I.S. were added (plus 
100 µL for calibrators and QCs only). Details of how the working solution of 
calibrators and QCs were prepared are provided in Table 11. Calibrator and QC 
working standards were different solutions, either prepared on different days, or by 
different individuals. 
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Table 11 – Preparation details of calibrator and QC solutions for the 
extraction, detection and quantitation of selected Synthetic Cannabinoid 
Receptor Agonists in blood and urine 
Final 
Concentration of 
Calibrator or QC 
(ng/mL) 
Volume of 50 
ng/mL working 
solution (µL) 
Volume of 500 
ng/mL working 
solution (µL) 
Volume of ACN 
(µL) 
CAL 0.05 5 0 995 
CAL 0.10 10 0 990 
CAL 0.20 20 0 980 
CAL 0.50 0 5 995 
CAL 1.00 0 10 990 
CAL 2.00 0 20 980 
CAL 5.00 0 50 950 
CAL 10.00 0 100 900 
CAL 25.00 0 250 750 
CAL 50.00 0 500 500 
QC 0.10 10 0 990 
QC 0.20 20 0 980 
QC 0.42 42 0 958 
QC 2.50 0 25 975 
  QC 15.00 0 150 850 
QC 42.00 0 420 580 
 
Extraction of analytes was induced by the addition of tBME (2 mL) to the prepared 
sample. The tubes were vortex mixed for ca. 30 sec. and centrifuged at 3000 rpm 
for 10 min. The solvent layer was then transferred to clean and labeled vials and 
evaporated under a stream of nitrogen at 40 °C. The analytes were reconstituted 
in 200 µL of a solution prepared to the MP starting conditions (e.g. 
MeOH:deionised H2O (50:50)). 
4.3.4.1. Optimisation of the Extraction Method for Application to Blood 
To gain the optimal recovery and minimal matrix effects for extraction, variations of 
extraction conditions were assessed. These are detailed in Table 12.  
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Table 12 – Experimental conditions for the optimisation of the extraction of 
selected Synthetic Cannabinoid Receptor Agonists from blood  
Experiment 
Mix Time 
(min.) 
Buffer Type 
Vol. Buffer 
(mL) 
Extraction 
Solvent 
Vol. 
Extraction 
Solvent 
(mL) 
1 5 
pH 6 0.1M 
phosphate 
1 tBME 2 
2 2 
pH 6 0.1M 
phosphate 
1 tBME 2 
3 10 
pH 6 0.1M 
phosphate 
1 tBME 2 
4 5 
pH 6 0.1M 
phosphate 
0.5 tBME 2 
5 5 
pH 9.3 0.01M 
carbonate 
0.5 tBME 2 
6 5 
pH 9.3 0.01M 
carbonate 
1 tBME 2 
7 5 
pH 6 0.1M 
phosphate 
1 tBME 1 
8 5 
pH 6 0.1M 
phosphate 
1 
Cyclohexane 
(1% ethyl 
acetate) 
1 
9 5 
pH 6 0.1M 
phosphate 
1 
Cyclohexane 
(1% ethyl 
acetate) 
2 
10 2 
pH 6 0.1M 
phosphate 
0.5 tBME 1 
 
Mixing was conducted on a flatbed mixer, and 4 mL plastic test tubes were used. 
Reconstitution was in ACN:deionised H2O (95:5):deionised H2O (30:70) with 2mM 
ammonium acetate and 0.1% formic acid. All variables of the experiments not 
detailed in Table 12 remained consistent with the method detailed in Section 4.3.4.  
Duplicate standards of 5 ng/mL extracted as per section 4.3.4 were compared with 
the corresponding standard extracted as per the varied technique in terms of 
recovery, matrix effects and process efficiency (Equation 6 – Equation 8).  
Equation 6 
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Equation 7 
                 
 
 
      
Equation 8 
                     
 
 
      
Where:  
A= peak area of an extracted standard 
B= peak area of a double blank extracted standard reconstituted in the unextracted 
standard 
C= peak area of an unextracted standard 
Recoveries and extent and type of ME were compared to determine the optimal 
process, with highest recovery and lowest ME being preferable.  
4.3.4.2. Optimisation of the Extraction Method for Application to Urine 
Optimisation of the extraction of SCRAs from urine was also undertaken, varying 
conditions as detailed in Table 13. 
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Table 13 – Experimental conditions for the optimisation of the extraction of 
selected Synthetic Cannabinoid Receptor Agonists from urine  
Experiment 
Mix Time 
(min.) 
Buffer Type 
Vol. Buffer 
(mL) 
Extraction 
Solvent 
Vol. 
Extraction 
Solvent 
(mL) 
1 5 
pH 6 0.1M 
phosphate 
1 tBME 2 
2 2 
pH 6 0.1M 
phosphate 
1 tBME 2 
3 2 
pH 6 0.1M 
phosphate 
0.5 tBME 1 
4 5 
pH4.5 0.04M 
sodium acetate 
1 tBME 2 
5 5 
pH4.5 0.04M 
sodium acetate  
0.5 tBME 2 
6 5 
pH4.5 0.04M 
sodium acetate 
0.5 tBME 1 
7 5 
pH 9.3 0.01M 
carbonate 
1 tBME 2 
8 5 
pH 9.3 0.01M 
carbonate 
0.5 tBME 2 
9 2 
pH 9.3 0.01M 
carbonate 
0.5 tBME 1 
10 2 
pH 6 0.0.04M 
sodium acetate  
0.5 tBME 1 
11 2 1M NaOH 0.5 tBME 2 
12 5 
pH 7.4 0.1M 
phosphate  
0.5 tBME 2 
13 5 None N/A MeOH 2 
14 5 None N/A MeOH 3 
15 5 None N/A ACN 2 
 
As with the blood experiments, 4 mL plastic test tubes and the flatbed mixer were 
used, as was reconstitution performed in the MP starting conditions. Comparison 
of the conditions was made by way of the results of Equation 6 – Equation 8 with 
the same desirable criteria as with blood.  
Examination of the optimal hydrolysis conditions for extraction of analytes from 
urine was also performed by comparing the process efficiency of extractions 
conducted according to Table 14 with unextracted standards of the same 
concentration incubated at room temperature for 1 H. 
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Table 14 – Experimental conditions for the optimisation of the hydrolysis of 
selected Synthetic Cannabinoid Receptor Agonists in urine 
Experiment Buffer β-glucuronidase Incubation Conditions 
1 
0.5 mL, pH4.5 
0.1M sodium 
acetate 
50 µL from Helix 
pomatia 
1 H at RT 
2 
0.5 mL, pH4.5 
0.1M sodium 
acetate 
50 µL from Helix 
pomatia 
1 H at 60 °C 
3 None 
50 µL from Helix 
pomatia 
1 H at RT 
4 None 
50 µL from Helix 
pomatia 
1 H at 60 °C 
5 None None 1 H at RT 
6 None None 1 H at 60 °C 
 
4.3.5. Method Validation – Blood 
The Scientific Working Group for Forensic Toxicology (SWGTOX) guidelines for 
method validation were used as a basis for the parameters validated and the 
acceptance criteria as detailed below.  
4.3.5.1. Linearity 
Linearity was assessed over 10 extracted calibrations using the calibration ranges 
given in Table 15 and using 1/χ weighting. The calibration was deemed acceptable 
if the correlation co-efficient was ≥0.99 with at least 4 calibration points within 
100% ± 20 accuracy. 
Table 15 – Concentrations of calibrators included in 
assessment of linearity for selected Synthetic Cannabinoid 
Receptor Agonists 
Calibrator 
Concentration of Parent 
Compound (ng/mL) 
Concentration of Metabolite 
(ng/mL) 
1 0.10 0.20 
2 0.20 0.50 
3 0.50 1.00 
4 1.00 5.00 
5 5.00 10.00 
6 10.00 25.00 
7 25.00 50.00 
 
4.3.5.2. Selectivity 
Selectivity was assessed by running drug-free standards and observing a 
response ≤25% of the peak area of the lowest calibrator in analyte channels.  
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4.3.5.3. Sensitivity 
The LOD was designated as the lowest standard at which the SNR of the ion 
transition giving the lowest response was ≥4. The LLOQ was set as 0.10 or 0.20 
ng/mL for parent compounds and metabolites respectively ensuring that this was ≥ 
the LOD for the compound.  
In order to determine the SNR a series of extracted standards were injected at 
0.01, 0.02, 0.05, 0.10, 0.20, 0.50, 1.00, 2.00 and 5.00 ng/mL. The height of the 
compound peak was measured as the signal, and the maximum height of the 
baseline in the area immediately adjacent to the compound retention time was 
measured as the noise. The signal height was divided by the noise to calculate the 
SNR. 
4.3.5.4. Accuracy 
Accuracy was assessed at 0.1, 2.5, and 15 ng/mL (parent compounds) or 0.2, 2.5 
and 42 (metabolites) over 5 replicates using the calculation given in Equation 1. 
Inter- and intra-assay accuracy were both calculated and deemed acceptable if 
within ± 20%. 
4.3.5.5. Precision 
Precision was assessed at 0.1, 2.5, and 15 ng/mL (parent compounds) or 0.2, 2.5 
and 42 (metabolites) over 5 replicates using the calculation given in Equation 2. 
Inter- and intra-assay precision were both calculated and deemed acceptable if the 
%CV was < 15. 
4.3.5.6. Recovery, Matrix Effects and Process Efficiency 
Recovery, matrix effects and process efficiency were all calculated for each 
analyte at 2.5 and 15 ng/mL, in duplicate, and according to Equation 6 – Equation 
8. Recovery of ≥ 50% and matrix effects not exceeding ± 30% were preferred. Ten 
sources of blank whole blood were used (i.e. not prepared as per Section 3.3.1.16) 
for these experiments. 
4.3.5.7. Interference Testing 
An unextracted solution containing the most commonly encountered prescription 
and abused drugs was prepared to give a concentration of 1 mg/L. This was 
injected on the instrument using the optimised method in triplicate and the 
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resulting XICs interrogated for peaks at or around the retention times of SCRA or 
I.S. peaks. 
The drugs included in the solution used are given in Table 16 . 
Table 16 – Panel of prescription and abused drugs included in the 
interference tests 
7-Aminoflunitrazepam  Amitriptyline  
Amphetamine  Benzoylecgonine  
Chlordiazepoxide  Chlorpheniramine  
Chlorpromazine  Citalopram  
Cocaine  Codeine  
Cyclizine  Desmethyldiazepam  
Diazepam  Dihydrocodeine  
Diltiazem  Diphenhydramine  
Etizolam  Lignocaine 
Lorazepam  MDA* 
MDEA  MDMA  
Methadone  Methamphetamine  
Mirtazapine  6-Monoacetylmorphine  
Morphine Nitrazepam 
Oxazepam Phenazepam 
Phencyclidine Temazepam 
Tetrahydrocannabinol Tetrahydrocannabinol acid metabolite 
Tramadol Zolpidem 
* Methylenedioxymethamphetamine, to distinguish from Misuse of Drugs Act 1971 
4.3.5.8. Autosampler Stability 
Five pooled extracted standards (1 mL extract) prepared at 2.5 and 15 ng/mL were 
injected 30 times each, in groups of 3, so the final injection of a concentration was 
approximately 46 H after the first injection. The peak areas and PAR were plotted 
over time to show the stability over the time period as compensated by the IS. 
4.3.6. Method Validation – Urine 
As compounds present in urine are no longer active pharmacodynamically, the 
concentrations of these compounds were not deemed as important as their 
presence or absence. The exception to this is the requirement to determine the 
concentration of a compound to corroborate or refute results of mandatory drug 
testing (MDT) in the prison setting (England and Wales), where a cut-off 
concentration is used to distinguish between active and passive inhalation. For this 
reason, the method was only validated quantitatively for the most commonly 
encountered analytes, with qualitative validation being deemed sufficient for the 
remaining analytes. The compounds for which quantitative validation was 
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undertaken were 5F-MDMB-PINACA O-desmethyl acid metabolite, MDMB-
CHMICA O-desmethyl acid metabolite and AB-FUBINACA valine metabolite. 
4.3.6.1. Linearity 
This was assessed for 5F-MDMB-PINACA O-desmethyl acid metabolite, MDMB-
CHMICA O-desmethyl acid metabolite and AB-FUBINACA valine metabolite as 
per 4.3.5.1. 
4.3.6.2. Selectivity 
This was assessed for all compounds as per 0. 
4.3.6.3. Sensitivity 
This was assessed for all compounds as per 4.3.5.3. 
4.3.6.4. Accuracy 
This was assessed for 5F-MDMB-PINACA O-desmethyl acid metabolite, MDMB-
CHMICA O-desmethyl acid metabolite and AB-FUBINACA valine metabolite as 
per 4.3.5.4. 
4.3.6.5. Precision 
This was assessed for 5F-MDMB-PINACA O-desmethyl acid metabolite, MDMB-
CHMICA O-desmethyl acid metabolite and AB-FUBINACA valine metabolite as 
per 4.3.5.5. 
4.3.6.6. Recovery, Matrix Effects and Process Efficiency 
This was assessed for all compounds as per 4.3.5.6, using blank urine in place of 
blood. 
4.3.6.7. Interference Testing 
This was assessed as per 4.3.5.7. 
4.3.6.8. Autosampler Stability 
This was assessed for all compounds as per 4.3.5.8. 
4.3.7. Validation – Intermediate Methods 
Due to the timing of this research, samples were received prior to full method 
optimisation and validation. In order to begin testing these samples, two 
intermediate methods were developed distinctly from the more comprehensive 
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method undergoing optimisation and these were validated for use with specific 
projects further described. These intermediate methods are denoted method 1.1 
and 1.2 and were assessed on selectivity and sensitivity as per sections 0 and 
4.3.5.3 respectively. Full details of these methods are provided in Table 24 and 
Table 25. 
4.3.8. Comparison of Prison ‘A’ and ‘B’ Samples  
During MDT in prisons, 2 samples of urine are collected from prisoners: one 
sample (the ‘A’ sample) is tested by the original laboratory, while the other (the ‘B’ 
sample) is stored for potential testing if the original result is challenged. Forensic 
Medicine and Science provides testing of ‘B’ samples as an additional service. A 
report is issued stating the compounds which have been detected above the cut-
off value (5 ng/mL) and the concentrations at which these were detected. A 
comment is then made stating whether the ‘B’ results are consistent with those 
reported by the original laboratory. The decision as to whether the results are 
consistent was made based on the finding of the same compounds at 
concentrations similar to the original findings, taking into account time since 
original analysis, storage during sample transfer and possible analyte instability. 
No statistical analysis is made to calculate the similarity because these factors are 
unknown. The accuracy was calculated for this work, however, using Equation 1, 
where    denotes the ‘B’ sample result and χ denotes the original ‘A’ sample result. 
The results of the ‘B’ sample analysis were compared to those of the original 
testing laboratory to ensure accuracy, and to assess stability of these compounds 
in urine.  
In order to do this, the ‘A’ and ‘B’ results were plotted against each other using the 
‘A’ and ‘B’ sample results as the y- axis and x-axis values respectively. The 
correlation co-efficient was then calculated using linear regression. An assessment 
of agreement and nature and extent of any random and/or systematic error was 
considered, along with potential analyte stability issues. 
The School of Medicine, Veterinary and Life Sciences Research Ethics Committee 
were contacted regarding this work, and provided a Letter of Comfort that a 
Research Ethics Application was not required for this work. This is included within 
Appendix B, in Section 9.2. 
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4.3.9. Analysis of Drug Packets 
Throughout 2016 packets of suspected SCRA products were analysed. 
Photographs of these packets are given in Figure 16 and show the front and back 
of products Afghan Black Ultra (formula 2A), Blueberry Haze Ultra (formula 4A), 
Kuber Khaini, Lunar Diamond, Pandora’s Box Unleashed and Tribal Warrior 
Ultimate. With the exception of Lunar Diamond, all the packets were empty of 
material. 
For analysis, rinse solutions of the packets were made with 2 mL MeOH. 
Approximately 5 mg of Lunar Diamond material was weighed out and 2 mL of 
MeOH was added to this. From these rinses, a 1 in 10 dilution was made by 
adding 100 µL of rinse to 900 µL of MeOH and mixing. LC-MS analysis was 
conducted on 1 in 100 dilutions of these solutions, adding 10 µL of diluted rinse to 
990 µL of reconstitution solution (ACN:H2O 30:70).  
These solutions were injected in duplicate, with an unextracted standard at 50 
ng/mL and analysed using method 1.2. 
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Figure 16 – Photographs of packets suspected of containing Synthetic 
Cannabinoid Receptor Agonists front (L) and back (R). These were analysed 
to determine their contents. 
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Figure 16 – Photographs of packets suspected of containing Synthetic 
Cannabinoid Receptor Agonists front (L) and back (R). These were analysed 
to determine their contents. 
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4.4. Results and Discussion 
Due to the fluid nature of the drugs market and chronology of the projects 
conducted within this research, 3 distinct methods were developed through the 
process detailed in Section 4.3.2 onwards: Methods 1.1, 1.2 and 2.1.These varied 
by drugs included and MP gradient (details given in Table 24 and Table 25). This 
ensured the panels of drugs included in the analysis for the projects were kept up 
to date with likely available compounds.  
4.4.1. Selection of Analytes 
 
Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
AB-CHMINACA N/A 
 
C20H28N4O2 
(356.5) 
AB-CHMINACA 
metabolite 1A 
N/A 
 
C20H28N4O3 
(372.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
AB-CHMINACA 
metabolite 2 
N/A 
 
C20H27N3O3 
(357.4) 
AB-FUBINACA N/A 
 
C20H21FN4O2 
(368.4) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
AB-FUBINACA 
metabolite 2B 
N/A 
 
C20H19FN4O4 
(398.4) 
AB-FUBINACA 
valine 
metabolite 
MMB-
FUBINACA 
metabolite 
AB-
FUBINACA 
metabolite 3 
 
C20H20FN3O3 
(369.4) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
AB-PINACA N/A 
 
C18H26N4O2 
(330.4) 
AB-PINACA 
N4OH pentyl 
N/A 
 
C18H26N4O3 
(346.2) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
5F-AB-PINACA N/A 
 
C18H25FN4O2 
(348.4) 
5F-ADB-
PINACA 
N/A 
 
C19H27FN4O2 
(362.4) 
AKB48 Apinaca 
 
C23H31N3O 
(365.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
AKB48 N5OH 
pentyl 
Apinaca 
N5OH pentyl 
 
C23H31N3O2 
(381.5) 
AKB48 N-
pentanoic acid 
Apinaca N-
pentanoic 
acid 
 
C23H29N3O3 
(395.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
5F-AKB48 5F-Apinaca 
 
 
C23H30FN3O 
(383.5) 
5F-AKB48 
N4OH pentyl 
5F-Apinaca 
N4OH pentyl 
 
C23H30FN3O2 
(399.5) 
AM2201 5F-JWH-018 
 
C24H22FNO 
(359.4) 
AM2201 N4OH 
pentyl 
5F-JWH-018 
N4OH pentyl 
 
C24H22FNO2 
(375.4) 
  77 
Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
AM2201 N5OH 
indole 
5F-JWH-018 
N5OH indole 
 
C24H22FNO2 
(375.4) 
APICA  
2NE1 
 
SDB-001 
 
JWH-018 
adamantyl 
carboxamide 
 
C24H32N2O 
(364.5) 
APICA N4OH 
pentyl 
2NE1 N4OH 
pentyl 
 
SDB-001 
N4OH pentyl 
 
JWH-018 
adamantyl 
carboxamide 
N4OH  pentyl 
 
C24H32N2O2 
(380.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
BB-22 Quchic 
 
C25H24N2O2 
(384.5) 
BB-22 3-carboxy 
indole 
Quchic 3-
carboxy 
indole 
 
C16H19NO2 
(257.3) 
FUB-PB-22 N/A 
 
C25H17FN2O2 
(396.4) 
MAM-2201 
N4OH pentyl 
5F-JWH-122 
N4OH pentyl 
 
C25H24FNO2 
(389.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
MDMB-CHMICA 
MMB-
CHMINACA 
 
C23H32N2O3 
(384.5) 
MDMB-CHMICA 
O-desmethyl 
acid metabolite 
MMB-
CHMINACA 
O-desmethyl 
acid 
metabolite 
 
C22H30N2O3 
(370.5) 
MDMB-
CHMINACA 
N/A 
 
C22H31N3O3 
(385.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
MAB-
CHMINACA 
ADB-
CHMINACA 
 
C21H30N4O2 
(370.5) 
MAB-
CHMINACA M1 
ADB-
CHMINACA 
M1 
 
C21H30N4O3 
(386.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
5F-MDMB-
PINACA 
5F-ADB 
 
C20H28FN3O3 
(377.5) 
5F-MDMB-
PINACA O-
desmethyl acid 
metabolite 
5F-ADB O-
desmethyl 
acid 
metabolite 
 
C19H26FN3O3 
(363.4) 
MMB2201 
AMB-PICA 
I-AMB 
 
C20H27FN2O3 
(362.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
MMB-
FUBINACA 
AMB-
FUBINACA 
FUB-AMB 
 
C21H22FN3O3 
(383.4) 
MMB-CHMICA 
AMB-
CHMICA 
 
C22H30N2O3 
(370.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
5F-NPB-22 
5F-PB-22 
indazole 
analogue 
 
C22H20FN3O2 
(377.4) 
PB-22 Qupic 
 
C23H22N2O2 
(358.4) 
PB-22 N5OH 
pentyl 
Qupic N5OH 
pentyl 
 
C23H22N2O3 
(374.4) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
PB-22 N-
pentanoic acid 
Qupic N-
pentanoic 
acid 
 
C23H20N2O4 
(388.4) 
PB-22 N-
pentanoic acid 
3-carboxyindole 
Qupic N-
pentanoic 
acid 3-
carboxy 
indole 
 
C14H15NO4 
(261.3) 
5F-PB-22 5F-Qupic 
 
C23H21FN2O2 
(376.4) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
5F-PB-22 3-
carboxy indole 
5F-Qupic 3-
carboxy 
indole 
 
C14H16FNO2 
(249.3) 
STS-135 
 
5F-APICA 
 
N-adamantyl-
1-
fluoropentyl 
indole-3-
carboxamide 
 
C24H31FN2O 
(382.5) 
STS-135 N4OH 
pentyl 
5F-APICA 
N4OH pentyl 
 
N-adamantyl-
1-
fluoropentyl 
indole-3-
carboxamide 
N4OH pentyl 
 
C24H31FN2O2 
(398.5) 
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Table 17 – Synthetic Cannabinoid Receptor Agonists included in one or 
more of the methods detailed in this research. Details of chemical formula, 
structure, molecular weight and any known aliases are given. 
Compound 
Name 
Aliases Structure  
Formula 
(MW) 
CUMYL-
PeGACLONE 
SGT-151 
 
C25H28N2O 
(372.5) 
 
After the conclusion of the practical aspect of the research, information was 
received from the retailer that the 5F-PB-22 3-carboxyindole metabolite drug 
standard used was actually a 5F-PB-22 ester isomer. As such the data relating to 
this compound was removed from the validation presented here. This compound 
was in the panel of a method employed for some cases discussed as a previously 
validated method was applied to these cases, using a drug standard from a 
different source. These cases will be highlighted as such. The parent compound, 
5F-PB-22, and another metabolite, PB-22 N-pentanoic acid, were included in the 
method so the detection of 5F-PB-22 use was possible.  
Figure 17 gives chemical and structural information relating to the intended and 
actual product received. This figure shows that the molecular weights are identical 
with respect to the resolution of the instrumentation used in this research. The 
most abundant ion transitions resulting from the fragmentation of both molecules 
were the same when infused on the MS.  
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5F-PB-22 3-Carboxyindole 
C14H16FNO2 
MW=249.28 
1H-Indole-carboxylic acid 5-fluoropentyl ester 
C14H16FNO2 
MW=249.28 
Figure 17 – Structural and chemical formulae and molecular weights for the 
intended and actual products provided as 5F-PB-22 3-carboxyindole.  
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4.4.2. Liquid Chromatography – Mass Spectrometry 
4.4.2.1. Infusion of Compounds 
Infusion of the compounds resulted in optimised parameters for the mass spectral 
fragmentation, collection and detection for the analytes. These parameters are 
shown in Table 18.  
 
Table 18 – Optimised tandem mass spectrometric parameters for 
Synthetic Cannabinoid Receptor Agonists included in one or more 
methods detailed in this research 
Analyte 
Precursor 
Mass 
Product 
Mass 
DP (V) EP (V) 
CEP 
(V) 
CE 
(eV) 
CXP 
(V) 
AB-CHMINACA 
357.2 241.2 31 4.0 28 29 4 
357.2 145.1 31 4.0 28 55 4 
AB-CHMINACA M1A 
373.2 257.3 31 4.5 28 29 6 
373.2 145.1 31 4.5 28 55 4 
AB-CHMINACA M2 
358.1 145.1 41 4.5 26 49 4 
358.1 241.1 41 4.5 26 25 6 
AB-FUBINACA  
369.1 109.1 31 6.5 28 55 4 
369.1 253.0 31 6.5 28 27 6 
AB-FUBINACA M2B 
399.0 109.1 31 5.0 30 53 4 
399.0 253.0 31 5.0 30 27 6 
AB-FUBINACA valine 
metabolite 
370.1 109.2 41 7.5 24 49 4 
370.1 253.0 41 7.5 24 25 4 
AB-PINACA 
331.2 215.2 26 4.5 16 27 4 
331.2 145.1 26 4.5 16 53 4 
AB-PINACA N4OH 
pentyl 
347.2 213.1 31 9.0 26 41 4 
347.2 145.1 31 9.0 26 53 4 
5F-AB-PINACA 
349.2 233.2 26 4.5 28 25 4 
349.2 304.2 26 4.5 28 17 6 
5F-ADB-PINACA 
363.2 233.1 31 7.0 26 29 4 
363.2 145.1 31 7.0 26 59 4 
AKB48  
366.2 135.2 56 4.0 28 27 4 
366.2 93.1 56 4.0 28 63 4 
AKB48 N5OH pentyl 
382.2 135.2 51 5.0 28 29 4 
382.2 93.2 51 5.0 28 69 4 
AKB48 N-pentanoic 
acid 
396.2 135.2 46 7.0 28 29 4 
396.2 107.2 46 6.5 20 61 4 
5F-AKB48 
384.2 135.2 46 7.5 22 29 4 
384.2 93.2 46 7.5 22 67 4 
5F-AKB48 N4OH pentyl 
400.2 135.2 56 6.5 30 29 4 
400.2 93.2 56 6.5 30 73 4 
AM2201 
360.1 155.1 61 8.0 22 31 4 
360.1 127.2 61 8.0 22 65 4 
AM2201 N4OH pentyl 376.1 155.1 61 7.0 26 33 4 
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Table 18 – Optimised tandem mass spectrometric parameters for 
Synthetic Cannabinoid Receptor Agonists included in one or more 
methods detailed in this research 
Analyte 
Precursor 
Mass 
Product 
Mass 
DP (V) EP (V) 
CEP 
(V) 
CE 
(eV) 
CXP 
(V) 
376.1 127.1 61 7.0 26 67 4 
AM2201 N5OH indole 
376.1 155.0 66 7.5 28 37 4 
376.1 127.1 66 7.5 28 71 4 
APICA 
365.2 135.2 76 7.0 26 41 4 
365.2 107.2 71 8.0 26 57 4 
APICA N4OH pentyl 
381.2 135.2 66 7.0 28 41 4 
381.2 107.2 71 4.5 28 63 4 
FUB-PB-22 
397.2 109.1 36 4.5 20 51 4 
397.2 252.1 36 4.5 20 19 4 
BB-22 
385.2 240.3 36 4.0 32 23 4 
385.2 144.1 36 4.0 32 47 4 
385.2 116.1 36 4.0 32 87 4 
BB-22 3-carboxy indole 
258.1 118.1 56 5.5 14 31 4 
258.1 132.1 56 5.5 14 25 4 
MAM2201 N4OH pentyl 
390.2 168.9 66 8.0 18 39 4 
390.2 141.1 66 8.0 18 59 4 
MDMB-CHMICA 
385.1 240.2 36 4.0 32 23 4 
385.1 144.1 36 4.0 32 47 4 
385.1 116.1 36 4.0 32 87 4 
MDMB-CHMICA O-
desmethyl acid 
metabolite 
371.2 240.2 31 6.5 28 21 6 
371.2 144.2 31 6.5 28 49 4 
MDMB-CHMINACA 
386.2 241.2 56 5.0 22 27 4 
386.2 326.2 56 5.0 22 19 6 
MAB-CHMINACA 
371.2 240.2 41 8.5 20 21 4 
371.2 144.1 41 8.5 20 51 4 
MAB-CHMINACA M1 
387.2 257.2 41 8.5 22 29 4 
387.2 145.2 41 8.5 22 57 4 
5F-MDMB-PINACA 
378.2 233.1 46 8.5 20 27 4 
378.2 145.1 46 8.5 20 57 4 
5F-MDMB-PINACA O-
desmethyl acid 
metabolite 
364.2 233.2 41 9.0 18 25 4 
364.2 145.2 41 9.0 18 55 4 
MMB2201 
363.2 232.1 31 7.5 20 21 4 
363.2 144.1 31 7.5 20 53 4 
MMB-FUBINACA 
384.1 109.2 51 5.5 28 55 4 
384.1 253.0 51 5.5 28 25 6 
MMB-CHMICA 
371.2 241.2 41 8 28 29 4 
371.2 145.1 41 8 28 57 4 
5F-NPB-22 
378.2 233.1 46 8.5 20 27 4 
378.2 145.1 46 8.5 20 57 4 
PB-22 
359.1 214.1 31 4.5 26 19 4 
359.1 144.1 31 4.5 26 51 4 
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Table 18 – Optimised tandem mass spectrometric parameters for 
Synthetic Cannabinoid Receptor Agonists included in one or more 
methods detailed in this research 
Analyte 
Precursor 
Mass 
Product 
Mass 
DP (V) EP (V) 
CEP 
(V) 
CE 
(eV) 
CXP 
(V) 
PB-22 N5OH pentyl 
375.1 230.1 31 5.0 26 21 4 
375.1 144.1 31 5.0 26 49 4 
PB-22 N-pentanoic acid 
389.0 244.1 26 4.5 30 19 4 
389.0 144.1 26 4.5 30 47 4 
5F-PB-22 
377.1 232.0 26 4.5 28 21 4 
377.1 144.1 26 4.5 28 53 4 
5F-PB-22 N-pentanoic 
acid 3-carboxyindole 
262.1 244.2 31 10.0 14 15 4 
262.1 144.1 31 10.0 14 33 4 
STS-135 
383.2 135.2 71 8.5 28 41 4 
383.2 107.2 76 8.0 28 59 4 
STS-135 N4OH pentyl 
399.1 135.1 81 8.0 20 41 4 
399.1 93.2 81 8.0 20 69 4 
CUMYL-PeGACLONE 
373.2 255.2 36 6.5 26 19 4 
373.2 167.2 36 6.5 26 65 4 
AB-FUBINACA-d4 373.1 109.2 26 7.0 26 53 4 
PB-22-d9 368.2 223.2 26 4.5 24 19 4 
AM2201-d5 365.2 155.1 61 8.0 26 31 4 
AKB48-d11 377.3 135.2 46 8.5 20 27 4 
AKB48 N5OH pentyl-d4 386.2 135.2 51 9.0 28 29 4 
 
The compounds detailed in Table 17 and Table 18 can be grouped together based 
on their structures and how these fragment in the MS source.  
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241
145
 
109
253
 
AB-CHMINACA AB-FUBINACA 
215
145
 
233
145
 
AB-PINACA 5F-MDMB-PINACA 
Figure 18 – Fragmentation at the carboxamide linkage, and between the 
indole/indazole core and tail in selected Synthetic Cannabinoid Receptor 
Agonists 
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240
144
 
109
253
 
MDMB-CHMICA MMB-FUBINACA 
232
+H = 144
 
MMB2201 
Figure 18 – Fragmentation at the carboxamide linkage, and between the 
indole/indazole core and tail in selected Synthetic Cannabinoid Receptor 
Agonists 
 
Fragmentation can take place between the nitrogen and carbon atoms in the 
carboxamide linkage, and between the nitrogen and carbon atoms joining the 
indole or indazole group to the tail group (Figure 18). This fragmentation pattern 
occurs in AB-CHMINACA and metabolites, AB-FUBINACA, metabolites and 
deuterated analogue, AB-PINACA and metabolite, 5F-AB-PINACA, 5F-ADB-
PINACA, MDMB-CHMICA and metabolite, MDMB-CHMINACA, 5F-MDMB-
PINACA and metabolite, MMB-FUBINACA, MMB2201, MAB-CHIMINACA and 
metabolite, and MMB-CHMICA. 
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135
135 - C2H4 = 107
135 - C3H6 = 93
 
5F-AKB48 
Figure 19 – Fragmentation at the adamantyl group in selected Synthetic 
Cannabinoid Receptor Agonists 
 
For AKB48, metabolites and deuterated analogues, 5F-AKB48 and metabolite, 
APICA and metabolite, and STS-135 and metabolite the fragmentation occurs at 
the adamantyl group (Figure 19). Cleavage of this after the nitrogen atom results 
in the m/z 135 ion, and the loss of C2H4 or C3H6 from this group results in the ions 
at m/z 107 and 93 respectively. 
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144
232
 
144
240
 
5F-PB-22 BB-22 
144
233
 
+H = 252
109
 
5F-NPB-22 FUB-PB-22 
Figure 20 – Fragmentation at the carboxyl linkage in selected Synthetic 
Cannabinoid Receptor Agonists 
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+3H = 118
+2H = 132
 
BB-22 3-carboxy indole 
Figure 20 – Fragmentation at the carboxyl linkage in selected Synthetic 
Cannabinoid Receptor Agonists 
 
Compounds containing the carboxyl linkage fragment at this position, either 
between the two oxygen atoms, or between the carboxyl group and the indole or 
indazole group (Figure 20). The two component parts are the primary fragments 
for PB-22, metabolites and deuterated analogue, 5F-PB-22, BB-22 and 5F-NPB-
22. Fragmentation also occurs between the indole core and tail for FUB-PB-22 
and the BB-22 3-carboxy indole metabolite. This happens before the first carbon 
atom in the tail group, and includes the remainder of the molecule for FUB-PB-22. 
In BB-22 3-carboxy indole, fragmentation occurs both before and after the first 
carbon atom in the tail group, resulting in fragments comprising the indole group 
alone and the indole group plus the first carbon atom from the tail.  
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155
127
 
AM2201 
141
169
 
MAM2201 N4OH pentyl 
Figure 21 – Fragmentation at the methanone linkage in selected Synthetic 
Cannabinoid Receptor Agonists 
 
AM2201, metabolites and deuterated analogue, and MAM2201 N4OH pentyl 
fragment around the methanone linkage (Figure 21). Fragmentation happens both 
before and after the oxygen molecule in this group, and resulting fragments 
include the naphthyl group and, in MAM2201 N4OH pentyl, the methyl group 
attached to this.  
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+H = 255
-H2O = 167
  
CUMYL-PeGACLONE 
Figure 22 – Fragmentation in the Synthetic Cannabinoid Receptor Agonist 
CUMYL-PeGACLONE 
 
Within the CUMYL-PeGACLONE molecule, fragmentation takes place between 
the tricyclic group and the pentyl chain, and the tricyclic group and the benzyl 
group. For the production of the fragment at m/z 255, the tricyclic and pentyl chain 
remain intact, while for the fragment at m/z 167, the tricyclic group is fully 
detached, and the carbonyl group is also removed. 
Because of these close structural resemblances and fragmentation patterns 
between compounds in the same classes of SCRAs, several compounds shared, 
or had very similar, ion transitions as far as the resolving power of the instrument 
allowed. These were: AM2201 N4OH pentyl/AM2201 N5OH indole, MDMB-
CHMICA/BB-22, 5F-ADB-PINACA/MMB2201 and 5F-MDMB-PINACA/5F-NPB-22, 
which shared identical transitions. In addition, MDMB-CHMICA and BB-22 were 
similar but not identical to MDMB-CHMINACA; 5F-ADB-PINACA and MMB2201 
were similar but not identical to 5F-MDMB-PINACA O-desmethyl acid metabolite; 
and 5F-MDMB-PINACA and 5F-NPB-22 were similar but not identical to 5F-PB-
22. The ion transitions which were similar but not identical to each other were 
AKB48/APICA, 5F-AKB48/STS-135, AKB48 N5OH pentyl/APICA N4OH pentyl, 
5F-AKB48 N4OH pentyl/STS-135 N4OH pentyl, AB-CHMINACA/AB-CHMINACA 
metabolite 2, and MMB-CHMICA/MAB-CHMINACA. For these reasons it was 
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important to have a chromatographic method with sufficient resolution between 
these compounds with identical or similar transitions. 
4.4.2.2. Mobile Phase Experiments 
From the experiments conducted in 4.3.3.2 it was determined that MP gradients F, 
H and R gave satisfactory retention and separation of analytes on the column for 
methods 1.1, 1.2 and 2.1 respectively. These MP gradient programmes are 
represented graphically in Figure 23. An example chromatogram from each 
method is shown in Figure 24 .  
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Mobile Phase programme F 
 
Mobile Phase programme H 
Figure 23 – Graphical representation of Mobile Phase gradient programmes 
F (top), H (middle) and R (bottom). The red line shows the percentage 
composition of Mobile Phase A (H2O with 2mM ammonium acetate and 0.1% 
formic acid); the blue line shows the percentage composition of Mobile 
Phase B (MeOH with 2mM ammonium acetate and 0.1% formic acid); and the 
green line shows the percentage composition of Mobile Phase C (ACN with 
2mM ammonium acetate and 0.1% formic acid). These programmes were 
used in Methods 1.1, 1.2 and 2.1 (top, middle and bottom respectively). 
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Mobile Phase programme R 
Figure 23 – Graphical representation of Mobile Phase gradient programmes 
F (top), H (middle) and R (bottom). The red line shows the percentage 
composition of Mobile Phase A (H2O with 2mM ammonium acetate and 0.1% 
formic acid); the blue line shows the percentage composition of Mobile 
Phase B (MeOH with 2mM ammonium acetate and 0.1% formic acid); and the 
green line shows the percentage composition of Mobile Phase C (ACN with 
2mM ammonium acetate and 0.1% formic acid). These programmes were 
used in Methods 1.1, 1.2 and 2.1 (top, middle and bottom respectively). 
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Method 1.1 
 
 
Method 1.2 
Figure 24 – Example chromatograms obtained from the Mobile Phase 
gradients employed in methods 1.1 (top), 1.2 (middle), and 2.1 (bottom) 
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Method 2.1 
Figure 24 – Example chromatograms obtained from the Mobile Phase 
gradients employed in methods 1.1 (top), 1.2 (middle), and 2.1 (bottom) 
 
Interrogation of the mixed standard injected and evaluated using these gradients 
showed baseline separation was achieved for all analytes with the same or similar 
(≤1 amu difference) ion transitions, with the exception of the shared BB-22/MDMB-
CHMICA transition for method 1.1. The discussion around the interference 
between BB-22 and MDMB-CHMICA as presented in section 3.5.2.5 is relevant 
here also. Retention times were identified from injections of individual compounds 
and noted for each analyte. Analytes were therefore identifiable and distinctive by 
either ion transition or retention time, including the distinction between MDMB-
CHMICA and BB-22 for methods 1.2 and 2.1. 
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4.4.3. Extraction of Analytes 
4.4.3.1. Extraction from Blood 
Experiments conducted in 4.3.4.1 identified experiment 10 as the optimal 
conditions for extraction of analytes from blood. This protocol is detailed in Table 
19 and was used in the optimised and validated method 2.1 as applied to blood. 
Table 19 – Optimised protocol for the extraction of 
selected Synthetic Cannabinoid Receptor Agonists from 
blood 
Parameter Conditions 
Volume of blood (mL) 0.5 
Buffer type 0.1M pH6.0 phosphate buffer 
Volume of buffer (mL) 0.5 
Extraction solvent tBME 
Volume of solvent (mL) 1 
Mixing time (min.) 2 
 
It was thought that the saline solution added to the packed red cells in the 
production of blank blood (see section 3.3.1.16) may be contributing towards 
unacceptable ME. It was therefore decided to prepare blank blood by mixing 
packed red cells 1:1 with deionised H2O rather than saline solution and 
investigating the recovery, ME and process efficiency of the optimised extraction 
protocol. The recovery, ME and process efficiency of the default, optimised (with 
saline) and optimised (without saline) extraction protocols are given in Table 20, 
with green boxes showing the most desirable results. Figure 25 shows the process 
efficiencies for the original and optimised extraction protocols in the form of a bar 
chart. From this, it is clear to see the improvement for some compounds, and 
detrimental effects for others.  
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Table 20 – Recovery, matrix effects and process efficiency of original and 
optimised protocols for the extraction of selected Synthetic Cannabinoid 
Receptor Agonists from blood. Results are given for blank blood prepared 
with and without saline 
Analyte 
Original 
Optimised 
(saline) 
Optimised (no 
saline) 
Rec 
(%) 
ME 
(%) 
PE 
(%) 
Rec 
(%) 
ME 
(%) 
PE 
(%) 
Rec 
(%) 
ME 
(%) 
PE 
(%) 
AB-CHMINACA 56 164 93 88 119 105 99 92 91 
AB-CHMINACA M1A 62 123 76 63 120 76 63 106 66 
AB-CHMINACA M2 50 113 56 72 85 61 83 89 74 
AB-FUBINACA 71 121 86 83 144 120 84 103 86 
AB-FUBINACA M2B 14 106 15 5 106 5 11 98 10 
AB-FUBINACA valine 
metabolite 
56 126 70 72 137 99 66 101 67 
MMB-FUBINACA 69 110 76 80 94 75 92 91 84 
AKB48  31 40 12 70 19 13 33 40 13 
AKB48 N5OH Pentyl 64 106 68 87 90 78 99 82 81 
AKB48 N-Pentanoic Acid 63 101 63 83 84 70 97 92 89 
5F-AKB48 47 76 36 97 36 34 45 90 41 
5F-AKB48 N4OH Pentyl 66 96 63 78 74 57 101 84 84 
PB-22 58 95 56 78 68 54 75 99 74 
PB-22 N5OH Pentyl 73 91 66 77 101 79 91 97 88 
PB-22 N-Pentanoic Acid 67 78 53 60 92 55 72 117 84 
5F-PB-22 69 90 62 80 85 68 86 99 86 
5F-NPB-22 70 91 63 67 96 64 84 101 85 
MDMB-CHMICA 50 113 57 88 68 59 87 78 68 
MDMB-CHMICA O-
desmethyl Acid 
74 130 96 71 80 56 74 85 63 
MDMB-CHMINACA 49 85 41 100 41 41 50 92 46 
BB-22 49 81 40 89 48 42 59 94 55 
BB-22 3-carboxyindole 56 96 53 80 60 48 92 82 75 
AM2201 60 98 59 86 71 61 82 88 73 
AM2201 N4OH Pentyl 74 86 64 73 87 63 87 102 89 
AB-PINACA 67 156 106 76 148 112 90 99 89 
AB-PINACA N4OH pentyl 56 158 89 59 179 105 59 118 70 
5F-AB-PINACA 73 175 128 75 163 123 81 119 96 
5F-MDMB-PINACA 65 107 70 80 93 74 91 96 87 
5F-MDMB-PINACA O-
desmethyl Acid 
59 167 99 60 147 88 72 100 73 
APICA 39 57 23 102 23 23 36 80 29 
APICA N4OH Pentyl 67 128 86 82 110 90 97 132 128 
STS-135 50 92 46 88 60 53 82 80 65 
STS-135 N4OH Pentyl 60 116 70 87 93 81 87 152 132 
MMB2201 75 119 89 78 117 91 95 92 88 
MAM2201 N4OH Pentyl 68 98 67 78 90 70 94 99 93 
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Figure 25 – Bar chart showing the comparison of the process efficiencies of the original and optimised protocols for the 
extraction of selected Synthetic Cannabinoid Receptor Agonists from blood. 
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In Table 20, the preferred values were considered ≥60% for recovery, ±20% for 
matrix effects and 60 – 120% for process efficiency. Acceptable but sub-optimal 
result were considered ≥40% for recovery, ±30% for matrix effects and 50 – 130% 
for process efficiency. Any result outside of these ranges should be considered 
when interpreting the results of analyses. It’s clear from this table that optimisation 
of the extraction and subsequent use of saline-free blank blood has improved the 
performance of the extraction. The number of preferred values increased from 65 
to 90 between the original method and the optimised method with no saline. 
Simultaneously, acceptable and undesirable results decreased from 26 to 7, and 
from 17 to 11 respectively. The results for AKB48 saw a decrease in recovery but 
improvement in ME from optimised with saline to the conditions without saline 
solution. The PE remained the same for both of these conditions so neither 
method is optimal. 
The results that are outwith acceptable ranges relate to AB-FUBINACA M2B, 
AKB48, 5F-AKB48, MDMB-CHMINACA, APICA and STS-135 N4OH pentyl. 
Results for all of these drugs show values below acceptable ranges for recovery 
and/or process efficiency, with the exception of STS-135 N4OH pentyl which 
shows high levels of ion enhancement and therefore process efficiency. Caution 
should be taken when reporting negative results for the former compounds as their 
presence may be masked by ion suppression or poor recovery. The instrumental 
response for these compounds should be examined closely and that for the lowest 
calibrator should be multiplied by the process efficiency to determine whether low 
concentrations of the drug could be identified as positive in samples, taking 
sample condition into account.  
Similar caution should be taken when reporting quantitative results for STS-135 
N4OH pentyl: while ion enhancement will not cause false positives in negative 
samples, it will affect the accuracy of quantitative results.  
These factors should be considered in determining whether the method is fit-for-
purpose for these drugs and whether they are included in the overall method at all. 
While further optimisation may allow for improvements in the recovery, matrix 
effects and, consequently, process efficiency, the extraction protocol is always 
going to be a compromise between all the analytes included. For this reason, the 
compounds that are known or suspected to be more common, such as MDMB-
CHMICA, 5F-MDMB-PINACA, AB-FUBINACA, 5F-PB-22, and their metabolites 
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have been prioritised over others. 5F-AKB48 is also high on the priority list 
however the recovery is not critically low for this compound, and the instrumental 
response is relatively high (see Figure 26). 
 
Figure 26 – Extracted ion chromatogram of 5F-AKB48 at 
50% limit of detection (0.05 ng/mL) showing a recovery 
of 45% would still allow a concentration of the limit of 
detection (0.10 ng/mL) to be clearly seen above 
background noise. Intensity is given in counts per 
second 
 
It can be seen that the panel of compounds used in the validated method contains 
additional analytes than were included in the optimisation experiments. This is due 
to the addition of these compounds latterly. It was therefore unknown whether the 
final extraction parameters are optimal for these compounds; however the 
performance of the extraction was determined for these during validation.  
4.4.3.2. Extraction from Urine 
Table 21 provides a summary of the optimum extraction conditions: experiment 
number 13 from Table 13. The results from the experiments conducted into 
extraction optimisation for urine in Section 4.3.4.2 are shown in Table 22 and 
Figure 27. The green boxes show the optimum results for recovery, process 
efficiency and matrix effects.  
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Table 21 – Optimised protocol for the extraction of 
selected Synthetic Cannabinoid Receptor Agonists 
from urine 
Parameter Conditions 
Volume of urine (mL) 0.5 
Buffer type 
No buffer 
Volume of buffer (mL) 
Extraction solvent MeOH 
Volume of solvent (mL) 2 
Mixing time (min.) 5 
 
Figure 27 shows clearly the improvement of the process efficiency between the 
original and optimised extraction protocols. 
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Table 22 – Recovery, matrix effects and process efficiency of original and 
optimised protocols for the extraction of selected Synthetic Cannabinoid 
Receptor Agonists from urine 
Analyte 
Original Optimised 
REC (%) PE (%) ME (%) REC (%) PE (%) ME (%) 
AB-CHMINACA 13 15 116 93 112 120 
AB-CHMINACA M1A 9 12 130 98 68 70 
AB-CHMINACA M2 13 12 91 77 88 114 
AB-FUBINACA 11 17 149 99 114 115 
AB-FUBINACA M2B 0 0 113 93 85 92 
AB-FUBINACA Valine 
Metabolite 
12 13 107 86 97 112 
MMB-FUBINACA 13 13 100 79 62 78 
AKB48  13 4 36 26 23 88 
AKB48 N5OH Pentyl 14 13 91 77 72 94 
AKB48 N-Pentanoic 
Acid 
14 13 93 78 69 88 
5F-AKB48 13 9 69 56 50 89 
5F-AKB48 N4OH Pentyl 15 14 91 81 71 88 
PB-22 1 1 90 66 44 66 
PB-22 N5OH Pentyl 0 0 68 95 66 70 
PB-22 N-Pentanoic Acid 8 6 73 98 78 79 
5F-PB-22 0 0 96 76 53 70 
5F-NPB-22 0 0 89 0 0 67 
MDMB-CHMICA 15 12 79 71 72 101 
MDMB-CHMICA O-
desmethyl Acid 
13 12 89 77 89 116 
MDMB-CHMINACA 13 9 68 59 53 90 
BB-22 1 0 74 65 43 66 
BB-22 3-Carboxy Indole 17 16 95 85 63 74 
AM2201 14 13 91 65 47 72 
AM2201 N4OH Pentyl 13 13 95 84 55 66 
AB-PINACA 14 17 126 91 113 124 
AB-PINACA N4OH 
pentyl 
10 13 138 102 80 78 
5F-AB-PINACA 13 14 108 102 152 149 
5F-MDMB-PINACA 14 14 104 78 63 81 
5F-MDMB-PINACA O-
desmethyl Acid 
10 12 121 86 109 126 
APICA 11 6 51 51 38 74 
APICA N4OH Pentyl 14 15 108 80 71 89 
STS-135 16 12 76 74 52 70 
STS-135 N4OH Pentyl 14 13 94 78 70 90 
MMB2201 14 15 107 94 80 85 
MAM2201 N4OH Pentyl 14 13 93 96 66 69 
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Figure 27 – Bar chart showing the comparison of the process efficiencies of the original and optimised protocols for the 
extraction of selected Synthetic Cannabinoid Receptor Agonists from urine.  
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While some of the results for the ME are better in the original protocol, the results 
for the recovery are significantly improved for all analytes with the exception of 5F-
NPB-22 by using the optimised method. Overall, in the optimised method, 31, 24 
and 17 compounds are in the preferred range for recovery, PE and ME 
respectively. The corresponding numbers for acceptable results are 3, 5 and 13 
compounds for recovery, PE and ME. Only 2 compounds are outwith the 
acceptable range for recovery; 7 for PE and 6 for ME.  
The compounds showing unacceptable results are AKB48, 5F-NPB-22 and APICA 
which show poor recovery and PE. 5F-AB-PINACA shows an unacceptably high 
degree of ME and, consequently, PE. While AKB48 is a high priority compound, 
based on the number of positive case samples observed, this and the other 
compounds giving unacceptable results are all parent molecules and are therefore 
unlikely to be encountered in authentic urine samples. As noted above, the 
optimisation process is a compromise to obtain the best results for the highest 
number of compounds and the conditions given in Table 21 were thought to 
provide sufficiently good results overall. 
A more in-depth assessment of recovery, PE and ME will be conducted in the 
method validation. 
The results for the experiments conducted into urine hydrolysis are given in Table 
23. Numbers 1 – 6 in this table refer to the number of experiment as detailed in 
Table 14. Conditions for experiment number 4 were determined to be the optimum 
and were included in the optimised method as applied to urine samples. From 
Table 23 it is clear that experiment 4 did not give highest PE values for all 
compounds, however it should be borne in mind that experiments 5 and 6 did not 
include any β-glucuronidase enzyme. As a result, these conditions would not bring 
about hydrolysis if glucuronidated forms of the metabolites were present in 
genuine samples. Similarly, experiments 1, 3 and 5 were all conducted at RT, 
meaning that the β-glucuronidase enzyme would be unlikely to act effectively in 
these conditions. The experiments were intended to provide more information on 
how the presence of buffer, enzyme and heat affected the experimental results in 
terms of PE and compound stability. The highest result in Table 23, therefore, 
does not necessarily mean the best experimental conditions. It was accepted that 
β-glucuronidase would be required to actively hydrolyse conjugated compounds, 
and, in the absence of any compound loss through heating, that higher than 
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ambient temperatures would be required for this. It is clear then, from the results of 
these experiments, that the presence of the buffer used was detrimental to the PE. 
Therefore conditions detailed in experiment 4 were taken forward. 
Table 23 – Results of the experiments into the hydrolysis of 
selected Synthetic Cannabinoid Receptor Agonists in urine. The 
conditions in experiment 4 were taken forward to induce 
satisfactory hydrolysis with acceptable process efficiency. 
Analyte 
Process Efficiency 
1 2 3 4 5 6 
AB-CHMINACA 63 57 101 93 86 79 
AB-CHMINACA M1A 50 50 94 93 77 83 
AB-CHMINACA M2 40 32 52 46 43 43 
AB-FUBINACA 63 60 103 307 90 90 
AB-FUBINACA M2B 0 0 0 0 0 0 
AB-FUBINACA valine metabolite 25 18 36 30 21 22 
MMB-FUBINACA 75 59 92 86 96 86 
AKB48  28 8 16 6 40 11 
AKB48 N5OH pentyl 61 51 85 82 83 78 
AKB48 N-pentanoic Acid 52 47 72 66 68 71 
5F-AKB48 57 22 42 30 77 44 
5F-AKB48 N4OH pentyl 62 54 92 87 85 80 
PB-22 65 39 50 49 85 68 
PB-22 N5OH pentyl 60 58 81 79 83 81 
PB-22 N-pentanoic Acid 27 19 31 24 21 31 
5F-PB-22 68 57 72 74 90 82 
5F-NPB-22 66 42 0 0 79 27 
MDMB-CHMICA 60 36 63 52 83 67 
MDMB-CHMICA O-desmethyl Acid 41 35 55 46 43 43 
MDMB-CHMINACA 60 24 48 34 82 49 
BB-22 53 26 32 31 75 53 
BB-22 3-carboxyindole 74 62 90 86 95 75 
AM2201 63 42 70 63 84 71 
AM2201 N4OH pentyl 58 54 71 69 79 78 
AM2201 N5OH indole 57 53 82 79 82 77 
AB-PINACA 64 64 128 126 91 89 
AB-PINACA N4OH pentyl 66 74 94 96 109 115 
5F-AB-PINACA 62 60 122 117 85 94 
5F-MDMB-PINACA 70 56 84 80 89 81 
5F-MDMB-PINACA O-desmethyl Acid 27 19 45 36 24 22 
APICA 42 15 23 16 60 30 
APICA N4OH pentyl 58 51 96 92 84 82 
STS-135 57 36 54 46 77 62 
STS-135 N4OH pentyl 58 53 92 87 82 81 
MMB2201 69 64 100 95 90 85 
MAM2201 N4OH pentyl 60 55 82 77 80 76 
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A summary of the parameters used for methods 1.1, 1.2 and 2.1 is given for 
reference in Table 24. The compound panels for the methods, and the I.S. used 
for each analyte is given in Table 25.  
Table 24 – Summary of extraction, hydrolysis (urine only), and instrumental 
parameters used in analytical methods applied to Emergency Department, 
post-mortem, Scottish Prison Service, Forensic Directorate, and Glasgow 
Drug Court cohorts. 
Parameter Method 1.1 Method 1.2 Method 2.1 
Hydrolysis protocol 
(urine only) 
50 µL β-
glucuronidase, 60 
°C for 1 H 
50 µL β-
glucuronidase, 60 
°C for 1 H 
50 µL β-
glucuronidase, 60 
°C for 1 H 
(no buffer) 
Extraction protocol 
0.5 mL blood/urine, 
1 mL pH6.0 
phosphate buffer, 2 
mL tBME, ca. 30 
second vortex mix 
0.5 mL blood/urine, 
1 mL pH6.0 
phosphate buffer, 2 
mL tBME, ca. 30 
second vortex mix 
0.5 mL blood, 0.5 
mL pH6.0 
phosphate buffer, 1 
mL tBME, 2 min. 
flatbed mix 
0.5 mL urine, 2 mL 
MeOH, 5 min. 
flatbed mix 
MP Gradient 
 
A = dH2O* 
B= MeOH* 
C=ACN:dH2O (95:5)* 
 
*with 2mM ammonium 
acetate and 0.1% 
formic acid 
F 
0-5 min: 40 % A, 
60% B 
5-10 min: ramped to 
10% A, 90% B 
10-20 min: 10% A, 
90% B 
20-20.1 min: ramped 
to 40% A, 60% B 
20.1-25 min:40% A,  
60% B 
H 
0-5 min: 40% A, 
60% B 
5-8.5 min: ramped to 
20% A, 80% B 
8.5-18 min: ramped 
to 10% A, 90% B 
18-20 min: 10% A, 
90% B 
20-20.1 min: ramped 
to 40% A, 60% B 
20.1-25 min: 40% A, 
60% B 
R 
0.-4 min: 60% A, 
40% C 
4-14 min: ramped to 
40% A, 60% C 
14-28 min: 40% A, 
60% C 
28-28.1 min: ramped 
to 20% A, 80% C 
28.1-40 min: 20% A, 
80% C 
40-40.1 min: ramped 
to 60% A, 40% C 
40.1-45 min: 60% A, 
40% C 
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Table 25 – Compound panels and internal standards used for Methods 1.1, 1.2 
and 2.1. 
Compound 
Method 
1.1 
Method 
1.2 
Method 
2.1 
I.S. 
AB-CHMINACA Yes Yes Yes AB-FUBINACA-d4 
AB-CHMINACA M1A Yes Yes Yes AB-FUBINACA-d4 
AB-CHMINACA M2 Yes Yes Yes AB-FUBINACA-d4 
AB-FUBINACA  Yes Yes Yes AB-FUBINACA-d4 
AB-FUBINACA M2B Yes Yes Yes AB-FUBINACA-d4 
AB-FUBINACA valine metabolite Yes Yes Yes AB-FUBINACA-d4 
AB-PINACA No Yes Yes AB-FUBINACA-d4 
AB-PINACA N4OH pentyl No No Yes AB-FUBINACA-d4 
ADB-FUBINACA No No Yes AB-FUBINACA-d4 
5F-AB-PINACA No Yes Yes AB-FUBINACA-d4 
5F-ADB-PINACA No No Yes AB-FUBINACA-d4 
AKB48  Yes Yes Yes AKB48-d11 
AKB48 N5OH pentyl Yes Yes Yes 
AKB48 N5OH 
pentyl-d4 
AKB48 N-pentanoic acid Yes Yes Yes 
AKB48 N5OH 
pentyl-d4 
5F-AKB48 Yes Yes Yes 
AKB48 N5OH 
pentyl-d4 
5F-AKB48 N4OH pentyl Yes Yes Yes 
AKB48 N5OH 
pentyl-d4 
AM-2201 No Yes Yes AM2201-d5 
AM-2201 N4OH pentyl No Yes Yes AM2201-d5 
AM-2201 N5OH indole No Yes Yes AM2201-d5 
APICA No Yes No AKB48-d11 
APICA N4OH pentyl No Yes Yes 
AKB48 N5OH 
pentyl-d4 
FUB-PB-22 No No Yes PB-22-d9 
BB-22 Yes Yes Yes PB-22-d9 
BB-22 3-carboxy indole Yes Yes Yes PB-22-d9 
CUMYL-PeGACLONE No No Yes AB-FUBINACA-d4 
MAM-2201 N4OH pentyl No No Yes AM2201-d5 
MAB-CHMINACA No No Yes AB-FUBINACA-d4 
MAB-CHMINACA M1 No No Yes AB-FUBINACA-d4 
MDMB-CHMICA Yes Yes Yes AB-FUBINACA-d4 
MDMB-CHMICA O-desmethyl acid 
metabolite 
No Yes Yes AB-FUBINACA-d4 
MDMB-CHMINACA Yes Yes Yes AB-FUBINACA-d4 
5F-MDMB-PINACA No Yes Yes AB-FUBINACA-d4 
5F-MDMB-PINACA O-desmethyl 
acid 
No No Yes AB-FUBINACA-d4 
MMB2201 No No Yes AM2201-d5 
MMB-CHMICA No No Yes AB-FUBINACA-d4 
MMB-FUBINACA No No Yes AB-FUBINACA-d4 
5F-NPB-22 No No Yes PB-22-d9 
PB-22 Yes Yes Yes PB-22-d9 
PB-22 N5OH pentyl Yes Yes Yes PB-22-d9 
  115 
Table 25 – Compound panels and internal standards used for Methods 1.1, 1.2 
and 2.1. 
Compound 
Method 
1.1 
Method 
1.2 
Method 
2.1 
I.S. 
PB-22 N-pentanoic acid Yes Yes Yes PB-22-d9 
PB-22 N-pentanoic acid 3-
carboxyindole 
Yes Yes No PB-22-d9 
5F-PB-22 Yes Yes Yes PB-22-d9 
STS-135 No Yes No AKB48-d11 
STS-135 N4OH pentyl No Yes Yes 
AKB48 N5OH 
pentyl-d4 
AB-FUBINACA-d4 Yes Yes Yes N/A 
PB-22-d9 Yes Yes Yes N/A 
AM2201-d5 No No Yes N/A 
AKB48-d11 No No Yes N/A 
AKB48 N5OH pentyl-d4 No No Yes N/A 
 
4.4.4. Method Validation – Method 2.1 applied to blood 
Due to the intended nature of the method and number of compounds included in 
its panel, it was decided to conduct a qualitative validation for all compounds with 
quantitative validation undertaken those compounds thought to be most likely 
encountered. Parameters relating to quantitation – linearity, accuracy and 
precision – were therefore not validated for all compounds.  
4.4.4.1. Linearity 
A linear calibration model using 1/χ-weighting was established for 26 compounds 
where quantitative validation was felt necessary, as demonstrated by correlation 
co-efficient values of ≥0.99 over 10 calibrations. The minimum values are given in 
Table 26. For all calibrations, 7 calibrators were used and the calculated 
concentrations for at least 6 of these were within ±20% of the expected value. 
Those calibration points outside ±20% were removed from the calibration. An 
example calibration curve for 5F-MDMB-PINACA O-desmethyl acid metabolite is 
shown in Figure 28. 
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Table 26 – Linearity of compounds selected for quantitative 
validation. All gave satisfactory correlation coefficients of 
≥0.99. 
Compound Minimum R (n=10) 
5F-MDMB-PINACA 0.9921 
5F-MDMB-PINACA O-desmethyl acid 0.9939 
MDMB-CHMICA 0.9919 
MDMB-CHMICA O-desmethyl acid 0.9950 
AB-FUBINACA 0.9995 
MMB-FUBINACA 0.9956 
AB-FUBINACA valine metabolite 0.9974 
5F-PB-22 0.9906 
PB-22 0.9959 
PB-22 N5OH pentyl 0.9908 
5F-AKB48 0.9942 
5F-AKB48 N4OH pentyl 0.9939 
AKB48  0.9973 
AKB48 N5OH pentyl 0.9979 
BB-22 0.9925 
BB-22 3-carboxyindole 0.9902 
AM2201 0.9996 
AM2201 N4OH pentyl 0.9913 
AB-PINACA 0.9965 
AB-PINACA N4OH pentyl 0.9960 
5F-AB-PINACA 0.9991 
5F-ADB-PINACA 0.9975 
MMB2201 0.9938 
MAM2201 N4OH pentyl 0.9913 
AB-CHMINACA 0.9984 
AB-CHMINACA M2 0.9967 
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Figure 28 – An example calibration curve for 5F-MDMB-PINACA O-desmethyl 
acid metabolite from Method 2.1, with 1/χ weighting, giving a correlation 
coefficient of 0.9993. This is representative of 10 calibrations assessed for 
linearity. 
 
4.4.4.2. Selectivity 
Selectivity was demonstrated for all compounds. An example blank XIC for 5F-
MDMB-PINACA O-desmethyl acid metabolite is given in Figure 29 (top), showing 
a lack of analyte response (left) and I.S. (right). An example of a low positive case 
sample (0.13 ng/mL, middle) and a higher positive case sample (7.4 ng/mL, 
bottom) is also given to demonstrate the difference to a blank sample. 
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Figure 29 – An example blank (top), low positive case sample (middle) and 
higher positive case sample (bottom) chromatograms for 5F-MDMB-PINACA 
O-desmethyl acid metabolite (left) with internal standard (right), 
demonstrating selectivity. Note the internal standard is erroneously referred 
to as AB-FUBINACA-d9 in the middle trace: AB-FUBINACA-d4 was used. The 
variation in retention time is due to inter-batch variation, and the use of 
different analytical columns and mobile phase batches. Intensity is given in 
counts per second. 
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4.4.4.3. Sensitivity 
The LODs and LLOQs for all compounds, determined as described in 4.3.5.3, are 
given in Table 27. The SNR are given in parenthesis for the LOD and an example 
of how these were calculated is given in Figure 30. 
Table 27 – Limits of Detection and Lower Limits of Quantitation for all 
Synthetic Cannabinoid Receptor Agonist compounds included in Method 
2.1, as applied to blood. The signal-to-noise ratios for the Limits of 
Detection are given in parenthesis. 
Compound LOD (ng/mL) (SNR) LLOQ (ng/mL)  
5F-MDMB-PINACA 0.02 (8) 0.10 
5F-MDMB-PINACA O-desmethyl acid 0.05 (5) 0.20 
MDMB-CHMICA 0.10 (9) 0.10 
MDMB-CHMICA O-desmethyl acid 0.20 (10) 0.20 
AB-FUBINACA 0.20 (11) 0.20 
MMB-FUBINACA 0.02 (8) 0.10 
AB-FUBINACA valine metabolite 0.10 (6) 0.20 
5F-PB-22 0.01 (7) 0.10 
PB-22 0.02 (6) 0.10 
PB-22 N5OH pentyl 0.02 (13) 0.20 
5F-AKB48 0.10 (5) 0.10 
5F-AKB48 N4OH pentyl 0.05 (6) 0.20 
AKB48  0.20 (5) 0.20 
AKB48 N5OH pentyl 0.10 (7) 0.20 
BB-22 0.05 (7) 0.10 
BB-22 3-carboxyindole 5.00 (18) 5.00 
AM2201 0.01 (6) 0.10 
AM2201 N4OH pentyl 0.01 (5) 0.20 
AB-PINACA 0.05 (8) 0.10 
AB-PINACA N4OH pentyl 0.10 (6) 0.20 
5F-AB-PINACA 0.10 (6) 0.10 
5F-ADB-PINACA 0.10 (8) 0.10 
MMB2201 0.02 (12) 0.10 
MAM2201 N4OH pentyl 0.01 (8) 0.20 
AB-CHMINACA 0.05 (7) 0.10 
AB-CHMINACA M2 0.05 (8) 0.20 
5F-NPB-22 0.02 (5) 0.10 
AB-CHMINACA M1A 0.20 (4) 0.20 
AB-FUBINACA M2B 5.00 (7)* 5.00 
AKB48 N-pentanoic acid 0.10 (6) 0.20 
APICA N4OH pentyl 0.05 (6) 0.20 
FUB-PB-22 0.02 (8) 0.10 
MDMB-CHMINACA 0.10 (8) 0.10 
PB-22 N-pentanoic acid 0.20 (19) 0.20 
STS-135 N4OH pentyl 0.05 (7) 0.20 
CUMYL-PeGACLONE 0.05 (12) 0.10 
MAB-CHMINACA 0.05 (14) 0.10 
MAB-CHMINACA M1 0.10 (5) 0.20 
MMB-CHMICA 0.10 (8) 0.10 
* 1 source of blank blood for AB-FUBINACA M2B had a SNR <3. 
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Figure 30 – Example of how the signal to noise ratio 
of the compounds was calculated. Intensity is given 
in counts per second. 
 
While additional noise can be observed around 3.00 min. in the baseline in Figure 
30, the compound peak would be baseline resolved from this so it was not 
deemed as an obstacle to accurate detection and thus the noise was measured 
closer to the retention time of interest.  
The LLOQ was set as the lowest calibrator (0.10 or 0.20 ng/mL for parent 
compounds and metabolites respectively) or the LOD if the SNR of this was ≥4, 
whichever was higher.  
Concentrations of SCRAs found in blood are typically very low due to their potency 
and the low dose required for effect. It is therefore essential that the method is 
sufficiently sensitive to detect these low concentrations. The LODs given in Table 
27 show good sensitivity for the majority of compounds. LODs for BB-22 3-
carboxyindole and AB-FUBINACA M2B are higher than ideal at 5.00 ng/mL. As 
these are metabolites the concentrations encountered in samples are likely to be 
higher, however an LOD of 5 ng/mL is too high to be able to say that this method 
is fit for the purpose of detecting AB-FUBINACA M2B and BB-22 3-carboxyindole. 
In addition to this, one of the sources of blank blood used to determine the LOD 
produced a SNR of <3 for AB-FUBINACA M2B.  
It should be noted here that the use of whole blood, including plasma, rather than 
diluted packed red cells, may affect the sensitivity of the method as SCRAs may 
bind to plasma proteins. Whole blood was used for the assessment of matrix 
effects, process efficiency and recovery and discussed in Section 4.4.4.5. 
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4.4.4.4. Accuracy & Precision 
Inter- and intraday accuracy and precision were determined for the 27 quantitative 
compounds. The data are shown in Table 28 and Table 29 for accuracy and 
precision respectively. All the values were within the criteria detailed in sections 
4.3.5.4  and 4.3.5.5 with 1 exception: the interday precision for PB-22 at 0.1 ng/mL 
was high, with a %CV of 16.9. While this is close to the acceptable criteria of 
≤15%, the LLOQ should be amended to 0.2 ng/mL for this compound, as precision 
and accuracy are within acceptable limits at this concentration and above. An 
LLOQ of 0.2 ng/mL is still acceptable for the purposes of this method. Data has 
not been included for BB-22 3-carboxyindole at 0.2 and 2.5 ng/mL as these 
concentrations are below the LOD for this compound (5 ng/mL).  
Taking these exceptions into account, the data show that the method described is 
sufficiently accurate and precise to allow reporting of analyte concentrations. QC 
material at suitable concentrations should, however, be included with every batch 
to ensure continuing fitness-for-purpose. 
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Table 28 – Intra- and interday accuracy of compounds selected for quantitative validation for Method 2.1 applied to 
Blood 
 
Compound 
Accuracy (%) 
Intraday (n=5) Interday (n=5) 
0.1 ng/mL 0.2 ng/mL 2.5 ng/mL 15 ng/mL 42 ng/mL 0.1 ng/mL 0.2 ng/mL 2.5 ng/mL 15 ng/mL 42 ng/mL 
5F-MDMB-PINACA 104.1 86.2 93.5 112.4   96.0 94.0 94.0 92.7   
5F-MDMB-PINACA O-desmethyl acid   106.5 113.6   102.2   96.0 103.1   100.2 
MDMB-CHMICA 80.0 95.2 107.6 115.6   108.0 97.0 101.0 91.0   
MDMB-CHMICA O-desmethyl acid   107.3 108.6   83.8   96.0 96.6   91.7 
AB-FUBINACA 103.4 99.7 108.7 110.3   100.0 103.0 98.8 100.5   
MMB-FUBINACA 77.5 84.6 97.9 98.2   84.0 91.0 103.2 94.6   
AB-FUBINACA valine metabolite   109.2 102.2   98.0   101.0 96.8   98.7 
5F-PB-22 98.3 88.1 89.9 95.3   94.0 94.0 107.0 103.2   
PB-22 102.4 97.0 108.9 107.1   96.0 96.0 101.9 100.5   
PB-22 N5OH pentyl   93.0 116.6   107.1   94.0 103.5   93.3 
5F-AKB48 108.7 97.9 96.5 88.5   100.0 102.0 100.2 90.2   
5F-AKB48 N4OH pentyl   111.2 119.0   104.3   92.0 93.4   90.7 
AKB48  90.2 91.2 115.9     90.0 102.0 100.3 97.6   
AKB48 N5OH pentyl   99.2 101.8   100.3   99.0 94.4   95.4 
BB-22 112.8 90.9 102.8 102.3   98.0 98.0 102.1 101.9   
BB-22 3-carboxyindole   N/A N/A   101.4   N/A N/A   113.7 
AM2201 99.0 89.2 97.5 97.6   98.0 104.0 102.0 99.5   
AM2201 N4OH pentyl   109.1 100.4   112.2   91.0 100.2   98.2 
AB-PINACA 99.9 103.7 100.8 103.2   94.0 101.1 101.7 100.3   
AB-PINACA N4OH pentyl   87.5 103.3   103   98.0 98.7   98.0 
5F-AB-PINACA 107.4 106.3 96.5 104.5   102.0 100.0 98.3 98.4   
5F-ADB-PINACA 104.6 110 112.5 114.8   98.0 104.0 104.0 106.9   
MMB2201 91 97.9 92.4 115.3   90.0 98.0 107.8 98.0   
MAM2201 N4OH pentyl   84.2 109.1   108.3   88.0 103.2   101.6 
AB-CHMINACA 108.5 106.6 98 98.8   96.0 99.0 103.4 100.2   
AB-CHMINACA M2   109.6 102.4   87.1   110.0 98.0   92.8 
 ‘N/A’ indicates the concentration is <LOD. 
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Table 29 – Intra- and interday precision of compounds selected for quantitative validation for Method 2.1 applied to 
Blood 
 
Compound 
Precision 
Intraday (n=5) Interday (n=5) 
0.1 ng/mL 0.2 ng/mL 2.5 ng/mL 15 ng/mL 42 ng/mL 0.1 ng/mL 0.2 ng/mL 2.5 ng/mL 15 ng/mL 42 ng/mL 
5F-MDMB-PINACA 1.7 2.6 3.7 4.4   10.6 7.9 3.0 9.5   
5F-MDMB-PINACA O-desmethyl acid   3.8 2.3   0.9   12.9 5.6   2.3 
MDMB-CHMICA 8.5 4.2 6.5 3.5   10.8 7.0 2.6 10.0   
MDMB-CHMICA O-desmethyl acid   9.5 1.9   7.9   12.5 7.2   8.2 
AB-FUBINACA 8.0 12.6 1.8 1.7   12.6 6.6 3.0 4.0   
MMB-FUBINACA 8.0 13.1 3.8 1.7   9.5 8.8 2.2 4.1   
AB-FUBINACA valine metabolite   9.7 3.8   2.9   6.6 3.5   3.9 
5F-PB-22 2.2 7.2 12.8 10.6   10.8 11.4 7.9 5.8   
PB-22 3.5 7.9 3.3 4.1   16.9 6.9 6.7 3.4   
PB-22 N5OH pentyl   4.8 8.0   6.2   5.2 7.0   10.0 
5F-AKB48 11.8 13.5 10 6.2   8.9 11.4 10.7 5.0   
5F-AKB48 N4OH pentyl   5.2 0.7   2.8   8.8 9.6   10.4 
AKB48  13.8 8.2 4.3     9.9 7.3 5.1 3.6   
AKB48 N5OH pentyl   3.7 2.7   2.0   3.8 6.0   4.9 
BB-22 2.5 9.8 6.2 2.2   14.9 6.1 5.6 9.0   
BB-22 3-carboxyindole   N/A N/A   3.3   N/A N/A   11.9 
AM2201 4.4 3.6 1.5 1.6   10.0 5.6 3.1 6.2   
AM2201 N4OH pentyl   3.3 7.3   2.1   6.4 6.3   11.4 
AB-PINACA 8.4 3.6 5 3.1   10.8 13.8 5.2 2.0   
AB-PINACA N4OH pentyl   7.9 4.9   4.7   6.1 3.7   6.5 
5F-AB-PINACA 14.2 8.7 7.2 2.7   14.4 7.1 5.0 6.9   
5F-ADB-PINACA 10.1 8.8 4.9 2.6   13.5 9.8 9.4 6.3   
MMB2201 10.1 2.9 13.8 6.7   12.2 2.5 4.7 8.1   
MAM2201 N4OH pentyl   6.15 5.7   2.8   8.5 7.3   11.2 
AB-CHMINACA 3.9 6.9 4.1 3.6   14.0 5.9 4.0 6.3   
AB-CHMINACA M2   10.2 7.2   4.0   9.5 12.6   8.1 
‘N/A’ indicates the concentration is <LOD.
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4.4.4.5. Recovery and Matrix Effects 
The results for the recovery and ME experiments are given in Table 30 and Table 
31 for 2.5 ng/mL and 15 ng/mL respectively. The term ‘absolute’ refers to the 
values obtained from using the peak areas in the calculation, whereas ‘I.S. 
compensated’ refers to the use of the peak area ratios. For these experiments, 
blank whole blood was used, rather than diluted packed red cells. The inclusion of 
components such as plasma here provides a relatively realistic account of the 
variation in samples this method was applied to.  
As expected, given their structural diversity, the results of the recovery and ME 
experiments are varied. Absolute recoveries are low for 5F-MDMB-PINACA O-
desmethyl metabolite, MDMB-CHMICA O-desmethyl metabolite, AB-FUBINACA 
valine metabolite, 5F-AKB48, AKB48, AB-CHMINACA M2, AB-FUBINACA M2B, 
AKB48 N-pentanoic acid, MDMB-CHMINACA and PB-22 N-pentanoic acid. These 
are improved to reasonable values when the I.S. is taken into account as a 
compensation for 5F-AKB48, AKB48, AB-CHMINACA M2, AKB48 N-pentanoic 
acid, BB-22, MDMB-CHMINACA and PB-22 N-pentanoic acid. AB-FUBINACA 
M2B is not recovered to any significant degree by the extraction employed in this 
method, leading to the high LOD exhibited in Table 27. As a result, analysis of this 
analyte using the proposed method does not meet acceptable criteria for quality. 
As demonstrated by the LODs and accuracy and precision values for the 
remaining compounds with sub-optimal recoveries, the - albeit low - recovery is 
sufficient to allow adequate and reproducible sensitivity and quantitation as 
required by the nature of the analytes, i.e. differing concentrations of interest for 
parent and metabolite compounds. 
Recoveries above 100% were observed for MDMB-CHMICA, PB-22, 5F-AKB48, 
BB-22, AM2201, MMB2201, 5F-NPB-22, APICA N4OH pentyl, FUB-PB-22, 
MDMB-CHMINACA, STS-135 N4OH pentyl, and CUMYL-PeGACLONE. Some 
instances of this could be due to the random error between different injections and 
indicate an almost complete recovery. Where the recovery is significantly over 
100%, this may indicate retention and build up on the analytical column. The 
impact of this on quantitation could be monitored by injecting the QCs before and 
after samples, and ensuring resulting concentrations are consistent.  
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For many of the compounds including MDMB-CHMICA, 5F-PB-22, PB-22 N5OH 
pentyl, 5F-AKB48, BB-22, AM2201 N4OH pentyl, MMB2201, MAM2201 N4OH 
pentyl, 5F-NPB-22, APICA N4OH pentyl, MDMB-CHMINACA, STS-135 N4OH 
pentyl, CUMYL-PeGACLONE and MAB-CHMINACA, the recovery is significantly 
greater than 100% for the I.S. compensated calculation. The method used a 
relatively low number of I.S. for the number of analytes included, due largely to the 
limited number of deuterated forms of SCRAs available and the prohibitive cost of 
these. It is therefore possible that some of the I.S. do not behave in a sufficiently 
similar way chemically to the compound. As a result, variation between the peak 
areas of the compounds and the I.S. in different standards may be exhibited, 
leading to variations in the PAR. This may be the case where the recovery for the 
I.S. compensated ME values is significantly over 100%. 
The ME results are equally variable, with both significant inhibition and significant 
enhancement observed. Significant inhibition was demonstrated by MDMB-
CHMICA, PB-22, 5F-AKB48, AKB48, BB-22, AM2201, MDMB-CHMINACA and 
CUMYL-PeGACLONE when the absolute values are interrogated. All of these 
compounds, with the exception of AM2201, are eluted towards the end of the run 
time. This is indicative of a build-up of sample artifact on the column causing a 
decrease in the analyte signal, and may be improved by further development of 
the MP gradient or extraction process. The ion suppression observed for AKB48, 
PB-22 and AM2201 is markedly improved when the I.S. compensated results are 
considered as deuterated forms of these compounds are used. The use of 
alternative I.S. for the other affected compounds could, therefore, be examined in 
future work.  
On the other hand, 5F-MDMB-PINACA O-desmethyl metabolite, AB-FUBINACA, 
5F-AKB48 N4OH pentyl, AB-PINACA, AB-PINACA N4OH pentyl, 5F-ADB-
PINACA, MMB2201, AB-CHMINACA, AB-CHMINACA M1A, APICA N4OH pentyl, 
PB-22 N-pentanoic acid, STS-135 N4OH pentyl, MAB-CHMINACA M1 and MMB-
CHMICA have significantly enhanced signals in the absolute values. These effects 
are mitigated by I.S. use for all the compounds except AB-PINACA N4OH pentyl, 
5F-ADB-PINACA, MMB2201, APICA N4OH pentyl, PB-22 N-pentanoic acid, STS-
135 N4OH pentyl and MMB-CHMICA. However, for 5F-PB-22, PB-22 N5OH 
pentyl, BB-22 3-carboxyindole, AM2201 N4OH pentyl, MMB2201, MAM2201 
N4OH pentyl, 5F-NPB-22, FUB-PB-22 and PB-22 N-pentanoic acid, the use of the 
I.S. makes ion enhancement more pronounced.  
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As well as looking at either ion suppression or enhancement, the general range of 
the ME values gave an indication of how variable these are for different sources of 
blank blood. As blood samples can vary drastically in condition, particularly post-
mortem samples, a great deal of care should be taken when interpreting the 
results of this analysis, both in terms of the calculated concentration and the 
presence or absence of analyte. The inclusion of a blank run, or wash method in 
between samples was not conducted here, but could be investigated to clean the 
column and improve variation and extent of ME. The results from the accuracy and 
precision validation, however, do provide confidence in the ability of this method to 
determine the presence and quantity of SCRAs in a sample. 
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Table 30 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects at 2.5 
ng/mL for Method 2.1 applied to blood. 
Compound 
2.5 ng/mL (n=10) 
Absolute  I.S. Compensated 
Recovery (%) Matrix Effects (%) Recovery (%) Matrix Effects (%) 
Min. Max. Min. Max. Min. Max. Min. Max. 
5F-MDMB-PINACA
1
 64 96 71 117 83 115 67 109 
5F-MDMB-PINACA O-desmethyl acid
1
 31 65 102 190 38 81 96 133 
MDMB-CHMICA
1
 45 120 29 102 60 143 22 93 
MDMB-CHMICA O-desmethyl acid
1
 23 43 62 93 30 109 40 93 
AB-FUBINACA
1
 69 87 98 138 94 105 94 102 
MMB-FUBINACA
1
 61 94 70 113 75 110 55 103 
AB-FUBINACA valine metabolite
1
 21 54 91 117 25 69 82 100 
5F-PB-22
2
 62 98 53 98 84 133 97 208 
PB-22
2
 53 117 25 102 78 101 90 120 
PB-22 N5OH pentyl
2
 74 89 101 137 69 134 108 494 
5F-AKB48
3
 34 130 9 113 45 146 10 106 
5F-AKB48 N4OH pentyl*
3
 63 96 69 147 85 120 87 116 
AKB48
4
 19 94 4 91 92 120 85 96 
AKB48 N5OH pentyl
3
 63 96 69 112 91 108 77 95 
BB-22
2
 38 128 11 103 65 181 33 121 
BB-22 3-carboxyindole
2
 40 80 45 105 61 125 99 163 
AM2201*
5
 50 124 36 107 96 103 89 98 
AM2201 N4OH pentyl
5
 72 89 94 124 71 159 95 279 
AB-PINACA
1
 71 89 73 135 89 108 74 100 
AB-PINACA N4OH pentyl
1
 58 68 105 242 70 87 105 187 
5F-AB-PINACA
1
 69 84 90 149 93 101 89 106 
* denotes where only 5 sources of blank blood were used due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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Table 30 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects at 2.5 ng/mL 
for Method 2.1 applied to blood. 
Compound 
2.5 ng/mL (n=10) 
Absolute  I.S. Compensated 
Recovery (%) Matrix Effects (%) Recovery (%) Matrix Effects (%) 
Min. Max. Min. Max. Min. Max. Min. Max. 
5F-ADB-PINACA
1
 69 83 104 206 90 104 103 145 
MMB2201
5
 73 105 94 163 68 166 106 363 
MAM2201 N4OH pentyl*
5
 70 89 101 125 71 135 97 257 
AB-CHMINACA
1
 68 86 83 144 86 100 84 132 
AB-CHMINACA M2
1
 37 70 70 96 45 83 49 87 
5F-NPB-22
2
 71 102 67 116 88 128 105 267 
AB-CHMINACA M1A
1
 53 72 93 142 73 93 93 109 
AB-FUBINACA M2B
1
 0 3 0 98 0 4 68 96 
AKB48 N-pentanoic acid
3
 37 75 78 138 58 111 80 124 
APICA N4OH pentyl
3
 59 133 66 178 67 150 49 181 
FUB-PB-22
2
 56 112 31 102 89 111 102 157 
MDMB-CHMINACA
1
 34 125 13 112 46 148 10 102 
PB-22 N-pentanoic acid
2
 32 54 89 155 44 87 96 388 
STS-135 N4OH pentyl
3
 58 120 80 157 75 136 59 170 
CUMYL-PeGACLONE
1
 52 119 26 103 66 197 12 94 
MAB-CHMINACA
1
 57 108 61 124 75 128 52 117 
MAB-CHMINACA M1
1
 66 81 99 178 85 102 98 127 
MMB-CHMICA
1
 63 92 64 203 80 109 45 192 
* denotes where only 5 sources of blank blood were used due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S.  
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Table 31 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects at 15 ng/mL 
for Method 2.1 applied to blood 
Compound 
15 ng/mL (n=10) 
Absolute I.S. Compensated 
Recovery (%) Matrix Effects (%) Recovery (%) Matrix Effects (%) 
Min. Max. Min. Max. Min. Max. Min. Max. 
5F-MDMB-PINACA
1
 63 96 80 122 80 110 73 108 
5F-MDMB-PINACA O-desmethyl acid
1
 31 65 101 173 38 78 98 123 
MDMB-CHMICA
1
 41 123 32 113 55 135 26 93 
MDMB-CHMICA O-desmethyl acid
1
 25 58 73 110 30 67 51 96 
AB-FUBINACA
1
 70 86 100 134 93 105 94 104 
MMB-FUBINACA
1
 59 101 76 120 75 115 57 112 
AB-FUBINACA valine metabolite
1
 19 56 97 116 23 67 82 100 
5F-PB-22
2
 62 98 65 107 84 141 101 209 
PB-22
2
 46 118 30 111 88 101 91 105 
PB-22 N5OH pentyl
2
 69 90 102 124 77 153 108 397 
5F-AKB48
3
 33 138 10 114 46 148 10 95 
5F-AKB48 N4OH pentyl
3
 64 91 81 142 91 113 82 106 
AKB48
4
 16 119 5 99 90 101 91 100 
AKB48 N5OH pentyl*
3
 66 91 81 116 92 102 84 96 
BB-22
2
 37 114 12 104 68 123 37 97 
BB-22 3-carboxyindole
2
 57 88 48 104 75 110 97 160 
AM2201*
5
 44 117 42 113 93 97 93 99 
AM2201 N4OH pentyl
5
 68 91 101 131 75 164 100 253 
AB-PINACA
1
 68 90 78 135 84 103 76 115 
AB-PINACA N4OH pentyl
1
 55 68 106 226 69 82 103 180 
5F-AB-PINACA
1
 72 89 81 146 94 110 79 108 
* denotes where only 5 sources of blank blood were used due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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Table 31 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects at 15 
ng/mL for Method 2.1 applied to blood 
Compound 
15 ng/mL (n=10) 
Absolute I.S. Compensated 
Recovery (%) Matrix Effects (%) Recovery (%) Matrix Effects (%) 
Min. Max. Min. Max. Min. Max. Min. Max. 
5F-ADB-PINACA
1
 72 88 105 185 94 102 101 139 
MMB2201
5
 71 91 107 155 76 172 108 316 
MAM2201 N4OH pentyl*
5
 65 92 104 124 77 142 104 253 
AB-CHMINACA
1
 69 86 96 146 87 99 87 128 
AB-CHMINACA M2
1
 36 74 77 111 60 84 55 97 
5F-NPB-22
2
 74 108 71 116 92 147 102 237 
AB-CHMINACA M1A
1
 53 72 96 145 70 87 90 115 
AB-FUBINACA M2B
1
 1 6 93 105 1 7 69 95 
AKB48 N-pentanoic acid
3
 46 74 91 143 66 116 74 117 
APICA N4OH pentyl
3
 53 122 74 178 67 150 49 181 
FUB-PB-22
2
 54 109 40 108 93 108 99 150 
MDMB-CHMINACA
1
 33 138 15 120 43 158 12 99 
PB-22 N-pentanoic acid
2
 36 66 92 144 56 100 104 345 
STS-135 N4OH pentyl
3
 55 110 90 154 92 135 58 142 
CUMYL-PeGACLONE
1
 49 126 28 106 62 144 22 94 
MAB-CHMINACA
1
 50 107 77 135 63 122 60 116 
MAB-CHMINACA M1
1
 63 78 99 177 83 93 97 130 
MMB-CHMICA
1
 64 93 67 198 80 106 47 184 
* denotes where only 5 sources of blank blood were used due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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4.4.4.6. Interference Testing 
None of the compounds tested produced any responses in the XICs of compounds 
of interest at a concentration of 1 mg/L.  
4.4.4.7. Autosampler Stability 
The results of the experiments into autosampler stability over ca. 46 hours fell 
roughly into 3 categories: upwards trend, stable/downward trend and no 
discernible trend. No significant differences were observed between experiments 
conducted at 2.5 and 15 ng/mL.  
The plot in Figure 31 for 5F-MDMB-PINACA is an example of an upwards trend 
and the majority of compounds exhibited this. An upwards trend was diagnosed by 
observing a sustained increase in peak areas which reached ≥120% of the t0 value 
and did not return to an area below this within the duration of the experiment. For 
all the compounds in which this trend was observed, the I.S. compensated for 
these effects, bringing the change much closer to within 100 ±20%, although 
sometimes still ca. 5 percentage points outside this range. The plots for 5F-ADB-
PINACA, AB-PINACA, AB-PINACA N4OH pentyl, AM2201 OH, MAB-CHMINACA 
and MAM-2201 N4OH pentyl still showed instability in the I.S.-compensated 
trends. This may be an indication that the I.S. chosen for these was not as 
chemically similar as it could be, and consideration should be made about 
selecting a different deuterated compound. As mentioned previously, the 
availability and cost of deuterated SCRAs is prohibitive to this, but expense may 
be justified if significant detrimental effects are observed. 
As seen in the previous section, the majority of ME observed are enhancing in 
nature. It was thought that the additive enhancement effects of the build-up of 
proteins on the column over time may have contributed towards the upward trend 
observed for the compounds. This would affect the deuterated compounds in the 
same way and thus the PAR would maintain a more stable trend than the 
compound peak areas taken alone. It is also possible that evaporation of the 
solvent took place in the autosampler, which was not temperature controlled 
(although RT was controlled and monitored). This would cause a concentration in 
analytes over time and lead to an observable upward trend, compensated by I.S. 
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Figure 31 – Stability on the autosampler, at room temperature, of 5F-MDMB-
PINACA over ca. 46 hours. Trends for 2.5 and 15 ng/mL concentrations are 
shown, along with the stability for the compound alone, and the peak area 
ratio. 
 
The stable/downward trend was observed in 5F-NPB-22, 5F-PB-22, AB-
FUBINACA M2B, AB-FUBINACA valine metabolite, MDMB-CHMICA O-desmethyl 
acid metabolite, MMB-CHMICA and PB-22 N-pentanoic acid. This trend was 
characterized by peak areas remaining within (or exiting and then returning to) the 
100 ±20% range while PAR values decrease. An example is given by PB-22 N-
pentanoic acid in Figure 32. In this example the PAR decreases outwith the 100 
±20% range, but this was not the case for all compounds showing this trend. It 
was not possible to determine whether the compounds were truly stable, or 
whether the ion enhancement and/or evaporation observed in compounds with an 
upward trend was counter-acted by decrease in analyte concentration through 
instability, giving the appearance of stability. None of the compounds that fall 
within this category used deuterated forms of themselves as I.S. so if the I.S. peak 
area was increasing, through ME for example, and the analyte peak area was 
either stable or decreasing this would show as a decrease in PAR over time. While 
the peak areas of the compounds exhibiting this trend were largely within the 
stable range (100 ±20%), with some outliers, a slight upwards trend was observed 
in some compounds, with peak areas increasing over time, albeit not above 120%. 
It is therefore possible that over a longer experimental period an increase would 
have been observed. Although PAR were observed to decrease over time, they 
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largely stayed within the stable range and so the effect of this on sample results 
should be minimal, however it is still a factor to consider in interpretation.  
 
Figure 32 – Stability on the autosampler, at room temperature, of PB-22 N-
pentanoic acid over ca. 46 hours. Trends for 2.5 and 15 ng/mL 
concentrations are shown, along with the stability for the compound alone, 
and the peak area ratio. 
 
The final observation category is increased variation with no discernible trend, as 
exemplified by 5F-AKB48 in Figure 33. While a slight upward and a slight 
downward trend may be observed in the peak areas and PAR respectively, the 
spread of the data (i.e. random error) was too great to say with any certainty 
whether the compounds were stable or not.  
In addition to 5F-AKB48, this was the case for AKB48 N5OH pentyl, BB-22, BB-22 
3-carboxyindole, and MDMB-CHMINACA. This may be an artifact of the significant 
ion suppression and large variability observed for ME in Table 30 and Table 31. 
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Figure 33 – Stability on the autosampler, at room temperature, of 5F-AKB48 
over ca. 46 hours. Trends for 2.5 and 15 ng/mL concentrations are shown, 
along with the stability for the compound alone, and the peak area ratio. 
 
While the experiment was designed so as to be an extreme example of how the 
assay may be run in a real-world situation, i.e. a sample being injected 40 hours 
after the beginning of the run, it is important to consider the stability of compounds 
when interpreting both positive and negative results. Re-injecting a calibrator or 
QC at the end of the sequence for longer runs is recommended to provide 
assurances that no significant changes have taken place to the concentration of 
analytes during the sequence duration.   
4.4.5. Method Validation – Methods 1.1, 1.2 and 2.1 applied to urine 
4.4.5.1. Linearity 
A linear calibration model using 1/χ-weighting was established for 5F-MDMB-
PINACA metabolite, MDMB-CHMICA metabolite and AB-FUBINACA valine 
metabolite, as demonstrated by correlation co-efficient values of ≥0.99 over 10 
calibrations. For all calibrations, a minimum of 6 calibrators were used between 
0.20 and 50 ng/mL, and the calculated concentrations of these were within ±20% 
of the expected value. 
An example calibration curve for AB-FUBINACA valine metabolite is given in 
Figure 34. 
 
0 
20 
40 
60 
80 
100 
120 
140 
160 
180 
200 
0 500 1000 1500 2000 2500 3000 
%
 t
0
 
Time (min.) 
5F-AKB48 
2.5 ng/mL Peak Area 
15 ng/mL Peak Area 
2.5 ng/mL PAR 
15 ng/mL PAR 
  135 
 
 
Figure 34 – Example calibration curve of AB-FUBINACA valine metabolite 
using Method 2.1 applied to blood, using 1/χ weighting, giving a correlation 
coefficient of 0.9972. 
 
4.4.5.2. Selectivity 
Selectivity was demonstrated for all methods by the observation of no response at 
a tR of interest in the XIC of analytes where the analyte was not present.  
Examples of blank chromatograms exhibiting selectivity for all methods are given 
in Figure 35. Figure 36 shows examples of low (<0.20 ng/mL) and higher (11 
ng/mL) positive case samples for AB-FUBINACA valine metabolite using method 
2.1. 
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Figure 35 – Example chromatograms from a blank standard, demonstrating 
selectivity from method 1.1 for AB-CHMINACA (top), method 1.2 for AB-
FUBINACA valine metabolite (middle), and method 2.1 for AM2201 N4OH 
pentyl (bottom). Analytes are shown on the left and internal standards on the 
right and intensity is given in counts per second. 
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Figure 36 – Example chromatograms from a low positive case sample (top) 
and a higher positive case sample (bottom) for AB-FUBINACA valine 
metabolite using method 2.1. The difference in retention times is due to 
inter-batch variation, different batches of mobile phase and different 
analytical columns. Intensity is given in counts per second. 
 
4.4.5.3. Sensitivity 
Limits of detection for methods 1.1, 1.2 and 2.1 are shown in Table 32 with the 
LLOQ and the SNR at the LOD for method 2.1 shown.  
Regarding methods 1.1 and 1.2, the purpose was to identify the presence of 
SCRAs in urine and a LOD of 0.2 ng/mL was deemed acceptable for this. For this 
reason, no standards of lower concentration were ran, although it is likely that the 
method could detect concentrations <0.2 ng/mL for most compounds. The only 
compound for which the LOD was determined to be significantly above an 
acceptable concentration was PB-22 N-pentanoic acid 3-carboxyindole, with an 
LOD of 25 ng/mL. While SCRAs are known to be present in the urine at higher 
concentrations than in blood, particularly metabolites, it is likely that concentrations 
of the compound would be <25 ng/mL in urine (80). Therefore it was decided that 
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this compound would not be reported, as it could not be certain that the compound 
was absent in samples. It was removed from standard solutions for subsequent 
method development. 
Optimisation work was conducted on the extraction protocol (see Section 4.3.4.2) 
and consequently the LODs for method 2.1 were generally improved. LODs for 
AB-CHMINACA M1A, AB-FUBINACA M2B and BB-22 3CI were increased to 2, 1 
and 1 ng/mL respectively. While this is not ideal, the optimisation process is a 
compromise, and the majority of compounds saw improvements in sensitivity 
through this. In addition, all of these compounds are metabolites, which are likely 
to be present in higher concentrations in urine, and for all but BB-22 other 
metabolites are included within the method to further the chances of detection.  
As the lowest calibrator was selected as the LLOQ for most compounds, it was 
decided to use a SNR of ≥4 for the LOD to ensure a clear distinction from noise. It 
is clear from Table 32 that some SNRs are much higher than 4, for example FUB-
PB-22, MAM2201 N4OH pentyl, and PB-22. This is because the standard at the 
next lowest concentration gave a SNR that was not consistently ≥4 for duplicate 
results in 3 sources of blank blood.  
Table 32 – Limits of Detection and Quantitation for Methods 1.1, 1.2 and 2.1 
in Urine. The mean signal-to-noise ratio at the Limit of Detection is also 
given. 
Compound  
LOD Methods 
1.1 and 1.2 
(ng/mL) 
Method 2.1 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
Mean SNR 
at LOD 
5F-AB-PINACA 0.2 0.50 0.50 6 
5F-ADB-PINACA N/A 0.10 0.20 7 
5F-AKB48 0.2 0.10 0.20 6 
5F-AKB48 N4OH pentyl 0.2 0.10 0.20 6 
5F-MDMB-PINACA 0.2 0.01 0.20 6 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
N/A 0.10 0.20 10 
5F-NPB-22 N/A 0.02 0.20 10 
5F-PB-22 0.2 0.01 0.20 9 
AB-CHMINACA 0.2 0.10 0.20 6 
AB-CHMINACA M1A 0.2 2.00 2.00 5 
AB-CHMINACA M2 0.2 0.10 0.20 14 
AB-FUBINACA 0.2 0.20 0.20 5 
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Table 32 – Limits of Detection and Quantitation for Methods 1.1, 1.2 and 2.1 
in Urine. The mean signal-to-noise ratio at the Limit of Detection is also 
given. 
Compound  
LOD Methods 
1.1 and 1.2 
(ng/mL) 
Method 2.1 
LOD 
(ng/mL) 
LLOQ 
(ng/mL) 
Mean SNR 
at LOD 
AB-FUBINACA M2B 0.5 1.00 1.00 8 
AB-FUBINACA valine 
metabolite 
0.2 0.20 0.20 8 
AB-PINACA 0.2 0.20 0.20 9 
AB-PINACA N4OH pentyl N/A 2.00 2.00 6 
AKB48 0.2 0.10 0.20 5 
AKB48 N5OH pentyl 0.2 0.20 0.20 9 
AKB48 N-pentanoic acid 0.2 0.05 0.20 4 
AM2201 0.2 0.01 0.20 7 
AM2201 N4OH pentyl 0.2 0.02 0.20 6 
AM2201 N5OH indole 0.2 N/A N/A N/A 
APICA   0.2 N/A N/A N/A 
APICA N4OH pentyl 0.2 0.20 0.20 8 
BB-22 3-carboxyindole 0.2 1.00 1.00 5 
BB-22   0.2 0.02 0.20 12 
FUB-PB-22 N/A 0.02 0.20 15 
MAM2201 N4OH pentyl N/A 0.02 0.20 14 
MDMB-CHMICA 0.2 0.10 0.20 10 
MDMB-CHMICA O-desmethyl 
acid metabolite 
0.2 0.20 0.20 14 
MDMB-CHMINACA 0.2 0.05 0.20 6 
MMB2201 N/A 0.01 0.20 7 
MMB-FUBINACA N/A 0.02 0.20 8 
PB-22 0.2 0.02 0.20 13 
PB-22 N5OH pentyl 0.2 0.05 0.20 9 
PB-22 N-pentanoic acid 3-
carboxyindole 
25 N/A N/A N/A 
PB-22 N-pentanoic acid 0.2 0.05 0.20 6 
STS-135   0.2 N/A N/A N/A 
STS-135 N4OH pentyl 0.2 0.10 0.20 6 
MAB-CHMINACA N/A 0.01 0.20 7 
MAB-CHMINACA M1 N/A 1.00 1.00 6 
CUMYL-PeGACLONE N/A 0.02 0.20 5 
MMB-CHMICA N/A 0.05 0.20 6 
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Examples of compounds present at their assigned LOD in Method 2.1 are given 
Figure 37. These show that the analyte response is easily distinguishable from 
baseline noise.  
 
 
AB-FUBINACA valine metabolite (left) @ 0.2 ng/mL with I.S. (right) 
 
 
5F-MDMB-PINACA metabolite (left) @ 0.1 ng/mL with I.S. (right) 
Figure 37 – Example extracted ion chromatograms of selected 
compounds (left) present at their assigned Limit of Detection with 
internal standard (right) in Method 2.1 applied to urine. The signal-to-
noise ratios are ≥4. Intensity is given in counts per second. 
 
4.4.5.4. Accuracy and Precision 
The results for 5F-MDMB-PINACA O-desmethyl acid, AB-FUBINACA valine 
metabolite and MDMB-CHMICA O-desmethyl acid metabolite for intra- and 
interday accuracy and precision are shown in Table 33 and Table 34 respectively. 
These show that the quantitation is both suitably accurate and shows good 
precision at a range of concentrations. The intraday precision for the MDMB-
CHMICA O-desmethyl acid metabolite at 0.2 ng/mL is slightly outside the 
acceptable limit of ±15%, and as such QC standards near to the LLOQ should be 
run with batches, and caution taking when reporting low concentrations. 
It was thought that the interday results would show more variation than intraday, 
but that was not the case for the 5F-MDMB-PINACA and MDMB-CHMICA O-
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desmethyl acid metabolites. It is known that these compounds suffer from a 
significant degree of ion enhancement when the PAR is considered, so it is 
possible that the main source of variation for these compounds is due to matrix 
variation and not random error.  
Table 33 – Intra- and interday accuracy for 5F-MDMB-PINACA O-desmethyl 
acid, AB-FUBINACA valine metabolite, and MDMB-CHMICA O-desmethyl 
acid for Method 2.1 applied urine. All compounds gave satisfactory results, 
within 100±20%. 
Compound 
Accuracy 
Intraday (n=5) Interday (n=5) 
0.2 
ng/mL 
2.5 
ng/mL 
15 
ng/mL 
42 
ng/mL 
0.2 
ng/mL 
2.5 
ng/mL 
15 
ng/mL 
42 
ng/mL 
5F-MDMB-
PINACA O-
desmethyl acid 
113 106 105 110 100 105 101 105 
AB-FUBINACA 
valine 
metabolite 
100 104 101 107 100 105 97 104 
MDMB-
CHMICA O-
desmethyl acid 
95 117 118 102 96 110 109 105 
 
Table 34 – Intra- and interday precision for 5F-MDMB-PINACA O-desmethyl 
acid, AB-FUBINACA valine metabolite, and MDMB-CHMICA O-desmethyl 
acid for Method 2.1 applied urine. With the exception of MDMB-CHMICA O-
desmethyl acid, all compounds gave results ≤15%. 
Compound 
Precision 
Intraday (n=5) Interday (n=5) 
0.2 
ng/mL 
2.5 
ng/mL 
15 
ng/mL 
42 
ng/mL 
0.2 
ng/mL 
2.5 
ng/mL 
15 
ng/mL 
42 
ng/mL 
5F-MDMB-
PINACA O-
desmethyl acid 
5.9 2.1 4.8 2.9 3.2 8.6 5.5 7.8 
AB-FUBINACA 
valine 
metabolite 
6.2 2.5 5.2 3.5 5.5 6.0 9.3 4.4 
MDMB-
CHMICA O-
desmethyl acid 
15.5 1.7 1.9 5.2 11.6 7.1 5.5 8.3 
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4.4.5.5. Recovery and Matrix Effects  
Table 35 and Table 36 show the recovery and matrix effects at 2.5 and 15 ng/mL 
respectively. 
Recoveries are higher and more consistent compared to those found with the 
blood extraction. All are within acceptable ranges, with the exception of the 
absolute values for 5F-AKB48 and AKB48 at 2.5 ng/mL, and these plus 5F-NPB-
22 and MMB-CHMICA at 15 ng/mL. For AKB48 and MMB-CHMICA, the 
compensation by the I.S. improves these, with a less significant improvement seen 
for I.S compensation for 5F-AKB48. Compensation by the I.S. for 5F-NPB-22 at 15 
ng/mL actually makes the recovery significantly more variable, suggesting the I.S. 
is not very suitable.  
With regards to ME, values are, again, more consistent and acceptable than the 
values for blood. Significant enhancement was seen for MDMB-CHMICA, 5F-
AKB48, BB-22, MDMB-CHMINACA and CUMYL-PeGACLONE. This was 
compensated by the I.S. for BB-22, to some extent, but not the other compounds.  
On the other hand, AM2201 N4OH pentyl, AB-PINACA N4OH pentyl, AB-
CHMINACA M1A and APICA N4OH pentyl suffered from significant inhibitory ME. 
The I.S. compensated slightly for the inhibition of AM2201 N4OH pentyl but did not 
do so for the other compounds. 
The absolute values for AKB48 show significant variation in the ME between 
sources of urine. As the I.S. used for this compound is a deuterated form of 
AKB48, a significant compensation is made, to bring the ME values within an 
acceptable range. 
Generally, the recoveries and ME observed were acceptable, however caution 
should be exercised with the more affected compounds, and in samples that are 
visibly dark, cloudy and/or viscous in appearance. 
 
* denotes where only 9 sources of blank blood were used due to retention time shift for compounds   ** denotes where only 6 sources of blank blood were used 
due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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Table 35 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects at 
2.5 ng/mL in  Method 2.1 applied to urine 
Compound 
2.5 ng/mL (n=10) 
Absolute  I.S. Compensated 
Recovery (%) Matrix Effects (%) Recovery (%) Matrix Effects (%) 
Min. Max. Min. Max Min. Max. Min. Max 
5F-MDMB-PINACA
1
 85 104 75 122 89 112 84 132 
5F-MDMB-PINACA O-desmethyl acid
1
 85 103 88 113 87 109 93 130 
MDMB-CHMICA*
1
 68 97 67 98 81 132 55 106 
MDMB-CHMICA O-desmethyl acid
1
 88 108 81 145 90 110 88 161 
AB-FUBINACA
1
 82 102 85 102 92 107 97 110 
MMB-FUBINACA
1
 90 107 82 97 91 121 73 107 
AB-FUBINACA valine metabolite
1
 83 101 71 99 91 106 79 112 
5F-PB-22**
2
 90 105 83 100 90 112 84 123 
PB-22
2
 75 100 83 117 94 102 96 108 
PB-22 N5OH pentyl
2
 84 106 59 89 79 121 50 153 
5F-AKB48*
3
 23 80 70 132 56 82 79 142 
5F-AKB48 N4OH pentyl
3
 84 111 68 104 94 112 75 117 
AKB48
4
 23 55 46 176 88 102 88 107 
AKB48 N5OH pentyl*
3
 80 109 79 97 92 106 93 100 
BB-22
2
 70 91 74 152 82 106 72 119 
BB-22 3-carboxyindole
2
 76 110 71 91 90 118 69 105 
AM2201*
5
 82 98 64 81 96 104 92 99 
AM2201 N4OH pentyl
5
 86 100 41 71 65 120 53 138 
AB-PINACA**
1
 94 104 87 106 90 106 92 115 
AB-PINACA N4OH pentyl
1
 85 106 42 67 90 113 47 71 
* denotes where only 9 sources of blank blood were used due to retention time shift for compounds   ** denotes where only 6 sources of blank blood were used 
due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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Table 35 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects at 
2.5 ng/mL in  Method 2.1 applied to urine 
Compound 
2.5 ng/mL (n=10) 
Absolute  I.S. Compensated 
Recovery (%) Matrix Effects (%) Recovery (%) Matrix Effects (%) 
Min. Max. Min. Max Min. Max. Min. Max 
5F-AB-PINACA
1
 86 107 87 127 93 107 96 144 
5F-ADB-PINACA
1
 77 101 77 122 86 108 87 149 
MMB2201
5
 87 99 66 96 84 113 85 143 
MAM2201 N4OH pentyl**
5
 94 104 61 78 99 109 74 110 
AB-CHMINACA
1
 83 111 82 102 87 112 91 111 
AB-CHMINACA M2
1
 82 108 83 110 92 111 85 129 
5F-NPB-22
2
 52 108 74 102 14 86 80 114 
AB-CHMINACA M1A
1
 80 102 44 66 77 104 50 70 
AB-FUBINACA M2B
1
 86 113 72 97 91 112 86 105 
AKB48 N-pentanoic acid
3
 82 107 64 90 93 116 67 101 
APICA N4OH pentyl
3
 85 114 48 95 92 118 54 96 
FUB-PB-22
2
 80 104 76 87 97 109 68 97 
MDMB-CHMINACA
1
 57 80 72 143 55 86 74 148 
PB-22 N-pentanoic acid
2
 82 102 58 90 94 120 49 106 
STS-135 N4OH pentyl
3
 82 106 53 114 83 116 55 127 
CUMYL-PeGACLONE
1
 75 96 75 131 81 97 77 133 
MAB-CHMINACA
1
 78 100 90 116 86 106 92 129 
MAB-CHMINACA M1
1
 85 102 63 93 95 104 71 104 
MMB-CHMICA
1
 83 101 80 109 86 111 80 124 
 
* denotes where only 9 sources of blank blood were used due to retention time shift for compounds   ** denotes where only 6 sources of blank blood were used 
due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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Table 36 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects 
at 15 ng/mL for Method 2.1 applied to urine 
Compound 
15 ng/mL (n=10) 
Absolute I.S. Compensated 
Recovery (%) 
Matrix Effects 
(%) 
Recovery (%) 
Matrix Effects 
(%) 
Min. Max. Min. Max Min. Max. Min. Max 
5F-MDMB-PINACA
1
 79 94 72 94 83 100 87 105 
5F-MDMB-PINACA O-desmethyl acid*
1
 84 99 95 120 88 105 101 150 
MDMB-CHMICA*
1
 68 89 73 116 71 96 87 118 
MDMB-CHMICA O-desmethyl acid
1
 48 95 84 187 80 98 91 232 
AB-FUBINACA
1
 82 97 79 98 86 100 100 115 
MMB-FUBINACA
1
 89 94 79 98 90 101 90 107 
AB-FUBINACA valine metabolite
1
 85 99 90 102 85 104 90 123 
5F-PB-22**
2
 86 93 81 107 93 111 89 107 
PB-22
2
 74 91 75 128 88 94 86 113 
PB-22 N5OH pentyl
2
 83 105 61 95 90 124 59 119 
5F-AKB48
3
 28 84 71 139 66 87 83 143 
5F-AKB48 N4OH pentyl
3
 74 96 85 100 81 97 87 111 
AKB48
4
 28 55 53 191 83 96 94 110 
AKB48 N5OH pentyl*
3
 73 95 80 111 79 100 91 110 
BB-22
2
 72 87 75 161 82 94 91 136 
BB-22 3-carboxyindole
2
 76 99 72 97 88 117 69 114 
AM2201*
5
 75 91 62 92 88 99 97 103 
AM2201 N4OH pentyl
5
 83 97 50 74 94 104 65 110 
AB-PINACA**
1
 91 93 83 98 89 100 96 112 
AB-PINACA N4OH pentyl
1
 75 100 43 77 78 98 52 84 
* denotes where only 9 sources of blank blood were used due to retention time shift for compounds   ** denotes where only 6 sources of blank blood were used 
due to retention time shift for compounds 
1
 Used AB-FUBINACA-d4 as I.S.   
2
 Used PB-22-d9 as I.S.   
3
 Used AKB48 N5OH pentyl-d4 as I.S.   
4
 Used AKB48-d11 as I.S.   
5
 Used AM2201-d5 as I.S. 
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Table 36 – Ranges for absolute and internal standard-compensated recovery and Matrix Effects 
at 15 ng/mL for Method 2.1 applied to urine 
Compound 
15 ng/mL (n=10) 
Absolute I.S. Compensated 
Recovery (%) 
Matrix Effects 
(%) 
Recovery (%) 
Matrix Effects 
(%) 
Min. Max. Min. Max Min. Max. Min. Max 
5F-AB-PINACA
1
 80 100 84 120 84 101 99 138 
5F-ADB-PINACA
1
 82 99 70 116 87 101 90 144 
MMB2201
5
 84 101 72 97 90 105 91 148 
MAM2201 N4OH pentyl**
5
 92 100 63 79 99 109 74 112 
AB-CHMINACA
1
 82 102 85 104 85 102 97 117 
AB-CHMINACA M2
1
 79 95 82 121 84 99 92 150 
5F-NPB-22
2
 46 93 71 111 10 80 77 117 
AB-CHMINACA M1A
1
 76 99 39 66 79 100 47 72 
AB-FUBINACA M2B
1
 84 105 71 87 87 109 81 108 
AKB48 N-pentanoic acid
3
 80 102 72 97 83 113 78 101 
APICA N4OH pentyl
3
 84 99 65 96 88 102 67 97 
FUB-PB-22
2
 80 94 74 93 94 105 79 107 
MDMB-CHMINACA
1
 64 83 81 145 66 120 88 152 
PB-22 N-pentanoic acid
2
 84 100 60 94 92 116 52 115 
STS-135 N4OH pentyl*
3
 80 98 75 122 84 103 75 117 
CUMYL-PeGACLONE
1
 76 92 69 139 80 100 83 146 
MAB-CHMINACA
1
 77 89 90 131 80 95 101 145 
MAB-CHMINACA M1
1
 81 103 64 89 84 102 77 105 
MMB-CHMICA*
1
 44 99 85 114 88 98 79 129 
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4.4.5.6. Interference Testing 
The experiments into potential interferences conducted in 4.3.5.7 and discussed in 
4.4.4.6 were done so using unextracted standards. As the instrumental method for 
blood and urine analyses is the same, these experiments show there is no 
response from any of the compounds tested. 
4.4.5.7. Autosampler Stability 
The graphs shown in Figure 38 – Figure 40 are representative of the trends seen 
for all compounds. 
Figure 38 is an example of the autosampler stability observed for all compounds 
with the exceptions of 5F-AKB48, AKB48, BB-22 and MDMB-CHMINACA. The 
peak areas for both 2.5 ng/mL and 15 ng/mL standards decreased over time to 
≥40% of the t0 value. For these compounds, the I.S. was observed to compensate 
well, keeping the change from t0 to within ± 20%. The I.S.-compensated plot for 
the MDMB-CHMICA metabolite did show an increase outwith ± 20% towards the 
latter stages of the experiment, which is certainly something to consider where 
sequence run times exceed 30 h.  
 
 
Figure 38 – Stability on the autosampler, at room temperature, of AB-
FUBINACA valine metabolite over ca. 46 hours. Trends for 2.5 and 15 ng/mL 
concentrations are shown, along with the stability for the compound alone, 
and the peak area ratio. 
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Figure 39 shows the trend seen for the autosampler stability of AKB48. This shows 
a high level of variation between the peak areas at both 2.5 and 15 ng/mL 
concentrations over time. This is possibly due to the low and relatively variable 
recovery of this compound. As the I.S. used for this compound is AKB48-d11, this 
compensated well for the variation to bring the change from t0 to within ± 20% until 
around 38 h, where it increases outside these limits. This increase is could be due 
either to degradation of AKB48-d11 or an increase in response from the AKB48, 
which did show significant ion enhancement effects. It is possible that matrix 
components are building up on the column during long runs and contributing 
towards AKB48 ion enhancement which does not have such a significant effect on 
the I.S. 
 
 
Figure 39 – Stability on the autosampler, at room temperature, of AKB48 
over ca. 46 hours. Trends for 2.5 and 15 ng/mL concentrations are shown, 
along with the stability for the compound alone, and the peak area ratio. 
 
Figure 40 shows the results of the autosampler stability experiments for 5F-
AKB48. This shows a high level of variation between both the 2.5 and 15 ng/mL 
experiments for both the peak area and I.S. compensated plots. As discussed in 0, 
this suggests that the I.S. used for 5F-AKB48 (AKB48 N5OH pentyl-d4) is not 
greatly suited for this compound. The variation in the peak areas for this 
compound and AKB48 is likely due to the variation in recovery and ME associated 
with these compounds. Quantitative validation for these compounds was not 
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undertaken in urine as they are no longer thought to be prevalent in use, and they 
are parent compounds which are rarely seen in urine. Given that the variation 
observed in the autosampler stability experiments suffers from a positive bias, the 
LOD should not be adversely affected by extended sequence run times.  
 
 
Figure 40 – Stability on the autosampler, at room temperature, of 5F-AKB48 
over ca. 46 hours. Trends for 2.5 and 15 ng/mL concentrations are shown, 
along with the stability for the compound alone, and the peak area ratio. 
 
As stated earlier regarding autosampler stability in blood extracts, injecting QC 
standards at the end of the sequence should ensure qualitative and quantitative 
results are valid where long run times are required. 
4.4.6. Comparison of Prison ‘A’ and ‘B’ Samples  
The comparison of results of analysis for prison ‘A’ and ‘B’ samples is given in 
Table 37. The ‘B’ results for cases where a defined value was reported (i.e. not 
>50 ng/mL) were plotted against the ‘A’ results and this is shown in Figure 41.  
From the results shown in Table 37, it appears there was a slight positive bias 
compared to the ‘A’ results initially, which then shifted to a slight negative bias 
from Case 5 onwards. From looking at the dates of receipt of Cases 4 and 5, it is 
clear that the extraction method changed from the tBME extraction to MeOH (see 
Section 4.3.4.2) between these two cases, explaining this shift. 
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From Case 5 onwards, the difference is minimal, with the exceptions of cases 10 
and 12, which are more significant. The original date of the ‘A’ analysis is 
unknown, as are the storage conditions during transfer to FMS. It is therefore 
possible that stability could have played a role in the decrease in concentration 
between ‘A’ and ‘B’ sample analysis, and that the period between ‘A’ and ‘B’ 
sample analysis is longer for cases 10 and 12.  
 
Table 37 – Comparison of results obtained from original ‘A’ laboratory and ‘B’ 
testing using methods developed in Section 4 for Synthetic Cannabinoid 
Receptor Agonist-positive urine samples obtained from prison mandatory 
drug testing. 
Case 
No 
'A' Sample Result ‘B' Sample Result 
Difference 
(%) Compound 
Conc. 
(ng/mL) 
Compound 
Conc. 
(ng/mL) 
1 
AB-FUBINACA 
metab. 
46 
AB-FUBINACA valine 
metab. 
>50  
(ca. 56) 
N/A 
2 
MDMB-CHMICA 
O-desmethyl acid 
metab. 
7 
MDMB-CHMICA O-
desmethyl acid metab. 
10 143 
3 AB-FUBINACA 
>100       
(ca. 380) 
AB-FUBINACA valine 
metab. 
460 N/A 
4 
AB-FUBINACA 
metab. 
43 
AB-FUBINACA valine 
metab. 
63 147 
5 AB-FUBINACA 
>100       
(ca. 
1000) 
AB-FUBINACA valine 
metab. 
>1250 N/A 
6 
AB-FUBINACA 6 
AB-FUBINACA valine 
metab. 
4.7 78 
5F-MDMB-PINACA 9 
5F-MDMB-PINACA O-
desmethyl acid metab. 
6.1 68 
7 
AB-FUBINACA 
metab. 
59 
AB-FUBINACA valine 
metab. 
56 95 
8 
Synthetic 
Cannabinoids 
not given 
5F-MDMB-PINACA O-
desmethyl acid metab. 
31 N/A 
9 ADB 13 
5F-MDMB-PINACA O-
desmethyl acid metab. 
13 100 
10 
5F-ADB desmethyl 
metabolite 
37 
5F-MDMB-PINACA O-
desmethyl acid metab. 
18 49 
11 
5F-ADB desmethyl 
metabolite 
8 
5F-MDMB-PINACA O-
desmethyl acid metab. 
5.4 68 
12 
AB-FUBINACA 
metab. 
26 
AB-FUBINACA valine 
metab. 
14 54 
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Because of the unknowns related to inter-analysis period and compound stability, 
the accuracy is not calculated on reporting results, but is shown here as a 
measure of agreement.  
The information contained within the ‘A’ Sample Result column in Table 37 is 
provided with the ‘B’ sample when it is delivered from the ‘A’ laboratory. The detail 
of information contained within varies and frequently contains the name of the 
parent drug rather than the specific metabolite. This is possibly due to the fact that 
it is the parent drug which is prohibited and the metabolite is simply used to prove 
ingestion of the parent drug. It should be noted that ADB is a synonym for MDMB-
PINACA, with 5F-ADB being a synonym for 5F-MDMB-PINACA.  
 
 
 
Figure 41 – Results of ‘A’ sample analysis (y-axis) plotted against results of 
‘B’ sample analysis (x-axis) using methods developed in Section 4. A 
coefficient of determination of 0.7719 indicates good correlation of results. 
 
The plot of results shown in Figure 41 shows a relatively good correlation between 
‘A’ and ‘B’ results, with a linear correlation co-efficient of 0.7719. It should be noted 
that the top calibrator is 50 ng/mL so the two samples quantified above this 
concentration would have the additional error associated with a dilution. The 
correlation appears to be tighter at lower concentrations, which is possibly due to 
the higher number of calibrators at the lower end of the calibration curve and a 
more accurate quantitation as a result. 
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It is acknowledged that the result of the ‘A’ sample analysis did not necessarily 
provide the true value, taking all errors that may be associated with this method 
into account. As the ‘A’ method was validated and provides evidence for legal 
proceedings, however, the comparison of results obtained from the method 
discussed here to the ‘A’ result provided valuable information regarding method 
performance. Overall, all of the results of the ‘B’ sample analysis were consistent 
with the ‘A’ sample analysis results, both in terms of compounds identified and 
concentrations detected.  
4.4.7. Analysis of Drug Packets 
The results from the analysis of drug packets, shown in Table 38, show the 
discrepancy in the compounds listed as ingredients on packaging and what the 
material actually contains. It is possible that some of the additional compounds 
detected were present from the re-use and poor maintenance of production 
equipment, poor quality control, or inaccurate description of starting materials. 
From the chemical structure it does not seem likely that any of the un-labeled 
compounds are present from degradation or transformation of any of the labeled 
compounds. 
Table 38 – Ingredients listed on packaging versus analytical findings for 
products suspected of containing Synthetic Cannabinoid Receptor Agonists 
Product 
Active Ingredients on 
Labeling 
Analytical Findings 
Afghan Black Ultra 
(Formula 2A) 
5F-AKB48, STS-135 
5F-AKB48, STS-135,  
5F-MDMB-PINACA,  
5F-PB-22 
Blueberry Hazel Ultra 
(Formula 4A) 
5F-AKB48, 5F-PB-22 
5F-AKB48, STS-135,  
5F-PB-22 
Kuber Khaini Tobacco No SCRAs detected 
Lunar Diamond  5F-AKB48 
5F-AKB48,  
5F-MDMB-PINACA, 
5F-PB-22 
Pandora’s Box Unleashed 5F-AKB48, 5F-PB-22, BB-22 
5F-NPB-22, MMB2201, 
5F-MDMB-PINACA, 
5F-PB-22 
Tribal Warrior Ultimate 5F-AKB48, 5F-PB-22 
5F-AKB48, STS-135, 
5F-PB-22 
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4.5. Conclusion 
Method 2.1 as discussed in Section 4 was validated and deemed to be of sufficient 
quality to allow sensitive and selective detection, and accurate and precise 
quantitation of the SCRAs detailed in blood and urine, with a few exceptions. The 
LODs for BB-22 3CI and AB-FUBINACA M2B in whole blood were too high to 
detect the low concentrations that SCRAs are known to be present at after use. 
Similarly, the urine LODs for these compounds plus MAB-CHMINACA M1, AB-
CHMINACA M1A and AB-PINACA N4OH pentyl were higher than optimal. 
Concentrations of SCRAs in urine samples, however, do tend to be higher than in 
blood.  
The use of packed red cells for the calculation of LOD and LLOQ in place of whole 
blood is acknowledged as a limitation, as the extent of the effect of plasma protein 
binding with SCRAs is unknown. 
No interferences were observed either between SCRAs in the method or from 
other compounds likely to be present in forensic samples, at suitable 
concentrations. 
The calibration model was determined to be linear over the range assessed and 
linearity was acceptable for all compounds for which this was measured.  
Accuracy and precision, where calculated, were found to be within the acceptable 
ranges. 
Matrix Effects showed variation and some significant enhancement and inhibition 
in blood, particularly for CUMYL-PeGACLONE, MDMB-CHMICA, BB-22, 5F-
AKB48, MDMB-CHMINACA, 5F-PB-22, AM2201 N4OH pentyl, AB-PINACA N4OH 
pentyl, MMB2201, MAM2201 N4OH pentyl and 5F-NPB-22. Further optimisation 
to the extraction protocol or MP gradient could improve these, however with the 
number of compounds included in the method, it will always be a compromise to 
obtain the best results. Investigation into more suitable I.S. may compensate for 
the ME, but will add expense to the assay. 
ME for the urine method were much less significant and variable, likely due to the 
nature of urine as a less complex matrix.  
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Stability under autosampler conditions was generally acceptable for up to ca. 46 h. 
The compounds for which variation was outside ±20% tended to be the 
compounds for which significant ME were observed. Due to this, and as expected, 
variation over time was lower in urine than in blood. 
The analysis of drug packets provides evidence both that this method is suitable 
for application to non-biological matrices, and also of the inaccurate nature of 
ingredients listings on product packaging. While limited in the scope of products 
tested, this work shows the drugs included in this method at the time of 
development are relevant to the compounds available to potential users and again 
highlights its fitness-for-purpose. 
Overall, the result from Section 4 is a powerful method for the detection and 
quantitation of the most commonly available compounds on the UK market in 
whole blood and urine samples.   
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5. Synthetic Cannabinoid Receptor Agonists in Scottish Sub-Populations 
5.1. Summary 
This chapter reports the application of the methods developed in Chapters 3 and 4 
to case samples from various cohorts representing various sub-populations of 
Scotland. As samples were received at various times throughout the process of 
method development, not all samples were analysed by the optimised and 
validated method, Method 2.1. Table 39 andTable 40, and Figure 42 provide a 
summary of the methods applied to each cohort, including extraction and 
instrument parameters and compounds included in each method. Table 39 also 
summarises the results of the analysis of each cohort in terms of participant 
numbers and positivity rate. These results are discussed in more detail in Sections 
5.2 – 5.6. 
 
Table 39 – Summary of analytical method used, participant numbers and 
results in terms of number of positive cases for the Emergency Department, 
post-mortem, Scottish Prison Service, Forensic Directorate, and Glasgow 
Drug Court cohorts 
Cohort 
Analytical Method 
Used  
Number of 
Participants 
% Positive 
Emergency 
Department 
See Figure 42 34 56 
Post-Mortem See Figure 42 250 11 
Scottish Prison 
Service – overall 
Method 1.1 
(see Table 40 and 
Figure 42) 
725 3 
Scottish Prison 
Service – admission 
432 5 
Scottish Prison 
Service - liberation 
285 0 
Forensic Directorate 
Method 1.2 
(see Table 40 and 
Figure 42) 
95 0 
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Table 39 – Summary of analytical method used, participant numbers and 
results in terms of number of positive cases for the Emergency Department, 
post-mortem, Scottish Prison Service, Forensic Directorate, and Glasgow 
Drug Court cohorts 
Cohort 
Analytical Method 
Used  
Number of 
Participants 
% Positive 
Glasgow Drug Court 
Method 1.2 
(see Table 40) 
73 1 
 
Table 40 – Summary of extraction, hydrolysis (urine only), and instrumental 
parameters used in analytical methods applied to Emergency Department, 
post-mortem, Scottish Prison Service, Forensic Directorate, and Glasgow 
Drug Court cohorts 
Parameter Method 1.1 Method 1.2 Method 2.1 
Hydrolysis protocol 
(urine only) 
50 µL β-
glucuronidase, 60 °C 
for 1 H 
50 µL β-
glucuronidase, 60 
°C for 1 H 
50 µL β-
glucuronidase, 60 
°C for 1 H 
(no buffer) 
Extraction protocol 
0.5 mL blood/urine, 1 
mL pH6.0 phosphate 
buffer, 2 mL tBME, 
ca. 30 second vortex 
mix 
0.5 mL blood/urine, 
1 mL pH6.0 
phosphate buffer, 2 
mL tBME, ca. 30 
second vortex mix 
0.5 mL blood, 0.5 
mL pH6.0 
phosphate buffer, 1 
mL tBME, 2 min. 
flatbed mix 
0.5 mL urine, 2 mL 
MeOH, 5 min. 
flatbed mix 
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Table 40 – Summary of extraction, hydrolysis (urine only), and instrumental 
parameters used in analytical methods applied to Emergency Department, 
post-mortem, Scottish Prison Service, Forensic Directorate, and Glasgow 
Drug Court cohorts 
Parameter Method 1.1 Method 1.2 Method 2.1 
MP Gradient 
 
A = dH2O* 
B= MeOH* 
C=ACN:dH2O (95:5)* 
 
*with 2mM ammonium 
acetate and 0.1% formic 
acid 
F 
0-5 min: 40 % A, 
60% B 
5-10 min: ramped to 
10% A, 90% B 
10-20 min: 10% A, 
90% B 
20-20.1 min: ramped 
to 40% A, 60% B 
20.1-25 min:40% A,  
60% B 
H 
0-5 min: 40% A, 
60% B 
5-8.5 min: ramped 
to 20% A, 80% B 
8.5-18 min: 
ramped to 10% A, 
90% B 
18-20 min: 10% A, 
90% B 
20-20.1 min: 
ramped to 40% A, 
60% B 
20.1-25 min: 40% 
A, 60% B 
R 
0.-4 min: 60% A, 
40% C 
4-14 min: ramped 
to 40% A, 60% C 
14-28 min: 40% A, 
60% C 
28-28.1 min: 
ramped to 20% A, 
80% C 
28.1-40 min: 20% 
A, 80% C 
40-40.1 min: 
ramped to 60% A, 
40% C 
40.1-45 min: 60% 
A, 40% C 
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Figure 42 – Chronological flow diagram of details of methods employed to detect Synthetic Cannabinoid Receptor Agonists in 
post-mortem samples between May 2015 and April 2019 
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5.2. Individuals Undergoing Emergency Department Treatment 
5.2.1. Introduction 
From May to November 2015 FMS was involved in a collaborative research 
project with the emergency department (ED) of Glasgow Royal Infirmary (GRI) to 
analyse clinical samples from individuals treated for suspected drug toxicity. The 
priority for this project was to analyse samples for NPS, but alcohol and traditional 
drugs of abuse were included in the battery of analyses if noted case 
circumstances indicated use of these substances, and sufficient sample volume 
was available.  
Ethical approval was not required as the work was deemed service development. 
Similarly, no consent was required from the sample donors. 
5.2.2. Method 
Samples of blood and/or urine were collected by clinicians at GRI ED in cases 
where an individual presented with symptoms indicative of drug toxicity. The 
original purpose of these samples was for clinical testing and diagnosis. No 
separate sample was collected for this project as it was not possible to get 
informed consent from impaired individuals. The remainder of the samples was 
sent, along with clinical observations and any available case history, by courier to 
FMS, where they were stored between 2 – 8 °C. As the sample received was what 
remained of the clinical sample, volume was sometimes limited and urine not 
always available. Samples were analysed within 21 days of receipt.  
SCRA analysis was assigned if case circumstances were indicative of SCRA use 
or if SCRA product(s) were noted as having been taken on sample documentation. 
SCRA analysis was conducted according to a previously developed method which 
included the analytes 5F-AKB48, AKB48 N5OH pentyl, 5F-PB-22 and 5F-PB-22 3-
carboxyindole (131). The 5F-PB-22 3-carboxyindole included in this method was 
from a different source than the faulty batch discussed in Section 4.4.1, and thus 
the results are valid for this compound in this cohort. If sample volume allowed, 
samples were also extracted and analysed for MDMB-CHMICA using the validated 
method detailed in 3.4. In cases where sample volume was limited, a decision was 
made as to whether to analyse for MDMB-CHMICA only or the wider panel. 
Additional analyses, conducted by laboratory staff, were assigned based on case 
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circumstances and sufficient sample volume, and these are detailed in Table 55, in 
Appendix C, Section 9.2. 
The results of all toxicological analyses were reported to clinicians at GRI ED on 
completion of individual case work. 
More comprehensive clinical details, such as heart rate, blood pressure, Glasgow 
Coma Score (GCS), Poison Severity Score (PSS), treatment and results of clinical 
tests were received after toxicological results had been obtained and were noted 
with toxicological findings. Due to the individual nature of each case, the clinical 
details available were not standardised. 
5.2.3. Results and Discussion 
Between 8th May and 27th November 2015, 98 cases in total were received from 
GRI ED for analysis. Of these, 34 (35%) cases were submitted for SCRA analysis. 
All cases included a blood sample and 11 cases contained blood and urine 
samples, both of which were analysed. Nineteen out of 34 cases (56%) showed 
use of SCRAs, with 14 (41%) cases negative for all SCRAs in all matrices 
available. Blood samples for 2 cases gave inconclusive results for the wider SCRA 
analysis, due to ion suppression from the matrix and insufficient volume to repeat, 
but were positive for MDMB-CHMICA. Urine samples gave negative results for the 
wider SCRAs analysis and MDMB-CHMICA in these cases, but the cases overall 
were designated positive as one drug had been detected in one matrix. One case, 
for which only one sample was received, was analysed for MDMB-CHMICA as the 
priority, and insufficient sample volume remained after this analysis for the wider 
SCRA analysis. This case was treated as inconclusive overall. The MDMB-
CHMICA method was only developed after the first 12 cases submitted for SCRA 
analysis had been completed and thus no information on the presence or absence 
of this drug in these initial samples is available. The results obtained are 
summarised in Table 41. 
The details of the MDMB-CHMICA analysis for this cohort have been published 
(72), and a copy of this paper is given in Appendix D, Section 9.4. 
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Table 41 – Summary of results for Emergency 
Department samples tested for Synthetic 
Cannabinoid Receptor Agonists 
Result No. Cases 
Positive 19 
  in 1 of 2 matrices 3 
  in all matrices 16 
Negative 14 
Inconclusive  1 
 
Detailed information regarding specific SCRAs, concentrations found, other drugs 
detected and clinical observations found in SCRA-positive cases can be found in 
Table 42. 
The cases positive for one or more SCRA comprised samples from 17 males 
(89%) and 2 females (11%). The ages ranged from 14 – 55 years with a mean and 
median of 24.9 and 21 years respectively. These data are in-keeping with other 
studies which have found younger males the most likely to use SCRAs (14, 23, 
133-135). In data collated from 35 studies into acute/sub-acute cases of SCRA 
intoxication conducted mostly in the USA, but also Germany, Hong Kong and 
Switzerland, the mean age of the affected individual was 22.6 years, with the 
median and mode both 20 years and the range 14 – 59 years (14). The split by 
sex was 79% male to 21% female (14).  
The detection of SCRAs in individuals as young as 14 in both the current study 
and other studies is concerning as the effects of these compounds on 
physiological and psychological development are not fully understood. O’Shea et 
al. found impairment in working memory and social interaction in adolescent rats 
treated with CP 55,940; effects which were absent in the adult rat control group 
(136). While far from conclusive, this indicates a difference in effect between the 
age groups. Negative pre-natal physiological and adolescent psychosocial 
development effects associated with cannabis use have also been reported (137). 
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The number of compounds present in positive ED cases in this study is presented 
in Figure 43. This shows the majority of positive cases contained 1 compound 
only, and none were found positive for more than 4 compounds.  
 
Figure 43 – Number of Synthetic Cannabinoid Receptor Agonists detected in 
samples within the Emergency Department cohort. 
13 
4 
1 1 
Number of Compounds 
Present in ED Cases 
1 
2 
3 
4 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
1* 5F-AKB48 (2 ng/mL) 
5F-PB-22 3-
carboxyindole (22 
ng/mL) 
Alcohol,  
Basic Drugs, DOA 
screen, 
Benzodiazepines 1 
Lorazepam (0.022 mg/L, 
administered in ED) 
24 y.o. male, reported to have taken 
'Vertex' and 'Cherry Bomb' products 
within 6 hours of presentation at ED. 
Sinus tachycardia and GCS of 6. 
Unresponsive initially, extremely 
combative, incontinent of urine, 
dilated pupils, recurrent 
hypoglycaemia, severe serotonin 
toxicity, rhabdomyolysis and febrile. 
Duration of hospitalisation was 10 
days. 
CNS 3,  
CVS 2,  
MS. 2,  
Liver 1, Kidney 
0, Blood 0, 
Muscle 3 
2* 5F-AKB48 (<1 ng/mL) None available 
Alcohol,  
Basic Drugs and 
DOA screen 
Alcohol (237 mg/100mL), 
DOA screen POS for 
benzodiazepines 
(insufficient for 
confirmation) 
18 y.o. male, reported to have taken 
'Damnation' product within 6 hours 
of presentation at ED. Sinus 
tachycardia and GCS of 14. Violent, 
incontinent of urine and recurrent 
hypoglycaemia. Duration of 
hospitalisation was 2 days. Same 
individual as cases 10, 14 and 17. 
CNS 3,  
CVS 0,  
MS 1,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
3* 5F-AKB48 (<1 ng/mL) 
5F-AKB48 N4OH 
pentyl (5 ng/mL), 
5F-PB-22 3-
carboxyindole (<1 
ng/mL) 
Alcohol,  
Basic Drugs and 
DOA screen 
None 
14 y.o. male, reported to have 
smoked an unspecified 'legal high' 
with cannabis within 3 hours of 
presentation at ED. GCS of 15. 
Exhibited agitation and paranoia. 
Duration of hospitalisation was 3 
hours. 
CNS 1,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
4* 5F-AKB48 (3 ng/mL) None available 
Alcohol,  
Basic Drugs,  
DOA screen, 
Cannabinoids 
THC-COOH (<4 ng/mL),  
Alcohol (200 mg/100 mL) 
22 y.o. male, reported to have taken 
'Black Mamba' product with alcohol 
within 2 hours of presentation at ED. 
GCS of 14. Exhibited abusive, 
aggressive behaviour and syncope. 
Duration of hospitalisation was 2 
hours. 
CNS 2,  
CVS 2,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
5* NEG 
5F-PB-22 3-
carboxyindole 
(Present) 
Alcohol,  
Basic Drugs and 
DOA screen 
None 
18 y.o. male, reported to have taken 
'Exodus' product with alcohol within 
6 hours of presentation at ED. 
Found collapsed but on arrival at ED 
GCS was 15. Duration of stay was 3 
hours. 
All 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
6* 
5F-PB-22 3-
carboxyindole 
(Present) 
5F-AKB48 N4OH 
pentyl (present), 
5F-PB-22 3-
carboxyindole 
(Present) 
Alcohol,  
Basic Drugs,  
DOA screen, 
Benzodiazepines 1 
Desmethyldiazepam 
(<0.10 mg/L),  
Chlordiazepoxide (Present)  
55 y.o. male, reported to have taken 
'Exodus Damnation' product within 2 
hours of presentation at ED. 
Exhibited a dissociative state with 
GCS of 13. Prescribed 
chlordiazepoxide. 
CNS 2,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
7 
MDMB-CHMICA (5 
ng/mL) 
None available 
Alcohol,  
Basic Drugs,  
DOA screen, 
Benzodiazepines 1 
Diazepam (0.075 mg/L), 
Alcohol (130 mg/100 mL) 
20 y.o. female, reported to have 
taken 'Sweet Leaf' product within 6 
hours of presentation at ED. Found 
unconscious, exhibited acute 
behavioural disturbance with sinus 
tachycardia and a GCS of 10. 
Duration of hospitalisation was 1.5 
days. 
CNS 2,  
CVS 1,  
MS 1,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
8 
5F-AKB48 (Present), 
5F-PB-22 (Present) 
None available 
 
Alcohol, 
Basic Drugs, 
DOA screen, 
Cannabinoids 
DOA screen POS for 
cannabinoids (NEG in 
confirmation) 
41 y.o. male, reported to have taken 
'Black Mamba' product within 4 
hours of presentation at ED. 
Unresponsive, hypothermic (temp. 
<33 °C), with sinus bradycardia and 
a GCS of 10. Duration of 
hospitalisation was 1 day. Same 
individual as case 9. 
CNS 2,  
CVS 3,  
MS 3,  
Liver, Kidney, 
Blood and 
muscle unknown 
9 
5F-AKB48 (Present), 
5F-PB-22 (Present), 
5F-PB-22 3-
carboxyindole 
(Present), 
MDMB-CHMICA (22 
ng/mL) 
None available 
Alcohol,  
Basic Drugs and 
DOA screen 
None 
41 y.o. male, reported to have taken 
'Black Mamba' product. 
Unresponsive, exhibited recurrent 
hypoglycaemia, hypothermia (temp 
<33 °C). Same individual as case 8. 
Unknown 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
10 5F-AKB48 (Present) None available 
Alcohol,  
Basic Drugs and 
DOA screen 
Diphenhydramine (0.20 
mg/L),  
Alcohol (93 mg/100 mL) 
18 y.o. male, reported to have taken 
'Exodus Damnation' and 
'Annihilation' products within 4 hours 
of presentation at ED. Presented 
with sinus tachycardia, vomiting and 
dizziness, GCS of 15. Duration of 
hospitalisation 2 hours. Same 
individual as cases 2, 14 and 17 
CNS 1,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
11 
5F-AKB48 (Present), 
MDMB-CHMICA (<5 
ng/mL) 
None available 
Alcohol,  
Basic Drugs,  
DOA screen, 
Cannabinoids 
THC-COOH (4 ng/mL),  
Alcohol (80 mg/100 mL) 
25 y.o. male, reported to have taken 
'Sweet Leaf' and 'Saint Row' 
products with alcohol within 4 hours 
of presentation at ED. Exhibited 
syncope, possible seizures and 
confusion, with a GCS of 14. 
Duration of hospitalisation was 3.5 
hours. 
CNS 2,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
12 
MDMB-CHMICA (<2 
ng/mL) 
None available 
Alcohol,  
Basic Drugs and 
DOA screen 
None 
15 y.o. male, reported to have taken 
'Red Exodus' product within 6 hours 
of presentation at ED. Exhibited 
profuse vomiting with GCS of 13. 
Duration of hospitalisation was 1 
day. 
CNS 1,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
13 5F-AKB48 (Present) None available 
Alcohol,  
Basic Drugs and 
DOA screen 
Methadone (0.27 mg/L), 
DOA screen POS for 
benzodiazepines and 
cannabinoids (insufficient 
for confirmation) 
43 y.o. male, reported to have taken 
a 'mixed cannabinoid' product within 
6 hours of presentation at ED. 
Found unconscious and febrile with 
hypoglycaemia and a GCS of 6. 
Treatment was ongoing 5 months 
after incident. 
CNS 3,  
CVS 0,  
MS 1,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
14 
AKB48 OH pentyl 
metabolite (Present) 
None available 
Alcohol,  
Basic Drugs and 
DOA screen 
Alcohol (138 mg/100 mL) 
18 y.o. male, reported to have taken 
'Exodus Damnation' product within 4 
hours of presentation at ED. 
Exhibited seizures prior to, and 
acute behavioural disturbance within 
ED. Sinus tachycardia and a GCS of 
15. Duration of hospitalisation was 
1.5 hours. Same individual as cases 
2, 10 and 17 
CNS 1,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
15 
MDMB-CHMICA (<1 
ng/mL) 
None available 
Alcohol,  
Basic Drugs,  
DOA screen, 
Benzodiazepines 2 
 
DOA screen POS for 
benzodiazepines 
(confirmation NEG) 
21 y.o. male, inmate at SPS facility, 
reported to have taken a 'legal high' 
product within 24 hours of 
presentation at ED. Exhibited drug-
induced psychosis and acute 
behavioural disturbance with a GCS 
of 14. Duration of hospitalisation 
was 3 hours. 
CNS 3,  
CVS 0,  
MS 1,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
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Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
16 
MDMB-CHMICA (<1 
ng/mL) 
NEG (tested for 
MDMB-CHMICA 
only) 
Alcohol,  
Basic Drugs,  
DOA screen, 
Cannabinoids 
THC-COOH (9 ng/mL),  
Alcohol (225mg/100 mL) 
16 y.o. female, reported to have 
taken 'Red X' with alcohol within 6 
hours of presentation at ED. 
Exhibited severe disorientation, 
acute behavioural disturbance 
(barking noises), sinus tachycardia, 
a GCS of 14 and mild hypothermia. 
Duration of hospitalisation was 1 
day. 
CNS 3,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
17 
MDMB-CHMICA (2 
ng/mL) 
5F-PB-22 3-
carboxyindole 
(Present) 
Alcohol,  
Basic Drugs,  
DOA screen, 
Benzodiazepines 2 
 
Alcohol (229 mg/100 mL) 
19 y.o. male, reported to have taken 
'Damnation' product within 6 hours 
of presentation at ED. Exhibited 
acute behavioural disturbance, 
increased limb tone, sinus 
tachycardia and a GCS of 12. 
Duration of hospitalisation was 1 
day. Same individual as case 2, 10 
and 14. 
CNS 3,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
 * MDMB-CHMICA analysis not performed.    DOA = Drugs of Abuse.    ED = Emergency Department.    y.o. = years old.    GCS = Glasgow Coma Scale.    CNS = Central 
Nervous System.    CVS = Cardio-Vascular System.    MS = Metabolic System.    POS = Positive.    THC = Tetrahydrocannabinol.    THC-COOH = 11-Nor-Δ9-THC-
carboxylic acid.    NEG = Negative.    SPS = Scottish Prison Service. 
 
 
 
171 
Table 42 – Clinical and toxicological findings in Emergency Department samples which are positive for Synthetic Cannabinoid 
Receptor Agonists. 
Case 
No.  
SCRA Findings 
Blood 
SCRA Findings 
Urine 
Additional Analyses 
Additional Toxicological 
Findings 
Clinical Observations 
Poison Severity 
Score 
18 
MDMB-CHMICA (1 
ng/mL) 
None available 
Alcohol,  
Basic Drugs,  
DOA screen, 
Cannabinoids, 
Benzodiazepines 2, 
Opiates 
 
Morphine (<0.05 mg/L), 
THC (5 ng/mL),  
THC-COOH (35 ng/mL),  
Diazepam (0.2 mg/L), 
Desmethyldiazepam (0.13 
mg/L) 
24 y.o. male, reported to have taken 
'Obliteration' product within 4 hours 
of presentation at ED. Was found 
unconscious. GCS of 13. Duration 
of hospitalisation was 1 day. 
CNS 1,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
19 
MDMB-CHMICA (4 
ng/mL) 
NEG 
Alcohol,  
Basic Drugs,  
DOA screen, 
Cannabinoids, 
Benzodiazepines 2 
THC-COOH (23 ng/mL),  
Diazepam (0.28 mg/L), 
Desmethyldiazepam (0.34 
mg/L),  
22 y.o. male, reported to have taken 
'K2' within 4 hours of presentation at 
ED. Exhibited dissociative state and 
syncope with sinus tachycardia and 
a GCS of 13. Duration of 
hospitalisation was 12 hours. 
CNS 1,  
CVS 0,  
MS 0,  
Liver 0, Kidney 
0, Blood 0, 
Muscle 0 
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The most commonly encountered compounds in this cohort were 5F-AKB48 
and MDMB-CHMICA (n=9), followed by 5F-PB-22 3-carboxyindole (n=6), 5F-
AKB48 metabolite (n=3) and 5F-PB-22 (n=2). The times since sample 
collection, windows of detection and analyte stability should all be borne in 
mind when interpreting the significance of these findings. The more frequent 
presence of the 5F-PB-22 metabolite, rather than the parent drug, in both 
blood and urine suggests 5F-PB-22 is broken down more rapidly in the body 
than 5F-AKB48, which was detected in parent form. It is also possible that 
5F-PB-22 continues to breakdown in the stored sample, while 5F-AKB48 
does not - at least not to the same extent. The dose and mechanism of action 
of 5F-PB-22 should also be considered when interpreting the concentrations 
and absence of parent drug. As no metabolite for MDMB-CHMICA was 
included in the method, no corresponding observations can be made for this 
drug. Overall, results are indicative that 5F-AKB48 was taken in 11 cases, 
MDMB-CHMICA in 9 cases and 5F-PB-22 in 6 cases. Due to the lack of 
information on SCRA pharmacodynamics generally, and for these 
compounds specifically, no interpretation of their contribution to adverse 
effects was made. SCRAs detected in blood were much more likely to be 
exerting a – potentially significant – physiological effect at the time of 
collection, compared to compounds detected in urine only. That being said, 
undetected active metabolites could have been present in the blood in cases 
where the urine only was found positive.  
The most commonly co-administered substance was alcohol (n=8), followed 
by benzodiazepines (n=5 confirmed, including 1 administered in hospital, 
plus 2 presumptive positive) and cannabis (n=5). The notes received for two 
cases (Case 1 and Case 6) highlighted that lorazepam was administered 
during hospital treatment (Case 1) or chlordiazepoxide was prescribed (Case 
6). Indeed benzodiazepines are mentioned in the NEPTUNE document on 
SCRA harms and their management as having been reported as some value 
in SCRA treatment (108). However, ED staff in this project noted specifically 
that no diazepam had been administered to these patients so use must be 
through GP prescription or illicit.  
The presence of alcohol as a co-administered substance in 42% of cases is 
not surprising, given its ubiquity in Scottish culture. The concentrations at 
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which it was found in cases, however, were moderately high: the mean and 
median concentrations were 167 and 169 mg/100mL respectively. Given the 
commonality of alcohol in the Scottish population, it is likely that the 
individuals possess some degree of tolerance to this. This tolerance would 
affect the physiological effects of alcohol on the individuals in question. 
Similarly, 5 (26%) cases were positive for the inactive Δ9-THC metabolite 11-
nor-Δ9-THC-carboxylic acid, and one case was positive for Δ9-THC itself. 
This is indicative of co-administration of cannabis and SCRAs; if not acutely 
co-administered then at least taken together over a broader period of weeks 
to months (as the Δ9-THC metabolite is known to be sequestered in fat, and 
be released over time). This finding is also reinforced in the literature (106). It 
is difficult, therefore, to separate the effect that might have been exerted by 
the SCRA from the effect of alcohol, any co-administered substances or the 
potentially synergistic effect of these.  
The GCS allows standardised communication regarding the consciousness 
of an individual. In order to calculate this, scores from 1-4 are given for ocular 
responsiveness; scores from 1-5 are given for verbal responsiveness; and 
scores from 1-6 are given for motor responses. These are summed to 
provide the overall score, with the maximum of 15 representing a completely 
conscious and alert subject (138). 
The GCS range found in the SCRA-positive cases described here was 6 - 15, 
with the mean and median being 12.6 and 13.5 respectively. While this 
indicates a variety in the severity of effects on consciousness, it suggests the 
majority of individuals’ consciousness was not significantly affected. The 
same range was found in a series of analytically confirmed SCRA-positive 
cases detailed by Abouchedid et al. with a mean of 13.9 and a median of 15 
(134).  
Similarly, the PSS was developed to categorise the severity of poisoning in 
qualitative and translatable terms. It assigns a number from 0 (asymptomatic) 
to 4 (fatal), with 1 (minor), 2 (moderate) and 3 (severe) in between (139). 
Individual scores can be given to different systems and organs: Central 
Nervous System (CNS), Cardiovascular System (CVS), Metabolic System 
(MS), Liver, Kidney, Blood and Muscle. 
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In the cases positive for SCRAs presented here, 7 cases (37%) exhibited no 
or mild symptoms on the PSS. With regards to CNS symptoms, 6 cases 
(32%) were categorised as severe and 5 cases (26%) were categorised as 
moderate.  
The second most commonly raised score on the PSS was for the CVS, with 2 
cases scoring at 2 and one each for 1 and 3. The majority of noted 
cardiovascular symptoms were sinus tachycardia (n=8, 42%), with only 1 
where sinus bradycardia was noted.  
Where noted and symptomatic, the MS was scored as 1 four times, and 2 or 
3 once each. The muscle and liver were scored as 3 once and 1 once 
respectively. The kidneys and blood showed no symptoms where scores 
were noted. 
With regards to behavioural symptoms, syncope, collapse or 
unresponsiveness was noted in 10 cases (53%); behavioural disturbance 
was noted in 5 cases (26%); combative, aggressive or violent behaviour was 
noted in 3 cases; seizures were noted in 2 cases; and agitation and paranoia 
was noted in 1 case. More physiological symptoms included hypoglycaemia 
(n=4), hypothermia (n=3) and severe serotonin toxicity (n=1). 
It was suspected that the hypothermia exhibited by some individuals was an 
action of the drug, as clinical staff treating the individuals in the ED noted the 
outside temperatures around the time of presentation to be ambient (ca. 12 
°C). Lowered body temperatures were also present in the majority (61%) of 
cases studied by Abouchedid et al. (134).  
The relationship between SCRAs and blood glucose concentration is not so 
clear. The hypoglycaemia presented here is not mirrored in the literature, 
with some studies describing hyperglycaemia as a symptom of SCRA toxicity 
(25). It is possible that the symptom described here is either coincidental, or 
present due to the action of additional drugs or generally poorer wellbeing in 
the affected individuals.  
The symptoms observed in this case series tend to agree with the findings of 
Tait et al., who conducted an analysis of adverse events associated with 
SCRA use in the literature (23). They also found that tachycardia was a 
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common presentation in cases of SCRA toxicity, in addition to the presence 
of seizures and vomiting in patients. Agitation, new onset psychosis, 
paranoia and hallucinations were noted as psychological effects presented in 
their study. The authors also warned that a non-specific toxidrome 
associated with SCRA use could lead to drug toxicity being overlooked as the 
aetiology of the symptoms. 
In another presentation of adverse health effects van Amsterdam, Brunt and 
van den Brink reported effects such as anxiety, panic attacks, agitation, 
delusions as well as nausea/vomiting, seizures, tachycardia, hypertension, 
hypokalaemia and hyperglycaemia (140). They were, however, clear to 
highlight the variation in adverse effects from the use of different SCRA 
compounds. 
Similarly, tachycardia, seizure, agitation and psychosis are described in 
SCRA-positive cases in Abouchedid’s study, and these symptoms plus 
vomiting are noted by Bäckberg et al. (134, 141). 
The interval between drug ingestion and presentation at ED was noted in 18 
cases and ranged from 2 – 24 hours (mean and median 5.7 and 5 
respectively). It is important to bear this in mind when considering the SCRA 
concentrations and clinical observations for each case. It is acknowledged 
that the number of SCRAs detected by this method is low, and that additional 
compounds – including additional, active metabolites of the parent 
compounds included and others – may contribute to the effects observed. 
Maintaining a panel of drugs which is up-to-date with current trends was a 
noted challenge of this project.  
The duration of hospitalisation ranged from 1.5 hours to > 5 months, with a 
mean and median of 30 and 7.8 hours (when the case with treatment 
ongoing after 5 months was excluded). The variation in length of treatment 
time is to be expected given the diversity of psychological and physiological 
effects described, and the relative novelty of SCRA toxicity to medical 
professionals. Guidelines such as those provided by NEPTUNE should allow 
a framework for ED staff to build experience in treating individuals exhibiting 
SCRA toxicity (108). This being said, the diagnosis of SCRA toxicity in this 
case series was confirmed weeks after presentation, and as yet, there is no 
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commercially available point of care test (POCT) which can detect all the 
SCRA compounds, or even those most likely to be encountered in the UK. As 
a result, the diagnosis of the symptoms as SCRA-related may be reliant on 
patient communication, which may not be possible if the patient is 
unconscious or suffering from psychological disturbances. It was not 
disclosed what treatment the individual in Case 13 was receiving 5 months 
after initial presentation, or whether this was linked to SCRA use.  
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5.2.4. Conclusion 
Whilst this data set is limited in size, and does not measure prevalence of 
SCRA use, the results show that these drugs are being used by individuals 
requiring hospital treatment. 
The effects of co-administered substances cannot be ruled out as 
contributing factors in the attendance at the ED. However, the detection of 
very low concentrations of SCRAs in the blood and associated physiological 
and psychological harms is indicative of highly potent substances. Of 
particular interest is Case 3 where a sub-nanogramme concentration of 5F-
AKB48 was detected in the blood sample along with a sub-nanogramme 
concentration of 5F-PB-22 3-carboxyindole and 5 ng/mL of 5F-AKB48 N4OH 
pentyl metabolite which were detected in the urine, with no co-administered 
substances detected. Whilst little interpretation of concentrations of SCRAs is 
possible, due to very limited pharmacodynamic data, it is important to 
consider the potentially significant contribution of SCRAs present in the blood 
to intoxication. While urinary concentrations will no longer be 
pharmacologically active, their presence does indicate SCRA use, and the 
possibility of undetectable active metabolites present in the blood remains. 
The time since sampling and possible instability should be borne in mind 
when considering the compounds detected, and the concentrations at which 
these were found, relative to the LOD. 
Further research with a larger sample size and including a broader range of 
analytes would be beneficial to gain a deeper insight into the medical 
consequences and demographics of SCRA use.   
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5.3. Post-Mortem Casework 
5.3.1. Introduction 
Forensic Medicine and Science (FMS) at the University of Glasgow (UG) 
provides a post-mortem toxicology service covering Greater Glasgow and 
Clyde (GGC), Lothian, Tayside, Ayrshire and Arran (AA), Dumfries and 
Galloway (DG) and Borders NHS regions. This encompasses the cities of 
Edinburgh, Glasgow and Dundee, and has a caseload in excess of 3800 
cases per year.  
Due to the constantly shifting trends relating to recreational drug use, the 
analyses required to cover this diverse group of compounds are particularly 
dynamic. The emergence of Novel Psychoactive Substances (NPS) made it 
necessary for FMS to develop methods to detect and quantify SCRAs in 
post-mortem case samples. The methods detailed in Chapter 4 were applied 
to the case samples described below, depending on the sample type and 
period of receipt. 
Ethical approval for mining data from the FMS case database was sought 
and received from the UG College of Medical Veterinary and Life Sciences 
(MVLS) REC. See Section 9.4, Appendix E, for details. 
5.3.2. Method 
5.3.2.1. Sample Collection 
Samples of blood and urine were collected by pathologists or mortuary 
technicians during PM. As standard, blood was collected from the femoral 
vein by dissecting the vessel and collecting the blood in a universal container 
as it empties. Depending on the condition of the cadaver, or circumstances of 
death, blood from different sites such as the axillary vein, chest or abdominal 
cavities may have been collected. Where available, urine was extracted from 
the bladder using a syringe and transferred into a universal container. Where 
a sample is referred to as preserved, this relates to the use of a container 
containing a pre-loaded mass of sodium fluoride and potassium oxalate.  
After collection, samples are delivered securely by courier to FMS where they 
are stored in a temperature-monitored fridge (maintained between 2 – 8 °C) 
for up to 3 months before transfer to a temperature-monitored freezer (≤ -18 
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°C). Generally, all analyses were conducted prior to sample freezing, but a 
low number of samples may have been frozen and thawed once prior to 
analysis.  
5.3.2.2. Sample Analysis  
SCRAs analysis was conducted on unpreserved blood and preserved urine 
where available and where sample volume allowed.  
Due to the nature of the project, and the time span covered (2015 – 2019), 
the specifics of the methods used to analyse samples varied. Either the 
original or optimised extraction protocol, detailed in Table 19, was used. The 
instrumental method adhered to the parameters detailed for methods 1.1, 1.2 
or 2.1. The only additional variation within methods was the panel of 
compounds covered, which was frequently updated to include additional 
compounds when they became potentially available on the NPS market. 
These were added at various stages throughout method development. For a 
small number of very early samples, the previously validated method used in 
Section 5.2 was employed. For this method, the 5F-PB-22 3-carboxyindole 
metabolite was included in the panel, and all samples positive for this 
compound were detected using the valid reference standard. Figure 42 
provides a summary of the details of different methods applied to PM 
samples over the period of study.  
Additional analyses for commonly encountered prescription and abused 
drugs, as well as alcohol and β-hydroxybutyrate (BHB) were conducted by 
laboratory staff, based on case circumstances. 
5.3.3. Results and Discussion 
The results from the analysis conducted in Section 5.3.2.2 are shown in 
Table 43. This table provides the date of case receipt, toxicological results, 
case circumstances and causes of death determined by the pathologist. Out 
of 250 cases tested for SCRAs between Summer 2015 and Spring 2019, 28 
cases were found positive for at least 1 SCRA in at least 1 biological sample, 
a positivity rate of 11.2%. 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
1 
15 June 
2015 
MDMB-CHMICA (1 ng/mL) 
(sub-clavian blood) 
5F-PB-22 3-carboxyindole 
(Present) 
Amitriptyline (0.12 
mg/L) 
44 y.o. male, found 
hanged 
1a - Hanging 
2 
28 July 
2015 
MDMB-CHMICA  (<1 ng/mL) NEG 
Alcohol (237 mg/dL) 
BHB (249 mg/L) 
Acetone ( <100 mg/L) 
38 y.o. male, alcoholic, 
found unresponsive at 
home 
1a - Complications of 
acute and chronic 
alcoholism 
3 
25 
September 
2015 
5F-AKB48  (Present) 
5F-PB-22 3-carboxyindole 
(Present) 
Sertraline (1.1 mg/L) 
Olanzapine (0.08 
mg/L) 
Zopiclone (<0.05 
mg/L) 
44 y.o. male, previous 
mental health issues, 
found unresponsive 
after bouts of vomiting 
1a - Coronary artery 
thrombus 
1b - Coronary artery 
atherosclerosis 
2 - Hypertensive heart 
disease 
4 
08 January 
2016 
5F-PB-22 (<0.5 ng/mL) 
AKB48 N5OH pentyl (<0.5 
ng/mL) 
MDMB-CHMICA (<0.5 ng/mL) 
None available 
Tramadol (0.94 mg/L) 
Citalopram (0.55 mg/L) 
52 y.o. male collapsed 
and became 
unresponsive after bouts 
of vomiting 
1a – Bronchopneumonia 
1b - Chronic Bronchitis 
and Emphysema 
2 Atherosclerotic 
Coronary Artery Disease 
and Synthetic 
Cannabinoid Intoxication 
 
 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
5 
04 March 
2016 
AKB48 N5OH pentyl 
(Present) 
NEG 
Morphine (0.06 mg/L) 
(6MAM in the urine) 
31 y.o. male found 
collapsed in prison cell 
1a - Adverse effects of 
heroin and AKB48 
N5OH pentyl 
6 
16 March 
2016 
AKB48 N5OH pentyl 
(Present) 
MDMB-CHMICA (Present ) 
AB-FUBINACA valine 
metabolite (Present) 
AB-FUBINACA M2B (Present) 
AKB48 N5OH pentyl (Present) 
AB-FUBINACA (Present) 
AB-FUBINACA valine 
metabolite (Present) 
AB-FUBINACA M2B (Present) 
Alcohol (12 
mg/100mL) 
COHb (51%) 
Methadone (1.2 mg/L) 
Etizolam (0.11 mg/L) 
THC-COOH (6 ng/mL) 
31 y.o. male found 
unresponsive in a house 
fire, “legal highs” and 
needles found at scene. 
Same scene as Case 8. 
1a - Smoke Inhalation 
and Carbon Monoxide 
Poisoning  
1b - House Fire 
2 Acute Drug Misuse 
7 
16 March 
2016 
AB-FUBINACA valine 
metabolite (Present) 
None available 
COHb (48%) 
Etizolam (0.016 mg/L) 
Morphine (<0.025 
mg/L) 
56 y.o. female, found 
unresponsive in a house 
fire, “legal highs” and 
needles found at scene. 
Same scene as Case 7. 
1a - Inhalation of Smoke 
and Carbon Monoxide 
Toxicity 
1b - House Fire 
2 Drug Misuse 
8 
25 May 
2016 
5F-PB-22 (<0.50 ng/mL) 
MDMB-CHMICA (<0.50 
ng/mL) 
None available 
Alcohol (11 
mg/100mL) 
BHB (39 mg/L) 
Flubromazepam 
(0.013 mg/L) 
THC-COOH (8 ng/mL) 
50 y.o. male found 
unresponsive at home, 
history of mental health 
issues, drug use and 
alcohol 
1a - Ischaemic heart 
disease and possible 
drug toxicity  
2 - Fatty degeneration of 
the liver 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
9 
08 June 
2016 
MDMB-CHMICA O-desmethyl 
acid metabolite (Present) 
NEG 
Alcohol (114 
mg/100mL) 
33 y.o. male, found 
collapsed in homeless 
accommodation 
1a - Complications of 
drug toxicity 
10 
04 July 
2016 
5F-MDMB-PINACA (Present) None available None 
37 y.o. male suspected 
of heroin and "legal 
high" use. Found 
collapsed on the toilet 
with the hood of his 
sweatshirt caught on the 
tap, appearing to have 
strangled him. "Cherry 
Bomb" found near body. 
1a - Hanging 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
11 
19 October 
2016 
NEG 
AB-FUBINACA valine 
metabolite (Present) 
Morphine (0.08 mg/L) 
Codeine (0.14 mg/L) 
(6MAM in the urine) 
Pregabalin (7 mg/L) 
Etizolam (0.006 mg/L) 
Diazepam (0.76 mg/L) 
Desmethyldiazepam 
(0.38 mg/L) 
Oxazepam (<0.05 
mg/L) 
Temazepam (<0.05 
mg/L) 
Tramadol (0.14 mg/L) 
THC-COOH (2 ng/mL) 
 
28 y.o. male with history 
of drug use and mental 
health issues, found 
unresponsive after 
injecting heroin 
1a - Adverse Effects of 
Heroin, Pregabalin, 
Tramadol, Diazepam 
and Etizolam 
 
12 
06 January 
2017 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(Present) 
AB-FUBINACA valine 
metabolite (Present) 
MDMB-CHMICA O-desmethyl 
acid metabolite (Present) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(Present) 
AB-FUBINACA valine 
metabolite (Present) 
MDMB-CHMICA O-desmethyl 
acid metabolite (Present) 
Alcohol (311 
mg/100mL) 
Fluoxetine (0.18 mg/L) 
Norfluoxetine (0.39 
mg/L) 
49 y.o. male alcoholic, 
"addicted" to legal highs, 
found unresponsive at 
home 
1a - Acute and chronic 
alcoholism in association 
with synthetic 
cannabinoid use 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
13 
30 May 
2017 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(<0.50 ng/mL) 
(ante-mortem blood) 
5F-MDMB-PINACA O-
desmethyl acid metabolite (1.1 
ng/mL) 
(ante-mortem urine) 
Methadone (0.11 
mg/L) 
Amitriptyline (0.19 
mg/L) 
Zopiclone (0.012 
mg/L) 
46 y.o. male found 
unresponsive in prison 
cell after witnessed 
strange behaviour. Died 
in hospital 
1a - Hypoxic brain injury 
1b - cardiac arrest 
1c - suspected drug 
toxicity 
14 
21 
September 
2017 
MDMB-CHMICA O-desmethyl 
acid metabolite (2.5 ng/mL) 
MDMB-CHMICA O-desmethyl 
acid metabolite (1.1 ng/mL) 
Fluoxetine (0.52 mg/L) 
Norfluoxetine (0.42 
mg/L) 
COHb (<10%) 
THC-COOH (20 
ng/mL) 
21 y.o. female with a 
history of mental health 
issues, found 
unresponsive in bed 
1a - Complications of 
anorexia nervosa 
15 
06 October 
2017 
5F-MDMB-PINACA (Present) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(7.4 ng/mL) 
5F-MDMB-PINACA O-
desmethyl acid metabolite (24 
ng/mL) 
Zopiclone (0.043 
mg/L) 
30 y.o. male found 
unresponsive in prison 
room 
1a - Adverse effects of 
5F-MDMB-PINACA 
16 
24 
November 
2017 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(0.05 ng/mL) 
AB-FUBINACA valine 
metabolite (0.11 ng/mL) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(<0.10 ng/mL) 
AB-FUBINACA valine 
metabolite (<0.10 ng/mL) 
BHB (>500 mg/L) 
Acetone (298 mg/L) 
23 y.o. male found 
unresponsive in 
supported 
accommodation 
surrounded by bags of 
“psychoactive 
substances” 
1a - diabetic 
ketoacidosis 
1b – Insulin dependent 
diabetes mellitus 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
17 
21 February 
2018 
5F-MDMB-PINACA (Present) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(Present) 
AB-FUBINACA valine 
metabolite (Present) 
5F-MDMB-PINACA (Present) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(Present) 
AB-FUBINACA valine 
metabolite (Present) 
Methadone (0.2 mg/L) 
Mirtazapine (0.02 
mg/L) 
Lignocaine (0.30 mg/L) 
46 y.o. male stabbed in 
prison 
 
1a - stab wounds of 
trunk 
 
18 
04 April 
2018 
AB-FUBINACA valine 
metabolite (0.29 ng/mL) 
AB-FUBINACA valine 
metabolite (1.5 ng/mL) 
Methadone (0.6 mg/L) 
Morphine (0.09 mg/L) 
Etizolam (0.06 mg/L) 
Pregabalin (30 mg/L) 
36 y.o. male found 
unresponsive 2 days 
after prison release, 
witnessed behaviour 
under the influence 
1a - multiple drug toxicity 
2 Coronary artery 
atheroma 
19 
02 May 
2018 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(3.0 ng/mL) 
AB-FUBINACA valine 
metabolite (0.19 ng/mL) 
5F-MDMB-PINACA O-
desmethyl acid metabolite (14 
ng/mL) 
AB-FUBINACA valine 
metabolite (0.90 ng/mL) 
Alcohol (11 
mg/100mL) 
Methadone (1.1 mg/L) 
Mirtazapine (0.19 
mg/L) 
49 y.o. male found 
unresponsive in prison 
cell 
1a - Methadone and 
synthetic cannabinoid 
receptor agonist 
intoxication 
20 
21 June 
2018 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(1.1 ng/mL) 
AB-FUBINACA valine 
metabolite (0.56 ng/mL) 
5F-MDMB-PINACA O-
desmethyl acid metabolite (2.7 
ng/mL) 
AB-FUBINACA valine 
metabolite (1.4 ng/mL) 
None 
33 y.o. male found 
hanged in prison cell 
1a - Hanging 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
21 
11 July 
2018 
5F-MDMB-PINACA (0.18 
ng/mL) 
5F-MDMB-PINACA O-
desmethyl acid metabolite (19 
ng/mL) 
(ante-mortem blood) 
None available 
Methadone (0.67 
mg/L) 
Mirtazapine (0.02 
mg/L) 
47 y.o. male found 
collapsed in prison cell 
after drugs being found 
concealed on his body 
1a - Myocardial 
infarction 
1b - Coronary artery 
atherosclerosis 
22 
05 October 
2018 
NEG 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(<0.20 ng/mL) 
6MAM (0.02 mg/L) 
Morphine (1.3 mg/L) 
Codeine (0.08 mg/L) 
THC-COOH (34 
ng/mL) 
38 y.o. male of no fixed 
abode, released from 
prison 4 days prior, 
found collapsed in car 
park 
1a - Heroin intoxication 
23 
27 
December 
2018 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(<0.10 ng/mL) 
(ante-mortem blood) 
NEG 
Diazepam (<0.05 
mg/L) 
Lorazepam (0.021 
mg/L) 
25 y.o. male collapsed 
while using prison gym, 
died in hospital 
1a - Basilar artery 
dissection 
24 
31 January 
2019 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(0.13 ng/mL) 
AB-FUBINACA valine 
metabolite (Present) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(0.24 ng/mL) 
AB-FUBINACA valine 
metabolite (11 mg/L) 
Alcohol (15 
mg/100mL) 
Methadone (0.98 
mg/L) 
Amitriptyline – 0.37 
mg/L 
43 y.o. male found 
hanged in prison cell 
1a - Hanging 
 y.o. = year old    NEG = Negative    BHB = β-hydroxybutyrate    6MAM = 6-monoacetyl morphine    COHb = carboxyhaemoglobin     
THC-COOH = 11-Nor-Δ9-THC-carboxylic acid     
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Table 43 – Circumstances and findings in Synthetic Cannabinoid Receptor Agonist-positive Post-Mortem casework 
Case 
No. 
Date of 
Receipt 
SCRA Findings in Blood SCRA Findings in Urine 
Additional 
Toxicological 
Findings in Blood 
Case Circumstances Cause of Death 
25 
04 February 
2019 
4F-MDMB-BINACA (0.07 
ng/mL) 
NEG 
Mirtazapine (0.02 
mg/L) 
36 y.o. male found 
hanged in prison cell 
1a - Hanging 
26 
12 February 
2019 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(0.12 ng/mL) 
AB-FUBINACA valine 
metabolite (Present) 
None available None 
27 y.o. male in prison, 
circumstances 
undisclosed 
Undisclosed 
27 
04 April 
2019 
AB-FUBINACA valine 
metabolite (5.3 ng/mL) 
5F-MDMB-PINACA O-
desmethyl acid metabolite 
(<0.20 ng/mL) 
AB-FUBINACA valine 
metabolite (11 ng/mL) 
EME (<0.25 mg/L), 
BZE (0.05 mg/L), 
Morphine (1.2 mg/L), 
Codeine (0.10 mg/L) 
(6MAM in the urine) 
40 y.o. male found 
unresponsive in 
homeless 
accommodation the day 
after prison release 
1a - Heroin and cocaine 
intoxication 
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From this table it is clear that the toxicological picture is often very complex, 
with a variety of different drugs, with different mechanisms of action, present 
in cases positive for SCRAs.  
Figure 44 shows the number of SCRA compounds detected in PM casework 
over the study period. The most commonly identified SCRAs, as identified 
from parent drug or metabolite, were 5F-MDMB-PINACA (n=14), MDMB-
CHMICA (n=8) and 5F-PB-22 (n=4). The AB-FUBINACA valine metabolite 
was present in 12 cases, but this compound is a shared metabolite of AB-
FUBINACA and MMB-FUBINACA so, with no parent compound detected, it 
is unclear which compound was ingested. The windows of detection for 
SCRAs have not been widely reported. Franz et al., have, however, found 
that the AB-FUBINACA valine metabolite was still detectable 13 days after a 
single ingestion of AB-FUBIANCA, and found evidence to indicate heavy 
consumption could lead to a period of elimination lasting for months (142). 
The high turnaround and short lifetime of SCRAs could account for the 
variety of compounds seen. For example 4F-MDMB-BINACA was only 
identified in 1 case, but this wass a relatively novel compound (at the time of 
writing) and if the time period of the study was extended, it is potentially the 
case that more incidences of this compound would be identified. The 5F-PB-
22 3-carboxyindole metabolite was not tested for cases received from early 
2016 onwards due to the faulty reference standard being used, and this only 
being discovered after the conclusion of practical work. The parent drug and 
another metabolite, PB-22 N-pentanoic acid, were included in the panel so 
the detection of 5F-PB-22 was possible. The relative abundances of the 
metabolites should be considered, though, and the fact that PB-22 N-
pentanoic acid was not seen where 5F-PB-22 3-carboxyindole was could be 
indicative that the latter is a much better identifier of use. The inadvertent use 
of a defective reference standard was unfortunate but unavoidable given the 
point at which the fault was discovered by the producer and communicated to 
the researcher. This highlights another challenge associated with working 
with compounds of such similar structures.  
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Figure 44 – Bar chart showing the number of cases Synthetic Cannabinoid Receptor Agonist compounds were detected in in 
post-mortem samples by month and year over the study period (June 2015 – April 2019) 
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From Table 43, it is clear that SCRAs were not quantified in every case. This 
was for a variety of reasons. For some batches, time constraints meant that a 
full calibration and QCs could not be run. As little pharmacological data exists 
regarding the interpretation of concentrations of SCRAs in PM samples it was 
determined that a qualitative result was sufficient for the case. In other 
batches, a calibration and QCs were run but calibrator removal and/or QC 
failure meant quantitative results could not be reported. After method 
optimisation and validation, the vast majority of results were reported as 
quantitative. For these reasons, and the complex toxidrome likely caused by 
co-administered substances, it is not possible to interpret the concentrations 
observed. It is clear to see, however, that the concentrations are generally 
very low, mostly in the sub-nanogramme per millilitre range for blood 
especially, highlighting the need for sensitive methods of detection. Table 44 
shows the concentrations of different compounds detected where quantitative 
results have been reported. The widest range was observed for the 5F-
MDMB-PINACA metabolite at 0.05 – 19 ng/mL. This is one of the most 
commonly seen SCRAs in PM casework since the method was validated, 
and as such has the highest number of quantitatively reported results.  
As little information is available regarding what might constitute a ‘significant 
concentration’ of SCRA compounds in PM samples, it is of limited value to 
report concentrations. Having said that, by providing quantitative information, 
an understanding of what concentrations might be present in certain 
circumstances, i.e. where no other cause of death is determined, can begin 
to be formed. If, for example, the concentration range detected in the blood 
for 5 cases where 5F-MDMB-PINACA has been mentioned as potentially 
contributing or causing death is available to a pathologist, they may be more 
confident in certifying additional deaths as related to this drug, where similar 
concentrations are detected. In order to collate this information, quantitative 
analysis is required. The concentrations reported in the publication relating to 
MDMB-CHMICA in the ED cohort (72) (see Appendix D, Section 9.4) have 
gone some way to remedy this, as they appear in the reference book 
Disposition of Toxic Drugs and Chemicals in Man (143). This book is referred 
to frequently by forensic toxicologists when interpreting concentrations of 
drugs. 
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Table 44 – Concentrations of Synthetic Cannabinoid Receptor 
Agonists detected in PM casework, in nanogrammes per litre, 
where reported quantitatively 
Compound N= 
Blood 
Concentrations 
(ng/mL) 
MDMB-CHMICA 4 <0.5 - 1 
MDMB-CHMICA O-desmethyl acid 
metabolite 
1 2.5 
5F-PB-22 2 <0.5 
AKB48 N5OH pentyl 1 <0.5 
AB-FUBINACA valine metabolite 5 0.11 - 5.3 
5F-MDMB-PINACA 1 0.18 
5F-MDMB-PINACA O-desmethyl acid 
metabolite 
9 0.05 - 19 
4F-MDMB-BINACA 1 0.07  
 
The most commonly co-administered substances were alcohol and 
methadone, observed in 7 cases each, at median concentrations of 15 
mg/100mL (range: 11 – 311 mg/100mL) and 0.67 mg/L (range: 0.11 – 1.2 
mg/L) respectively. Cannabis metabolites (THC, THC-COOH) were detected 
in 5 cases, a similar proportion to the ED cohort discussed in Section 5.2.3 
(19% in PM cases compared with 26% in ED cases). The high incidence of 
alcohol, methadone and cannabis metabolites in this cohort is not 
unexpected for various reasons. As mentioned in Section 5.2.3, alcohol use 
is widespread in both Scottish culture and Western culture more generally, 
and is commonly detected in the PM casework conducted in this laboratory. 
Similarly, cannabis is the most widely used drug worldwide (144). The effects 
of cannabis as similar to SCRAs make it a likely candidate to be used by the 
same individuals, either at the same or different times. Methadone is 
commonly present in PM casework, having been implicated in 47% of drug-
related deaths in 2018 (114). The combined effects of SCRA and alcohol 
and/or methadone use are not characterised. It is possible that the CNS 
depressant effects of both these substances could counteract certain 
stimulant-type effects reported in SCRA use such as tachycardia and 
aggressive behaviour. Alternatively, alcohol could exacerbate psychoactive 
effects of SCRAs and cause further behavioural disturbances in the form of 
aggression and agitation. Similarly, the co-administration of methadone may 
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cause CNS depression such as bradycardia, as was observed in the ED 
cohort. In addition to this, the presence of methadone may be problematic if 
emergency medical professionals are required to provide benzodiazepines to 
treat SCRA toxicity. 
As a drug group, antidepressants (amitriptyline, sertraline, citalopram, 
mirtazapine, fluoxetine (and metabolite norfluoxetine)) are present in 11 
cases. This could either suggest pre-existing mental health conditions in 
SCRA users, or could indicate a detrimental effect of SCRA use on mental 
health. Antidepressants are also an unfortunately common feature in PM 
casework and it is possible that their detection in SCRA-positive cases is 
simply an artifact of their commonality.  
The cohort consisted predominantly of males (93%), in the age range 23 – 52 
years (mean and median: 38 years). The 2 females included in the cohort 
were 21 and 56 years old. Abouchedid et al. found an age range of 18 – 44 
years (median: 31 years) in a cohort of 18 individuals found positive for 
SCRA from a group presenting to hospital with acute recreational drug 
toxicity (134). In 4 case studies, discussing 8 fatalities involving various 
SCRAs, by Shanks, Behonick et al., the ages ranged from 17 – 41 years 
(mean: 27, median: 28) and 63% were male (93, 145-147). The demographic 
identified in this study therefore conforms to the general trend seen in the 
literature of a relatively wide age range of predominantly male users.  
Individuals in 14 cases (52%) were either currently incarcerated or had been 
liberated from prison in the few days preceding death. While SCRA use is 
known to be a problem within prisons (103, 104, 111), it should be noted that 
samples from individuals who died whilst within or recently released from 
prisons were preferentially analysed for SCRAs. The potential effects of this 
preferential testing should also be borne in mind when considering the 
demographics of the SCRA-positive PM cases, with respect to the 
demographics of the prison population. The use of SCRAs in prison is 
covered in more detail in Section 5.4. 
A number of different causes of death were reported for this cohort. For the 
purposes of this discussion, these have been split into the following 
headings: drug-related, alcohol-related, medical/natural, hanging, house fire, 
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and homicide. Out of the 27 cases positive for SCRAs, the majority of the 
causes of death fall within the drug-related category, with 8 cases (30%). Of 
these, 3 cases (38%) name a SCRA in the cause of death. The cause of 
death for Case 15 is ‘adverse effects of 5F-MDMB-PINACA’, to the author’s 
knowledge the only case in Scotland which is purely SCRA-related. The 
other drugs included in these cases were heroin (inferred from the detection 
of metabolites, n=4), methadone (n=1), pregabalin (n=1), diazepam (n=1), 
etizolam (n=1), and tramadol (n=1) These are all drugs that are commonly 
detected in drug-related deaths in Scotland. 
Medical/natural deaths account for 7 of the 27 deaths (26%). Case 4 falls into 
this category, but does mention synthetic cannabinoid intoxication in section 
2 (detailing other significant conditions contributing to the death but not 
related to the disease or condition causing it). Five cases (19%) had hanging 
noted as the cause of death, with 4 of these (80%) being hangings in prison. 
As discussed previously, the preferential nature of testing samples from 
individuals in prison should be borne in mind when considering these 
numbers. Hanging appears to be quite highly represented in this cohort, so 
further investigation into the role SCRAs play in cases of hanging deaths 
would provide more information. For example, whether SCRAs have a 
negative psychological impact on users, or whether their use is more 
prevalent in individuals with pre-existing psychological conditions. Alcohol-
related causes of death and house-fires were noted on the death certificates 
in 2 cases each, with homicide by stab wounds noted for 1 case.  
Overall SCRAs are mentioned in the cause of death for 5 cases (19%) in this 
cohort. While there have been reports of fatal cases of SCRA intoxication 
(93, 145-148), information about the pharmacodynamics and clinical 
symptoms for SCRAs in general as well as specific compounds is still very 
limited. Particularly as there are often underlying medical conditions or co-
administered substances in fatal cases making the determination of the 
mechanism of death highly complex.  
It should be noted that Case 5 actually names a SCRA metabolite in the 
cause of death. It is unclear whether the pathologist meant that the 
metabolite itself contributed specific toxicity to the individual, or whether this 
was taken as a marker of presence of the parent compound, which 
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contributed towards the death. There is evidence that the metabolite in 
question, AKB48 N5OH pentyl, does retain efficacy at the cannabinoid 
receptors (97), but even less is known about the pharmacodynamics and 
toxicity of SCRA metabolites.  
Case 26 is subject to a Fatal Accident Inquiry (FAI) still ongoing at time of 
submission (September 2019), as such, circumstances and cause of death 
are not disclosable. 
The causes of death for all cases tested for SCRAs are shown, by 
percentage, in Figure 45. Causes of death for 4 cases were undisclosed and 
do not feature in these data. From this it is clear that drugs played a role in 
the deaths of half of the cohort. Causes of death were unascertained in the 
second largest group (17%). It should be noted, however, that pathologists 
would often resubmit cases for additional analyses for less-commonly 
encountered compounds if a cause of death could not be determined from 
initial pathological, histological or toxicological findings. Consequently, an 
artificially large proportion of cases tested for SCRAs would be 
unascertained. The third and fourth most common cause of death in cases 
tested for SCRAs were medical/natural (15%) and suicide (11%). It is 
possible that the preferential testing of individuals who died in prison is 
responsible for this, as these are common causes of death among 
incarcerated individuals. These medical/natural deaths, for example, may not 
have been subjected to PM investigation if the deceased was not in a 
custodial institution, and thus SCRA analysis would not have been 
conducted. There were minor contributions towards the cohort of individuals 
who died as a result of an accident, alcohol-related issues, a house fire, 
homicide, or a road traffic collision. 
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Figure 45 – Pie chart showing the causes of death for all cases tested 
for Synthetic Cannabinoid Receptor Agonists, by percentage. The 
cause of death for 4 cases were undisclosed and so are not included in 
this chart. 
 
5.3.4. Conclusions 
The application of the methods developed for the detection and quantitation 
of SCRAs in blood and urine to PM casework has shown that SCRAs are 
being used by a variety of people in the Scottish population. The numbers of 
cases where SCRAs have been detected are considerably lower than those 
for the likes of opioids, benzodiazepines and cocaine, however. From the 
categories and circumstances of deaths in SCRA-positive cases, it is 
apparent that the types of cases where SCRAs are detected tend to be in 
abusers of other recreational drugs, and individuals within, or recently 
released from, prison.   
The cases where SCRAs have been detected are generally quite complex 
from a toxicological view point, with little interpretation of toxicity possible. 
The demographics of positive cases are similar to those found elsewhere in 
the literature, and indeed to those of Scottish drug users in general.  
Due to the novelty of SCRAs and the lack of understanding regarding what 
constitutes a ‘toxic’ concentration, there is currently little value in reporting 
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concentrations in PM cases. As has been the case with other newly emerged 
drugs, such as etizolam and gabapentin, it is thought that as pathologists 
become more familiar with SCRAs and concentrations found in different case 
types that they will consider the concentrations to a higher degree. It is, 
therefore, useful to continue to quantitatively report concentrations in order to 
build up more information on concentrations considered important by 
pathologists in determination of causes of death. 
This work has provided evidence that SCRAs are being used in a prison 
environment, but care must be taken not to over-interpret this point, as 
individuals with recent incarceration were preferentially tested for SCRAs. 
Likewise, the apparent correlation with SCRA use and suicide by hanging is 
perhaps something that could be investigated further, but may be another 
complication of the high number of prison cases (as 4 out of 5 hanging cases 
were in prison).  
As discussed previously, the potential effect of the time between sampling 
and analysis, and compound instability should be considered. Similarly, the 
panel of drugs tested did not cover all SCRAs. Overall, however, important 
information on the nature of cases where SCRA use was detected has been 
obtained by this work. 
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5.4. Individuals Admitted to or Liberated From a Scottish Prison Service 
Facility  
5.4.1. Introduction 
For the month of November every year all individuals entering and leaving 
Scottish Prison Service (SPS) facilities are tested for drugs of abuse in urine 
using a point of care testing device, in a scheme called Annual Addictions 
Prevalence Testing (AAPT). This scheme covers the most commonly used 
drugs of abuse including cannabis, opiates, cocaine and amphetamines, 
however it does not include NPS such as SCRAs. It has been reported in the 
mainstream media that SCRAs in particular are commonly used in prisons in 
the UK (103, 149, 150). It is thought this may be due to their legality prior to 
the Psychoactive Substances Act 2016 (PSA), the absence of point-of-care 
tests sensitive and specific enough to detect their presence, and their 
reported effects on the perception of time (namely to speed up the passing of 
time, leading to their nickname ‘bird killers’)(111). Whether reports of 
widespread use of SCRAs in prisons are justified, however, remains unclear 
as there is a lack of prevalence studies in this area.  
It was the aim of this project to assess the scale of use of SCRAs in 
individuals being admitted to or liberated from SPS facilities in November 
2015, by way of additional testing on the AAPT samples.  
NHS Ethical Approval was granted from the NHS West of Scotland REC 
under reference WS/15/0207. Conditions of this approval included the 
informed consent of participants, and in order to achieve this information and 
consent forms were provided to participants during sample collection (see 
Appendix F, Section 9.6). These had undergone review from the REC. 
5.4.2. Method 
5.4.2.1. Sample Collection  
In order to conduct the AAPT, NHS staff collected urine from individuals 
undergoing the admission to or liberation from SPS. After testing for the 
standard panel, the individual was asked to sign a consent form and the 
remainder of the original urine sample was labeled as ‘admission’ or 
‘liberation’ and sent by courier to FMS. On receipt at FMS, the samples were 
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labeled with a unique identifier which denoted the prison from which it was 
received and were placed in a freezer (≤-18 °C) to await analysis.  
5.4.2.2. Sample Analysis 
Method 1.1 was applied to these samples, comprising the analytes listed in 
Table 25, and the extraction and hydrolysis protocols and MP gradient 
detailed in Table 40. 
For initial screening tests, two calibrators, at 0.5 and 10 ng/mL, were 
extracted along with the samples. For confirmation of screen-positive 
samples, a calibration was run for assessment of concentration. Table 45 
shows details of the preparation of standards for screening and confirmation 
methods.  
 
  
Table 45 – Preparation of calibrators and QC for the confirmation of 
Synthetic Cannabinoid Receptor Agonist screen-positive samples in 
the Scottish Prison Service cohort. 
CAL 
Final 
Concentration in 
urine (ng/mL) 
Volume of 500 ng/mL 
Working Standard 
Solution (µL) 
Volume of ACN (µL) 
1 0.2 2 998 
2 0.5 5 995 
3 1.0 10 990 
4 5.0 50 950 
5 10.0 100 900 
6 25.0 250 750 
7 50.0 500 500 
QC 4.2 42 958 
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5.4.3. Results and Discussion 
Between the 1st and 30th November 2015, 725 samples were collected from 
the 7 prisons included in the study. The number and type of samples 
collected, and the percentage of the 2015 AAPT scheme cohort these 
comprise, are detailed in Table 46, broken down by SPS facility. It should be 
noted that the AAPT is mandatory for individuals undergoing admission to or 
liberation from SPS facilities in the month of November every year, while 
inclusion in the additional NPS project was voluntary, with explicit consent 
obtained. 
 
Table 46 – Details of the Scottish Prison Service facilities, type and 
number of samples, and proportion of the Annual Addictions 
Prevalence Testing sample received for this cohort. 
Facility 
No. 
Admission 
Samples 
No. 
Liberation 
Samples 
Total No. 
Samples 
% of AAPT 
Samples – 
Admission 
% of AAPT 
Samples – 
Liberation 
HMP 
Addiewell 
69 34 109* 97 103† 
HMP 
Barlinnie 
109 63 173* 47 49 
HMP 
Cornton 
Vale 
62 25 87 87 86 
HMP 
Edinburgh 
27 35 62 77 81 
HMP 
Greenock 
6 20 26 86 95 
HMP Low 
Moss 
19 40 60* 53 105† 
HMP 
Perth 
140 68 208 91 78 
Total 432 285 725* N/A N/A 
* Six samples from HMP Addiewell and one each from HMP Barlinnie and HMP Low Moss 
were not labeled as admission or liberation and could not be identified as either. 
† 
Number of samples tested in NPS project is greater than those reported as collected during 
the APT. 
 
Inclusion in this study was generally high, with >75% coverage of all AAPT 
participants for all facilities except HMP Barlinnie, and admission samples 
from HMP Low Moss. The number of samples received labeled as liberation 
from HMP Addiewell and HMP Low Moss were higher than those reported in 
the AAPT (151). This appears to be error in the recording or reporting of the 
SPS AAPT results, or mis-labeling of samples for this study by staff collecting 
the samples. 
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Reasons for the variation, and occasional reduction in participation could be 
reflective of variation in the techniques employed by staff in providing 
information on the study and obtaining consent for this. Alternatively, it could 
be indicative of a higher incidence of NPS use and/or distrust of SPS or 
research staff. As the lowest participation rate was observed at HMP 
Barlinnie, which collected the highest number of samples for the AAPT, it is 
possible that staff were simply very busy and did not have the time to discuss 
the NPS project with potential participants either fully or at all. Generally the 
mean recruitment of participants was good, at 77% for admission and 85% 
for liberation, however the voluntary element to participation means this 
cannot be classified as a prevalence study. 
5.4.3.1. HMP Addiewell 
HMP Addiewell, situated in West Lothian, was opened in 2008 and houses 
up to 700 low-, medium- and high-security male offenders (152). Table 47 
shows the results of the samples received from this facility. All of the samples 
received were negative for SCRAs with the exception of 1 sample which was 
not labeled as admission or liberation.  
Table 47 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Addiewell 
Sample Type No. negative No. positive 
Admission 69 0 
Liberation 34 0 
Unlabelled 5 1 
TOTAL 108 1 
 
5.4.3.2. HMP Barlinnie 
HMP Barlinnie, on the outskirts of Glasgow, was opened in 1882 and has a 
capacity of 1019, although the average number in custody for 2013 – 2014 
was 1305 (153, 154). HMP Barlinnie houses male offenders who are on 
remand or have been convicted and have sentences less than 4 years, as 
well as offenders serving life sentences who are approaching a potential 
release date (153). Of the samples received from this facility, 8 were found 
positive for SCRAs, all being admission samples.  
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Table 48 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Barlinnie 
Sample Type No. negative No. positive 
Admission 101 8 
Liberation 63 0 
Unlabelled 1 0 
TOTAL 165 8 
 
5.4.3.3. HMP Cornton Vale 
Located in Stirling, HMP Cornton Vale is the only all-female prison in 
Scotland and, at the time of the study, accommodated the majority of the 
female offenders in Scotland. This prison has a design capacity of 119 but 
has been reported to house around 340 inmates (155, 156). 
Of the samples received from HMP Cornton Vale, 7 admission samples were 
determined to be positive for SCRAs. All samples labeled as liberation were 
negative. 
Table 49 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Cornton Vale 
Sample Type No. negative No. positive 
Admission 55 7 
Liberation 25 0 
TOTAL 80 7 
 
5.4.3.4. HMP Edinburgh 
HMP Edinburgh originally opened in 1924, but was entirely rebuilt in the late 
1990s – early 2000s and now holds around 900 offenders of all types (157). 
Only 1 positive sample was detected from the HMP Edinburgh cohort, which 
was labeled as an admission sample. 
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Table 50 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Edinburgh 
Sample Type No. negative No. positive 
Admission 26 1 
Liberation 35 0 
TOTAL 61 1 
5.4.3.5. HMP Greenock 
HMP Greenock opened in 1910 and houses all types of male offenders, as 
well as all types of female offenders since 2002 (158, 159). It currently has 
the capacity for around 250 inmates (158). 
All the samples received from HMP Greenock were found negative for 
SCRAs. 
Table 51 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Greenock 
Sample Type No. negative No. positive 
Admission 6 0 
Liberation 20 0 
TOTAL 26 0 
 
5.4.3.6. HMP Low Moss 
The renovated HMP Low Moss, on the outskirts of Glasgow, was opened in 
2012, although there had been a prison on the site since 1968. It has a 
design capacity of 784 and houses all types of male offenders (160). 
All the samples received from HMP Low Moss were found negative for 
SCRAs. 
Table 52 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Low Moss 
Sample Type No. negative No. positive 
Admission 19 0 
Liberation 40 0 
Unlabelled 1 0 
TOTAL 60 0 
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5.4.3.7. HMP Perth 
Whilst HMP Perth was originally completed in 1812, the most recent 
renovations took place in 2007 (161). This prison accommodates an average 
of 678 male offenders of all types (161). 
SCRAs were detected in 4 samples from HMP Perth – all labeled as 
admission samples. 
Table 53 – Results of Synthetic Cannabinoid Receptor 
Agonist testing of samples from HMP Perth 
Sample Type No. negative No. positive 
Admission 136 4 
Liberation 68 0 
TOTAL 204 4 
 
5.4.3.8. Overall Results 
Out of the 725 samples received overall, 21 were positive – 2.9%. All of the 
positive samples were labeled as admission samples, except one from HMP 
Addiewell which was unlabeled. Therefore, the percentage of admission 
samples which were positive for SCRAs was 4.9%. These data could be 
perceived as encouraging, as it appears that SCRAs are being used before, 
and on admission to, prison, but that this use is decreasing to zero on 
liberation. However, it is important to consider the reason behind SCRA use 
and the motivation for abstinence on liberation from prison. It has been 
reported that SCRAs are used in prison for a number of reasons, 
predominantly related to their psychoactive effects and lack of detection. The 
benefits of the former are the alleviation of boredom, escapism and feeling of 
time passing faster (111). The latter relates to the lack of suitably sensitive 
and specific mandatory drug testing instrumentation. It could be possible, 
then, that the use of SCRAs is just not appealing to individuals on their way 
out of prison in the same way as it is to those on their way in. Similarly, 
individuals undergoing liberation from prison could fear that their being under 
the influence of SCRAs could prevent their release, and abstain for the short 
term.  
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Figure 46 shows the equivalent results for the DOA testing conducted by the 
SPS for the AAPT. It is important to remember that this testing is not 
voluntary so all individuals must participate. Bearing this in mind, it is clear 
that the prevalence of SCRAs within this group is significantly lower than for 
most ‘traditional’ drugs of abuse. 
It is important to note that all of the drugs tested reduce from admission to 
liberation, with the exception of the opiate substitutes methadone and 
buprenorphine (and methamphetamines but the number is insignificant on 
admission). The reduction of SCRAs on liberation then fits in with the general 
trend of drug use in this context. 
 
 
 
Figure 46 – Results from the Scottish Prison Service Annual Addictions 
Prevalence Testing for traditional drugs of abuse (151), showing 
relatively low positivity rate of Synthetic Cannabinoids Receptor 
Agonists. 
 
The individual compounds and the number of samples in which these were 
detected are given in Table 54. This data shows that the AB-FUBINACA 
valine metabolite was the most commonly encountered compound with 15 
samples positive. This compound is also a metabolite of MMB-FUBINACA, 
however MMB-FUBINACA was not reported in the UK until May 2016 so the 
presence of the metabolite is more likely to have resulted from the ingestion 
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of AB-FUBINACA (94, 162). While the rapidly changing nature of SCRA 
popularity must be considered, the relatively high detection rate of this 
compound in this cohort was also evident in the PM cohort (see Section 5.3).  
 
Table 54 – Numbers of Synthetic Cannabinoid Receptor 
Agonists detected in Scottish Prison Service samples. 
Compound No. of Samples 
AB-FUBINACA valine metabolite 15 
AB-FUBINACA metabolite 2B 1 
BB-22 3-carboxyindole  7 
BB-22 or MDMB-CHMICA 1 
AKB48 N5OH pentyl 6 
AKB48 N-pentanoic acid metabolite 5 
PB-22 N-pentanoic acid metabolite 3 
AB-CHMINACA metabolite 1A 2 
AB-CHMINACA metabolite 2 1 
 
After the AB-FUBINACA valine metabolite, the most commonly encountered 
compound was the BB-22 3-carboxyindole metabolite. A response was 
observed in the BB-22/MDMB-CHMICA transition for one sample, and it was 
believed this was BB-22 as the BB-22 3-carboxyindole metabolite was also 
present in this sample. Research not available at the time of the study, but 
published at a later date stated that the BB-22 3-carboxyindole metabolite is 
also produced from the amide hydrolysis of MDMB-CHMICA (84). This 
metabolite, however, is present in minor quantities when MDMB-CHMICA is 
administered (<1% of the mean area ratio, and ranked number 30 of 31 
metabolites in terms of prevalence in 10 samples). Findings in the PM cohort 
(see Section 5.3) where the MDMB-CHMICA and BB-22 are 
chromatographically resolved, and the MDMB-CHMICA O-desmethyl acid 
metabolite is included in the method, have indicated that the BB-22 3-
carboxyindole metabolite is not detected where MDMB-CHMICA use is 
demonstrated (by presence of parent drug and/or major metabolite). It is, 
therefore, much more likely that the compound administered was BB-22 
rather than MDMB-CHMICA in this case. The similarities between many 
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SCRAs and the likelihood of common metabolites in general should be borne 
in mind when reporting results where no parent drug is detected.  
AKB48 metabolites (N5OH pentyl and N-pentanoic acid) were detected in 11 
samples in total. Again, it is possible that these metabolites could arise from 
de-fluorination and further metabolism of 5F-AKB48, however the lack of the 
5F-AKB48 N4OH pentyl – specific to 5F-AKB48 – strongly indicates this is 
not the case.  
The PB-22 N-pentanoic acid metabolite was detected in 3 cases. This 
metabolite is common to PB-22 and its fluorinated analogue, 5F-PB-22 (80).  
AB-CHMINACA metabolites 1A and 2 were detected in 2 and 1 sample(s) 
respectively. The sample in which AB-CHMINACA metabolite 2 was detected 
also contained metabolite 1A.  
The potential instability of compounds should be borne in mind when 
considering the significance of the compounds detected, as rapid metabolism 
could lead to under-representation in these findings. 
 
 
Figure 47 – Co-administration of Synthetic Cannabinoid Receptor 
Agonists as detected in Scottish Prison Service samples. 
 
With regards to the number of compounds detected in positive samples, co-
administration was observed, as demonstrated in Figure 47. The majority of 
positive cases (62%) only contained 1 detected compound, however 1 
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sample was found to contain 8 compounds, indicating the use of 5 distinct 
parent compounds. 
The packaging for some SCRA products is often inaccurate with regards to 
type and number of compounds the product contains. For this reason it is not 
possible to know whether the incidence of co-administration of compounds 
was intentional. 
After England and Wales, Scotland has the highest rate of imprisonment in 
Western Europe (104). Due to the lack of studies, it is not known what the 
prevalence of SCRA use is within custodial institutions in Scotland, or indeed 
the U.K. Surveys such as the Scottish Crime and Justice Survey or Crime 
Survey for England and Wales do not include individuals in prison so the 
incidences of drug use are not reflective of this population. The seizures of 
SCRAs in prisons in England and Wales has increased from <100 in 2010 to 
over 700 in 2014 (104). In a survey of 625 prisoners across multiple English 
and Welsh prisons, 33% reported ‘spice’ use in the last month, with prisoners 
estimating rates of between 40 – 90% of prisoners using SCRAs during 
group discussions (104). Of these individuals who had used in the last 
month, 46% admitted to using ‘almost daily’; which, if extrapolated, equates 
to almost 13000 individuals using SCRAs almost daily in prison. A rate of 
4.9% of admission samples and 2.9% of all samples positive for SCRAs in 
this study seems low in comparison. However, it is important to consider the 
difference in the populations in terms of what point of their prison sentence 
they are currently at.  
5.4.4. Conclusions 
The work conducted in this section indicates that SCRAs were being used by 
individuals undergoing admission to SPS facilities in November 2015. 
Compared to more ‘traditional’ drugs of abuse, the proportion of people using 
SCRAs on admission to prison was low, and this number reduced to zero on 
liberation. This follows the trend seen in other drugs of abuse, with the 
exception of opioid substitutes. It is important to consider, however, that this 
work did not test the same individuals on admission and liberation.  
While the study was relatively small in scale, and did not include all 
participants of the AAPT scheme, recruitment to this project was generally 
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high. As with all the work discussed, it is important to bear in mind that only a 
selection of SCRAs were included within the testing panel, and it is possible 
that the samples may have contained drugs that were not detected. 
Nonetheless, information on the scale of use and types of compounds used 
was gained, and the use of multiple compounds by the same individual was 
observed.  
As mentioned previously, analysis of urine samples from individuals currently 
within their prison sentence would provide valuable information on the real 
scale of use of SCRAs in Scottish prisons. Similarly, a repeat of the work 
during another round of the AAPT would show what changes have occurred 
in SCRA trends since November 2015.  
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5.5. Individuals Undergoing Psychiatric Treatment from the NHS Greater 
Glasgow and Clyde Forensic Directorate 
5.5.1. Introduction 
There are approximately 220 patients under the care of the NHS Greater 
Glasgow and Clyde Forensic Directorate (NHS GGC FD) managed in 
medium secure, low secure and community settings. This includes the 
national medium secure learning disability service based at the Rowanbank 
clinic. The patient cohort has a range of diagnoses, although the majority 
(around 70%) have a primary diagnosis of schizophrenia. Many forensic 
patients have co-morbidity (76% of those in community setting), with either 
harmful use of or dependency on illicit substances and/or alcohol. The vast 
majority of patients are detained under a section of either the Mental Health 
(Care and Treatment) Scotland Act (2003) or the Criminal Procedure 
(Scotland) Act 1995. It is routinely a condition of the patient’s suspension of 
detention or condition of discharge that they should not use illicit substances, 
alcohol or NPS. 
Patients under the care of the forensic psychiatric services are regularly and 
randomly screened for drugs of abuse. This is done using an immunoassay 
screen and confirmation by either GC-MS (opiates and methadone), LC-
MS/MS (amphetamines) or LC-TOF-MS (everything else). It is unknown if 
this cohort of patients are using NPS such as SCRAs, as they are not known 
to be routinely detected by current urine screening tests. 
The aim of this study was therefore to estimate the prevalence of use of 
SCRAs in patients undergoing treatment by the NHS GGC FD; and to assess 
the ability of the current drug detection systems in place at the NHS GGC FD 
to detect NPS. 
NHS Ethical Approval was granted from the NHS West of Scotland REC 
under reference 15/WS/0263. See Appendix G, Section 9.7, for ethical 
approval documentation. 
  
 210 
 
5.5.2. Method 
5.5.2.1. Sample Collection 
Urine samples were collected from individuals under the treatment of the 
NHS GGC FD and were sent to a sub-contractor for testing for the standard 
panel of drugs of abuse. Patients were provided with an information sheet 
and asked to sign a form if they consented to their inclusion in this study. 
These forms were reviewed by the NHS REC and are provided within 
Appendix G, Section 9.7. The remainder of the sample was sent by courier to 
FMS, along with a corresponding copy of the drug testing results, and a list of 
their prescribed drugs. The samples and paperwork did not contain any 
information that would make them traceable to an individual by FMS, and 
were paired by a unique number noted on samples and paperwork. The 
results of the drug testing and the prescription information would likely make 
them identifiable to FD staff, however. Only one sample per individual was 
received at FMS; no individual was tested repeatedly. 
On receipt at FMS, the samples were placed under freezer storage to await 
analysis. 
5.5.2.2. Sample Analysis 
Method 1.2 was applied to these samples, comprising the analytes listed in 
Table 25, and the extraction and hydrolysis protocols, and MP gradient 
detailed in Table 40. 
5.5.3. Results and Discussion 
Between 1st November 2015 and 30th November 2016, 95 urine samples 
were received by FMS. All samples received were found negative for the 
SCRAs contained within the analysis panel. 
Due to the nature of SCRAs as high potency CB1 agonists with high affinity, 
they have been linked to adverse psychological effects (14, 140, 163). It is 
therefore a positive finding that individuals experiencing poor psychological 
health were not found to be using these compounds.  
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It is, however, important to remember that these individuals were informed 
that they would be tested for drugs, albeit testing was conducted at random 
appointments. Similarly, while the panel is believed to include the SCRAs 
most likely to be encountered in this population, it is not exhaustive, 
particularly with regards to metabolites. The samples were frozen upon 
receipt at FMS, but as little is known regarding stability of SCRAs, it should 
be borne in mind that negative results could arise from the decay of the 
compounds included in the panel. 
5.5.4. Conclusions 
The results from this work indicate that individuals under the treatment of the 
NHS GGC FD do not use SCRAs, particularly the SCRAs included in method 
1.2.  
While this is positive from a treatment point of view, it is important to bear in 
mind that the individuals knew when they would be tested for drugs, and that 
the panel of SCRAs tested was not exhaustive.  
One of the reasons proposed for SCRA use is to avoid detection in drugs 
tests, so it is apparent from analysis conducted that this is not the case for 
this cohort. Similarly, the drugs included in this panel were detected in other 
cohorts around the time of this study, so it is known that some of the 
compounds, at least, were available for use.  
Due to the lack of cases positive for SCRAs in this cohort, it was not possible 
to determine whether the current systems in place for the detection of drugs 
of abuse, particularly NPS, were fit-for-purpose. It does appear, however, 
that the clinical mechanisms used for promoting and ensuring abstinence 
from drugs of abuse are working. 
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5.6. Individuals Under a Drug Treatment Order from the Glasgow Drugs 
Court 
5.6.1. Introduction 
The Glasgow Drug Court (GDC) is a special court within the Scottish judicial 
system, but run by the NHS, which applies treatment-based options and 
mandatory drug testing in place of custodial sentences to offenders with 
histories of drug addiction or misuse.  
Individuals under the jurisdiction of the GDC attend to provide a urine sample 
for drug testing at a pre-arranged time. A dipstick test is employed, which 
covers the most commonly abused drug groups including benzodiazepines, 
opiates, cocaine and amphetamines, however does not detect SCRAs. 
Practitioners within the GDC had observed behaviour which they suspected 
was due to drug use, but the results of their analyses were negative, and 
consequently they suspected the undetected use of NPS. 
Given the suspected scale of SCRA, particularly in the offending population, 
it was deemed necessary to assess the use of these drugs within individuals 
involved in the GDC system. 
This work was considered service development, and as such, ethical 
approval from the NHS Research Ethics Committee was not required. Ethical 
approval was sought and granted from the UG MVLS REC under application 
number 200140101. See Appendix H, Section 9.8, for ethical approval 
documentation. 
5.6.2. Method 
5.6.2.1. Sample Collection 
Samples were refrigerated after donation and initial on-site testing, then 
transferred to FMS on a monthly basis. On receipt at FMS, samples were 
given a unique identifier and placed in a freezer (≤ -18 °C) to await analysis.  
Samples were accompanied by completed questionnaires about the 
individual’s drug use (provided in Appendix I, Section 9.9). These were 
reviewed by the REC prior to the project beginning, and help was provided to 
the donor to complete these by NHS staff if required.  
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5.6.2.2. Sample Analysis 
Method 1.2, detailed in Chapter 4 was applied to these samples, comprising 
the analytes listed in Table 25, and the extraction and hydrolysis protocols 
and MP gradient detailed in Table 40 . 
5.6.3. Results and Discussion 
Between 31st August 2015 and 19th February 2016, 73 samples were 
received with completed questionnaires. 
There were no questionnaires that listed brand names or any other term 
considered to refer to SCRAs specifically. However, of the 73 questionnaires, 
27 (37%) stated that ‘cannabis’, ‘hash’ or ‘weed’ was used with any 
frequency.  
The results of the analysis were negative for the SCRAs and their 
metabolites tested in all samples with the exception of one. This sample was 
positive for the AKB48 N5OH pentyl and N-pentanoic acid metabolites, and 
MDMB-CHMICA O-desmethyl acid metabolite. The corresponding 
questionnaire stated that the participant smoked one draw of herbal cannabis 
every other day. Based on this response, it is unclear whether the individual 
was aware they were taking these drugs. 
The prevalence of SCRAs in this cohort was therefore found to be 1.4%. 
One of the reasons suggested for the perceived popularity of NPS is their 
use in avoiding positive drug tests. Based on this, it may be reasonable to 
suspect that individuals used to abusing cannabis might use SCRAs if they 
were subject to mandatory drug testing. The result of this, albeit small-scale, 
study is interesting as it suggests this not to be the case. It is possible that 
the treatment they are receiving from the NHS regarding their problematic 
drug use has contributed towards drug abstinence. This being said, the 
limiting factors noted previously in this work should be considered here as 
well, namely the panel of SCRA compounds being limited and the potential 
instability of the compounds. In addition to this, the fact that individuals were 
aware of when the drug testing would take place meant that they could 
abstain for the preceding period.  
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5.6.4. Conclusions 
While the use of SCRAs was detected in this cohort, only one sample was 
positive, and it is unclear whether the use was intentional. As such, it is 
apparent that SCRA use is not a significant problem within individuals under 
the jurisdiction of the GDC.  
As discussed for previous projects, it is important to bear in mind the 
incomplete panel of drugs tested, and the potential for compound instability, 
or extended time since sample collection, to cause false negative results. 
Having said that, it appears from this work that any unusual behaviour 
exhibited by individuals governed by the GDC was not due to the use of 
SCRAs. Nor do the individuals tested appear to be using SCRAs to avoid 
detection of more ‘traditional’ drugs of abuse.  
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6. Conclusions and Limitations 
The use of SCRAs in the UK is an issue that is widely perceived as 
problematic, and is frequently highlighted by mainstream media. Evidence to 
support or refute these claims is challenging to produce as the trends of 
SCRA use are rapidly changing, and analytical detection in biological 
matrices is complex. 
Through the work conducted and detailed here, a method was developed, 
optimised and validated for the detection and quantitation of SCRAs in blood 
and urine samples. The most likely to be encountered compounds were 
identified and the analytical method was deemed fit-for-purpose for detecting 
and quantifying these. Limits of detection generally ranged from 0.01 – 0.20 
ng/mL in blood and urine; sufficient to see the low concentrations of SCRAs 
present after use. Accuracy and precision, within and between batches, were 
found to be acceptable for the compounds quantitatively validated, and 
linearity was established over the calibration range of interest, with 1/χ 
weighting applied. The compounds were generally stable with ±20% of the t0 
injection when left under autosampler conditions for ca. 46 H, when 
compensated with the I.S. No interferences were observed in the analytical 
results where commonly encountered prescription and abused drugs were 
injected at a realistically encountered concentration. 
As with all analytical techniques, certain limitations apply to this method. 
Significant matrix effects were observed for some compounds, predominantly 
in blood, which are likely to affect calculated concentrations in some PM 
samples. The sensitivity of the method as applied to blood was assessed 
based on the extraction from diluted packed red cells, rather than whole 
blood. As such it is unknown how the inclusion of plasma in whole blood 
would affect the LODs and LLOQs. 
Additionally, the compounds included in the panel were chosen based on 
intelligence suggesting they were available to the Scottish population. The 
panel was not exhaustive and the stability of these compounds in biological 
samples is unknown. It is possible, then, that samples were positive for 
compounds not included in the panel, or concentrations had reduced below 
LODs, thus giving false negative results.  
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Intermediate methods were developed and validated to ensure they were fit 
for purpose in terms of sensitivity and selectivity. 
These methods were then applied to 1177 samples collected from cohorts 
covering a variety of Scottish sub-populations: individuals presenting at an 
ED with suspected recreational drug toxicity; deceased individuals 
undergoing post-mortem examination; individuals undergoing admission to or 
liberation from SPS facilities; individuals under the care of the NHS GGC FD; 
and individuals under the jurisdiction of the GDC.  
The results showed that the compounds selected for the method were being 
used within the Scottish population to varying degrees. No SCRAs were 
detected in the NHS GGC FD cohort (n=95), and only 1 sample was positive 
in the GDC cohort (n=73). This indicates that these groups of individuals are 
not using SCRAs in significant numbers to avoid detection of drug use, or for 
any other reason. Within the cohort of individuals presenting at the ED of GRI 
who were tested for SCRAs (n=34), 56% were found positive for one or more 
compound in one or more sample. This number was 11% in PM cases tested 
for SCRAs (n=250). Within samples collected from the SPS cohort, 5% of 
admission samples (n=432 in total) were found positive, and 3% overall 
(n=725 in total).  
These results correlate with expectations of the low use of SCRAs relative to 
traditional drugs of abuse in Scottish sub-populations; indeed, SCRA use 
was found to be even lower than expected. Positive results were found in 
higher numbers in the ED and PM cohorts, as anticipated, due to analysis 
taking place on samples from participants suspected of using these 
compounds. Numbers of positive results in the FD and GDC cohorts were 
significantly lower than expected, particularly regarding the GDC cohort, 
where GDC staff had suspected SCRA use.  
While qualitative results for SCRAs are sufficient for the purposes of this 
research in assessing scale and nature of use, particularly in urine samples, 
valuable quantitative information was gained in ED and PM cohorts. 
The most commonly encountered compounds were the AB-
FUBINACA/MMB-FUBINACA shared metabolite, MDMB-CHMICA and 
metabolite, 5F-MDMB-PINACA and metabolite, 5F-PB-22 and metabolites 
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and 5F-AKB48 and metabolites. These compounds are among those 
commonly reported in literature from the UK and also featured in WEDINOS 
results. These results indicated that a relatively limited number of SCRAs 
were being used. In that respect, the panels of compounds selected appear 
to have been suitable for the context within which this research was 
conducted. It was accepted, however, that the addition of novel compounds 
was reactive in nature and no attempt at anticipation of future trends in 
compounds was made as this was outside the scope of the work. 
A number of limitations should be considered regarding these projects, 
however. Individuals from the NHS GGC FD and GDC cohorts knew they 
would be drugs tested and it is possible that they could abstain from use for 
the testing period. It has been suggested that SCRAs are used to avoid 
detection in populations undergoing drugs testing, though, and this is not 
apparently the case based on these results. Cases were only put forward for 
SCRA analysis when SCRA use was suspected for the ED and PM samples, 
not for every case, positively biasing the results. Consent was required from 
participants for the SPS and NHS GGC FD projects, and this could be 
withheld if participants had been using SCRAs. The projects discussed in this 
work cannot therefore be considered true prevalence studies.  
Overall, the research described here provides invaluable information 
regarding the scale of use, specific compounds ingested and potential groups 
vulnerable to SCRA use in Scotland. The quantitative aspect of this work with 
regards to ED and PM cohorts can begin to address the lack of reference 
concentration ranges available for SCRA concentrations in living and 
deceased populations. This information can be used by practitioners of 
forensic toxicology, emergency medicine, and public policy to guide practice 
and employ techniques to detect SCRA use.  
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7. Further Work 
The nature of drug use, particularly relating to SCRAs and NPS more 
generally, means that the compounds likely to be encountered in forensic 
casework will be constantly changing. For a method to continue to be fit-for-
purpose it will need to be updated frequently as new compounds become 
available on the market. Continual quantitative revalidation is not very 
practical for a busy laboratory and it would be beneficial for a screening 
method, potentially on instrumentation such as quadrupole-time-of-flight 
(QTOF), to be developed. This would allow for quick identification of positive 
samples by comparison to a library of drugs, and then quantitation of 
compounds which appear to have some market longevity could be conducted 
by a method such as that developed in this work. 
With regards to the method detailed in this thesis, further optimisation of the 
extraction protocol for blood, and/or the MP gradient might go some way to 
improve the variation and degree of ME observed for some compounds. 
Similarly, exploration of alternative I.S. may compensate for these ME. 
An expansion of the cohorts tested would provide more data on the scale and 
nature of SCRA use in Scotland. For example, testing samples from 
individuals undergoing mandatory workplace drug testing would add 
evidence as to whether SCRAs are used in place of cannabis to avoid 
detection, or not. Likewise testing samples from individuals currently serving 
sentences in prison – rather than being admitted to or liberated from prisons 
– could add to this knowledge. A more in-depth examination of the role of 
SCRAs in suicide cases could be conducted to provide more context around 
the apparent association between SCRAs and hanging observed in the PM 
cohort.  
In addition, given the time scale of the projects, repeating the work in, for 
example, the ED and SPS facilities would provide information on how the 
drug trends in these contexts have shifted since the original analysis. 
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9. Appendices 
9.1. Appendix A – Mobile Phase Gradients Tested in Section 4.3.3.2 
 
 
Figure 48 – Graphical representation of MP Gradient System A 
 
 
Figure 49 – Graphical representation of MP Gradient System B 
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Figure 50 – Graphical representation of MP Gradient System C 
 
 
Figure 51 – Graphical representation of MP Gradient System D 
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Figure 52 – Graphical representation of MP Gradient System E 
 
 
Figure 53 – Graphical representation of MP Gradient System F 
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Figure 54 – Graphical representation of MP Gradient System G 
 
 
Figure 55 – Graphical representation of MP Gradient System H 
 
 240 
 
 
Figure 56 – Graphical representation of MP Gradient System I 
 
 
Figure 57 – Graphical representation of MP Gradient System J 
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Figure 58 – Graphical representation of MP Gradient System K 
 
 
Figure 59 – Graphical representation of MP Gradient System L 
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Figure 60 – Graphical representation of MP Gradient System M 
 
 
Figure 61 – Graphical representation of MP Gradient System N 
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Figure 62 – Graphical representation of MP Gradient System O 
 
 
Figure 63 – Graphical representation of MP Gradient System P 
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Figure 64 – Graphical representation of MP Gradient System Q 
 
 
Figure 65 – Graphical representation of MP Gradient System R 
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9.2. Appendix B – Letter of Comfort from MVLS REC regarding the 
comparison of Prison ‘A’ and ‘B’ samples 
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9.3. Appendix C – Details of additional analyses in Emergency 
Department cases 
Table 55 – Details of Additional Analyses 
Analysis Analytes Included 
Alcohol 
Quantitates ethanol and acetone; qualitatively identifies 
acetaldehyde, methanol and isopropanol 
Basic Drugs 
A general screening method which qualitatively identifies 
many basic drugs and quantitates commonly used 
drugs. 
Drugs of Abuse Screen 
Presumptively identifies amphetamine, benzodiazepines, 
buprenorphine, cannabinoids, cocaine and related 
compounds, methadone, methamphetamines, and 
opiates 
Cannabinoids Quantitates Δ9-THC, 11-Nor-Δ9-THC-carboxylic acid 
Benzodiazepines 1 
Quantitates diazepam, desmethyldiazepam, temazepam, 
oxazepam, chlordiazepoxide, lorazepam, nitrazepam, 7-
aminoflunitrazepam, etizolam, phenazepam, diclazepam, 
delorazepam, lormetazepam, flubromazepam and 
pyrazolam 
Benzodiazepines 2 
As Benzodiazepines 1, plus deschloroetizolam, 
nifoxipam, meclonazepam, clonazolam and 
flubromazolam 
Opiates 
Quantitates morphine, 6-monoacetyl-morphine (6-MAM), 
codeine and dihydrocodeine 
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9.4. Appendix D – Analysis and Clinical Findings of Cases Positive for the 
Novel Synthetic Cannabinoid Receptor Agonist MDMB-CHMICA 
Permission to reproduce this article has been sought and granted by Taylor 
and Francis, publishers of Clinical Toxicology. This article is availble in full 
here: https://www.tandfonline.com/doi/full/10.1080/15563650.2016.1186805 
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9.5. Appendix E – Research ethics approval documentation – Post-
Mortem casework  
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9.6. Appendix F –  Research ethics approval documentation – Scottish 
Prison Service 
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9.7. Appendix G – Research ethics approval documentation – Forensic 
Directorate 
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9.8. Appendix H – Research ethics approval documentation – Glasgow 
Drugs Court 
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9.9. Appendix I – Questionnaire completed by Glasgow Drug Court cohort 
participants 
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